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Abstract
During the last decade, genomics have been widely used to the characterization of the molec-
ular basis of common diseases. Genome-wide association studies (GWAS) have been highly
successful in characterizing the genetic variation that influences human traits including the
susceptibility to common diseases. In metabolomics, recent improvements of analytical
technologies have enabled the analysis of complete metabolomic profiles. Using this ap-
proach, high-throughput metabolomics studies have already demonstrated a high potential
for the discovery of disease biomarkers.
The use of powerful high-throughput measurement technologies has resulted in the gen-
eration of large datasets of biological variation. In order to extract relevant information from
this data, highly specialized bioinformatics methods are required. This thesis is focused
on the development of new methodological tools to improve the processing of genomics
and metabolomics high-throughput data. These new tools have been used in the analysis
framework of the Immune-Mediated Inflammatory Diseases (IMIDs) Consortium. The IMID
Consortium is a large Spanish network of biomedical researchers on autoimmune diseases,
which holds one of the largest collections of biological samples from this group of diseases,
as well as healthy controls.
The first analysis tool that has been developed is a computationally efficient algorithm
for the simultaneous genotyping of single nucleotide polymorphisms (SNPs) and copy num-
ber variants (CNVs) using microarray data. This bioinformatics tool, called GStream, inte-
grates the genotyping of both types of genomic variants into a single processing pipeline.
We demonstrate that the developed algorithms provide a significant increase in genotyping
accuracy and call rate when compared to previous algorithms. Using GStream, researchers
performing large-scale GWASs will not only benefit from the combined and fast genotyping
of SNPs and CNVs but, more importantly, they will also improve the accuracy and therefore
the statistical power of their studies.
The second tool that was developed during this thesis was FOCUS, a bioinformatics
framework that provides a complete data analysis workflow for high-throughput metabolomics
studies based on one-dimensional nuclear magnetic resonance (NMR). FOCUS workflow
includes quality control, peak alignment, peak picking and metabolite identification. The
algorithms included in FOCUS were designed to overcome several technical challenges of
NMR that can dramatically affect the quality of the results. FOCUS allows users to easily
obtain high-quality NMR peak feature matrices, which are ready for chemometric analysis,
as well as metabolite identification scores for each peak that greatly simplify the biological
interpretation of the results. When tested against previous NMR data processing method-
ologies, FOCUS clearly showed a superior performance, even in datasets with high levels of
spectral unalignment.
The final research work included in this thesis is a GWAS in Crohn’s disease (CD) clin-
ical phenotypes. CD is the most prevalent chronic inflammatory disease of the bowel, and
is characterized by segmental and transmural inflammation of the gastrointestinal tract.
CD is a highly heterogeneous disease, with patients showing different degrees of severity.
The identification of the genetic basis associated with disease severity is therefore a ma-
jor objective in CD translational research. The present PhD thesis includes the first GWAS
of clinically relevant phenotypes in CD. A total of 17 phenotypes associated with different
clinical complications were analyzed. In this study, we identified new genetic regions sig-
nificantly associated to complicated disease course, disease location, mild disease course,
and erythema nodosum. These findings are of high relevance since they show, for the first
time, the existence of a genetic component for disease heterogeneity that is independent of
the genetic variation associated with susceptibility to CD.
Resum
Durant la darrera dècada, la genòmica ha jugat un paper clau en la caracterització de la base
molecular de les malalties complexes. Els estudis d’associació de genoma complet (GWAS)
han permès la caracterització de les regions genètiques que influencien fenotips humans tals
com la susceptibilitat a desenvolupar una malaltia complexa. En metabolòmica, millores
recents en les tecnologies analítiques han impulsat l’obtenció de perfils metabolòmics en
grans cohorts de mostres. Els estudis resultants han demostrat també un gran potencial per
al descobriment de biomarcadors d’utilitat en malalties humanes.
L’aplicació de les tecnologies high-throughput permet generar grans conjunts de dades
de variació biològica. Per tal d’extreure la informació de rellevància d’aquestes dades es
requereix l’aplicació de potents eines bioinformàtiques. Aquesta tesi està centrada en el
desenvolupament de nous mètodes per a millorar i agilitzar el processament de dades
genòmiques i metabolòmiques high-throughput, així com la seva posterior implementació en
forma d’aplicacions bioinformàtiques. Aquestes noves eines han estat incorporades al flux
d’anàlisi del consorci IMID (malalties inflamatòries mediades per immunitat). Aquest con-
sorci és una xarxa espanyola que aglutina un gran nombre d’investigadors biomèdics amb
l’interès comú de l’estudi de malalties autoimmunes. El consorci IMID disposa d’una de les
col·leccions més extenses de mostres biològiques de pacients d’aquest grup de malalties, així
com d’individus sans control.
La primera eina bioinformàtica implementada consisteix en un conjunt d’algoritmes que
integren el genotipat de polimorfismes de nucleòtid simple (SNPs) i variacions de nombre de
còpies (CNVs) sobre dades de microarrays de genotipat. Aquesta eina, anomenada GStream,
incorpora de forma eficient tot el flux d’anàlisi necessari per al genotipat en GWAS. S’ha de-
mostrat que els algoritmes desenvolupats milloren significativament la precisió del genoti-
pat i augmenten el nombre de variants genètiques identificades respecte a les metodologies
anteriors. La utilització d’aquesta eina permet doncs ampliar el nombre de variants genè-
tiques analitzades i correctament genotipades, incrementant de forma significativa el poder
estadístic dels estudis genètics GWAS.
La segona eina desenvolupada durant el curs d’aquesta tesi ha estat FOCUS. Es tracta
d’una eina bioinformàtica integrada que inclou totes les etapes de processat d’espectres
de ressonància magnètica nuclear (NMR) per a estudis de metabolòmica. El flux d’anàlisi
inclou el control de qualitat, l’alineament/quantificació de pics espectrals i, finalment, la
identificació dels metabolits associats a cadascun dels pics quantificats. Tots els algoritmes
han estat dissenyats per a corregir els biaixos i errors que sovint limiten considerablement
la qualitat dels resultats i que són un dels reptes tècnics no resolts més importants de la
metabolòmica actual. FOCUS obté directament una matriu numèrica d’alta qualitat llesta
per a l’anàlisi quimiomètric, i genera uns scores d’identificació que simplifiquen la inter-
pretació biològica dels resultats. FOCUS ha assolit un rendiment significativament superior
al de metodologies prèvies.
Aquesta tesi conclou amb el primer GWAS de fenotips clínics de malaltia de Crohn. Aque-
sta malaltia IMID és la malaltia inflamatòria intestinal de major prevalença, i es caracteritza
per la inflamació del tracte gastrointestinal. La malaltia de Crohn és molt heterogènia,
amb pacients que presenten graus molt diferents de gravetat. La identificació de variants
genètiques associades als fenotips d’aquesta malaltia és, per tant, un dels objectius més
rellevants per a la investigació translacional. Un total de 17 fenotips han estat analitzats
utilitzant cohorts de descobriment i validació per tal d’identificar i replicar loci de risc as-
sociats a cadascun d’ells. Els resultats de l’estudi han permès identificar, per primer cop,
regions genètiques associades a l’evolució de la malaltia, la localització de l’afectació i les
manifestacions extraintestinals. Aquests resultats són de gran rellevància ja que no tan sols
han permès identificar noves vies biològiques associades a diferents fenotips clínics, sinó
que també demostren, per primer cop, la existència d’un component genètic de la hetero-
geneïtat a la malaltia de Crohn i que és independent de la variació genètica associada al risc
de patir la malaltia.
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1 | Introduction
1.1 Thesis outline
The current thesis has been developed by the student Arnald Alonso at the Rheumatology
Research Group of the Vall d’Hebron Hospital Institute of Research (GRR-VHIR), under the
supervision of Dr. Sara Marsal and Dr. Antonio Julià.
This thesis has taken place during the execution of the singular and strategic project IMID-Kit
(PSE-010000-2006-6, Ministerio de Economía y Competitividad). This project, coordinated
by Dr. Sara Marsal (GRR-VHIR), is a multicentric collaborative project of the IMID Con-
sortium (IMIDC). The IMIDC is a Spanish network of researchers that includes more than
80 clinical departments of university hospitals from Spain, and is focused in the study of
immune-mediated inflammatory diseases (IMIDs) through the analysis of high-throughput
molecular (omics) data. IMIDs are a group of prevalent autoimmune diseases of unknown
etiology that are characterized by sharing common inflammatory pathways (i.e. TNF-α
pathway1). These chronic diseases are known to produce a relevant socio-economic burden
due to their increased use of healthcare resources, as well as the reduction of quality of life
and productivity of IMID patients2. One of the main milestones of the IMID-Kit project has
been the collection of biological samples and associated clinical information from more than
13,000 patients from six of the most prevalent IMIDs: rheumatoid arthritis (RA), psoriasis
(PS), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC) and systemic lu-
pus erythematosus (SLE). The analysis of the genomic and metabolomic data obtained from
these large patient cohorts has been the starting point for the development of this thesis.
This thesis is divided in two sections. The first section is based on the development of
new algorithms and software tools for the processing of genomic and metabolomic high-
throughput data. The main objectives of these methods were to improve the accuracy and
usability. In the second section, the first genome-wide association analysis (GWAS) of CD
clinical phenotypes, the most prevalent inflammatory bowel disease (IBD), has been per-
formed.
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In the first section, an algorithm (GStream, Chapter 3) for the simultaneous genome-wide
genotyping of single nucleotide polymorphisms (SNPs) and copy number variants (CNVs)
has been developed. This algorithm has been designed to solve different technical chal-
lenges associated with SNP and CNV genotyping in GWASs based on genotyping microar-
rays: (1) the absence of bioinformatics tools that integrate the simultaneous genotyping of
both types of polymorphisms, and (2), the low performance of previous CNV genotyping
methods in microarray data. GStream efficiently integrates the whole genotyping process
(quality control, SNP and CNV genotyping) in a single software tool. The genotyping per-
formance has been quantitatively compared against previous state-of-the-art methods using
different Illumina genotyping microarrays, together with publicly available SNP and CNV
reference datasets.
Second, a bioinformatics tool for the processing of metabolomics data (FOCUS, Chapter 4)
has been implemented to improve the quantification of spectral peaks in metabolomics data
from nuclear magnetic resonance (NMR) studies. FOCUS software was designed to solve
several technical challenges that critically limit the application of NMR to high-throughput
metabolomics studies. These limitations are the introduction of significant biases in peak
positions associated with the sample chemical environment, and the lack of reliable auto-
matic metabolite identification methods. The most important contributions of FOCUS have
been: (1) the inclusion of a new spectral alignment algorithm that significantly outper-
forms previous methods, (2) a new metabolite identification algorithm that uses multiple
peak features to perform metabolite assignment, and (3), the integration of the entire NMR
data processing workflow in a single user-friendly software tool.
The two bioinformatics tools implemented in this first section of the thesis -GStream and
FOCUS- have been published in top-tier journals (Plos One3, IF: 3.53; Analytical Chemistry4,
IF: 5.83) and are distributed as open-source software tools (www.urr.cat/ software).
The second section of this thesis is devoted to the analysis of the omics data from patients
included in the IMID-Kit project. In this study the work performed by the PhD student has
allowed the identification of several genetic variants associated to Crohn’s disease (OMIM
266600) phenotypes (Chapter 5). CD is a prevalent (20-150 cases per 100,000 persons5)
chronic inflammatory disease characterized by the chronic inflammation of the gastrointesti-
nal tract6. This persistent intestinal inflammatory activity leads to multiple disease-related
complications like intestinal stenosis, fistulas, and abscesses that significantly reduce the
quality of life of CD patients6;7. From a clinical perspective, the study of the more severe
disease phenotypes, such as those that require bowel resection, is of high importance. These
clinically relevant phenotypes have shown a significant level of aggregation within individ-
ual families8;9, thereby suggesting that there is a genetic basis for disease heterogeneity. To
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date, several genetic association studies10–14 have investigated the association of previously
known CD risk loci with disease phenotypes, but only genetic variants in NOD2 locus have
been consistently associated15;16. The present work represents the first GWAS of clinically
relevant phenotypes in CD, which include disease location, disease behavior, disease course,
age at onset and extraintestinal manifestations.
The results of this study have been published in the top-tier journal of the medical specialty
(Gastroenterology17, IF: 13.93).
In addition to the previous works, the PhD student Arnald Alonso has also been actively
involved in the elaboration of two review articles in metabolomics. The first manuscript
provides a state-of-the-art in metabolomics methodology (Alonso et al. 2015, Appendix D.1),
and the second manuscript comprehensively reviews the most recent results of this high-
throughput technology in the study of IMIDs (Julià et al. 2014, Appendix D.2).
Figure 1.1 shows the distribution over time of the different projects and studies related with
this thesis.
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1.2 Genomics
Genome-wide association studies (GWAS) have played an important role in the identifi-
cation of associations between common genetic variants and the susceptibility to complex
diseases18–21. The development of the microarray technology in the early 2000s was a key
point for the success of GWASs. Genotyping microarrays22 are technological platforms de-
signed to capture most of the common variation of the human genome by simultaneously
genotyping thousands of SNPs23. In addition to SNPs, CNVs are also an important source of
genetic variation24. CNVs are defined as DNA segments larger than 1,000 basepairs (bps)
that are present at variable copy number in comparison with a reference genome25. Re-
cent studies have demonstrated their importance based on their high frequency, functional
impact and role in human disease26–30. The development of genotyping microarray and
comparative genomic hybridization (CGH) technologies has enabled the inclusion of CNVs
in GWAS analyses31. Compared with CGH, genotyping microarrays have the advantage of
allowing the genotyping of both SNPs and CNVs. Nevertheless, since genotyping microar-
rays were initially designed for SNP genotyping, powerful algorithms were needed to deal
with the technical challenges of CNV genotyping. The absence of such methodological tools
motivated the development of GStream genotyping software (Chapter 3).
The following subsections provide an introduction to the genomics concepts that are directly
related with the work developed during this thesis.
1.2.1 The human genome
The human genome consists of approximately 3·109 DNA bps distributed in 23 chromosome
pairs that are located in the cellular nucleus. From these, 22 are autosomal chromosomes
(i.e. chromosomes 1 to 22), and the remaining two chromosomes are the sex chromosome
pair (XX in women and XY in men). In addition to these 23 chromosome pairs, the human
genetic information consists also of mitochondrial chromosomes that are located in the mi-
tochondria. Mitochondrial chromosomes are circular (∼16,600 bps), and are only inherited
from the mother.
The Human Genome Project (HGP)32 was crucial for the characterization of the human
genome sequence. This project took place between 1990 and 2003, and involved a large
effort of multiple public research centres to complete the human DNA sequence33. In paral-
lel, a similar, privately funded project was also performed by the company Celera Genomics,
created by the biology researcher Craig Venter34. Once merged, both datasets constituted
the first reference sequence of the human genome, clearly one of the major achievements
of science.
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The DNA sequence of an individual provides its genetic information and influences the reg-
ulation and development of the organism. The DNA sequence contains the information
required to synthesize ribonucleic acid (RNA) and protein molecules, which perform and
regulate all the cellular functions that, at a higher organizational level, provide functionality
to the tissues and organs of an individual. DNA molecules are composed of two nucleotide
strands that form a double helix (Figure 1.2). Nucleotides are the base units of DNA, and
are made up of a sugar, a phosphate group and one of the four following nitrogenous bases:
adenine (A), thymine (T), guanine (G) or cytosine (C). Nitrogenous bases characterize the
genomic information that provides each nucleotide which, in turn, characterizes the DNA
sequence of an organism. Both DNA strands are bound together by hydrogen bonds, which
occur between each base on one strand and its complementary on the other strand. Only
two combinations of nitrogenous bases can be bound together by hydrogen bonds: adenine-
thymine (2 H bonds) and cytosine-guanine (3 H bonds). Therefore, the nucleotide sequence
of one strand automatically determines the sequence of the complementary strand.
Figure 1.2: DNA molecule. DNA structuctural units: sugar (S), phosphate group (P)
and nitrogenous base. Nucleotides of the same strand bind together by phosphodiester
bonds while both strands bind together by hydrogen bonds. As shown in the figure,
hydrogen bonds determine the specificity of base pairing: adenine-thymine (2 H bonds)
or cytosine-guanine (3 H bonds) nucleotides. Source: Pray L et al35.
Genes are defined as segments of the genome that are copied into ribonucleic acid (RNA)
molecules. This biochemical process is performed by RNA polymerase enzymes and is
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known as transcription (Figure 1.3). Messenger RNA molecules (mRNAs) are the group
of RNAs that provides the information to synthesize proteins through the process called
translation (Figure 1.3). mRNA translation occurs in the ribosome, a complex molecular
structure made of (ribosomal)RNA and proteins. Ribosomes build up proteins by translat-
ing groups of three consecutive nucleotides (i.e. codons) into specific amino acids, a unique
relation known as the genetic code. Together, transcription and translation are known as
the central dogma of biology, and its discovery lead to the still ongoing biotechnological
revolution.
To date, more than 20,000 protein-coding genes have been described in the human genome36;37.
The structural units that compose genes are (Figure 1.3):
• Exons: The nucleotide sequences of the gene that will be translated into an amino-acid
sequence by ribosomes.
• Introns: DNA sequences that are copied into mRNA molecules but are not translated
into amino-acids. These regions are placed between exons and are removed from the
RNA molecule through a biochemical cut-and-paste process known as splicing.
Exons only comprise 2.8% of the human genomic DNA. The remaining genomic sequence
is categorized as intronic (42.3%) or intergenic (54.9%)39. Although intronic and inter-
genic regions do not code for proteins, they have increasingly shown to be crucial for the
regulation of genetic activity in cells:
• Non-coding RNA: RNA segments that are transcribed but not translated. This type of
RNA includes long and small non coding RNAs. Non-coding RNAs have a wide range
of functions such as gene expression regulation (Figure 1.4)40.
• Regulatory elements: DNA sequences that are the binding sites of proteins that control
the rate of transcription of genetic information from DNA to mRNA (i.e. transcription
factors)39. The most abundant regulatory elements in the genome are promoters,
enhancers and silencers. Promoters are sequences immediately adjacent to the be-
ginning of the gene (cis-regulatory elements), while enhancers and silencers are gene
expression regulation sequences that can act on distant genomic locations or even in
different chromosomes (trans-regulatory elements).
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Figure 1.3: Structural organization of the genome and transcription/translation
processes. In transcription, the DNA sequence is copied to the mRNA molecule. Non
coding regions (introns) are further removed, and exons are then assembled (splicing).
The resulting mRNA molecule is then translated into an amino-acid sequence that will
lead to an active protein. Source: Hiller S et al38.
1.2.2 Human genome variation
The DNA sequence of the human genome is different between individuals. These differences
in sequence are known as genomic or genetic variants, and are major contributors to the
phenotipic variability observed in humans, including the risk to develop a certain disease.
From a classical genetics point of view, human diseases can be grouped into two groups:
mendelian diseases and complex diseases. Mendelian diseases are diseases caused by a
single, highly penetrant mutation, and are characterized by clear inheritance patterns within
families. Complex diseases, instead, are caused by the aggregated effect of multiple genetic
variants and their interaction with different environmental factors (Figure 1.5).
Single nucleotide polymorphisms
A SNP is a single DNA basepair variation, where two or more different nucleotides can be
observed within a given population. Like any other DNA polymorphism, the set of observed
nucleotides in a SNP are called alleles. Figure 1.6 shows an example of this type of variation
where the two observed SNP alleles correspond to a cytosine (C) and a guanine (G). In most
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Figure 1.4: Non-coding RNAs. Types of non-coding RNAs. Source: Quintal A et
al40.
Figure 1.5: Spectrum of genetic mutations and variations. Mendelian mutations
are rare and highly penetrant for an inherited disorder. Conversely, common genetic
variants confer a much smaller risk for the phenotype, and interact with other genetic
variants and environmental factors to produce complex diseases.
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SNPs only two alleles are identified and therefore, they are generally considered biallelic.
Given that the human genome is diploid (i.e. there are two copies of each chromosome),
three possible allele combinations (genotypes) can be observed in a single individual. For
the previous case, the three possible genotypes are two homozygotes (CC and GG individu-
als) and one heterozygote (CG or GC individuals).
Alele 2    Guanine (G)
Alele 1    Citosine(C)
Figure 1.6: Single nucleotide polymorphism. The left panel shows the two sequence
variants (alleles) at a single DNA basepair. The right panel shows how these two alleles
lead to three genotype possibilities in diploid organisms. The alleles are generally called
according to the positive DNA strand.
A SNP is defined by its physical position in the chromosome (i.e. basepair) and by its al-
leles. Depending on the frequency of each allele in a given population, SNP alleles are
referred as the minor or major alleles. The information of the allele frequencies of one SNP
is usually reported using only the minor allele frequency (MAF). SNPs are relevant for the
study of the genetic basis of human diseases since they are highly abundant in the human
genome (approximately 1 SNP every 100-200 bps). The reference SNP database (dbSNP,
www.ncbi.nlm.nih.gov/ snp) maintained by the National Center for Biotechnology Informa-
tion (NCBI, USA) stores information about a total of 116 million human SNPs (dbSNP Build
142; Figure 1.7). From these, 47.6 million SNPs (41.0%) are located in coding regions, 45.4
million in introns (39.1%) and 2.2 million in exons (1.9%). According to their functional
impact, exon SNPs are classified into three main categories:
• Synonymous SNPs if they do not lead to a change in the amino-acid sequence of the
resulting protein.
• Non-synonymous missense SNPs if they lead to an amino-acid change in the resulting
protein.
• Non-synonymous nonsense SNPs if they lead to a gain or a loss of a stop codon that
produces a shortened or elongated version of the protein, respectively.
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Figure 1.7: SNP properties as described in NCBI dbSNP database. This fig-
ure shows an example of the data that characterizes one particular SNP (i.e. SNP
rs1950902). The upper panel (A) provides information about the SNP alleles and their
corresponding MAFs. The second panel (B) gives the SNP position within the genome
and the third panel (C) shows the genomic context of the SNP. In this example, the third
panel shows how the SNP is located in the coding region of MTHFD1 gene. Finally, the
fourth panel (D) gives information about the allelic and genotypic frequencies of the
SNP in different reference populations.
Structural variants
In addition to SNPs, structural variants are also a common source of genetic variability
in the human genome41. When multiple human genomes are compared, the number of
basepair differences due to structural variation are higher than those due to single basepair
mutations26–30;42. Structural variants are ubiquitous in the human genome, and have been
associated to the development of Mendelian as well as complex diseases43;44.
Structural variants can be classified into three categories (Figure 1.8):
• Copy number variants (CNVs): This type of variation is characterized by gains or
losses of long DNA sequences (from 100 bps up to thousands of bps). There exist
three CNV types:
– Deletions: Loss of a DNA segment with regard to the reference genome.
– Amplifications: Gain of one or more copies of a DNA segment with regard to the
reference genome.
11
Chapter 1 Section 1.2
– Insertions: A new DNA segment that is not present in the reference genome is
added to the DNA sequence.
• Tandem repeats: DNA segments characterized by the adjacent repetition of two or
more nucleotides. Tandem repeats can be classified into microsatellites (repeated
motif < 10 bps) or minisatellites (repeated motif > 10 bps).
• InDel: Similar to CNVs, they refer to gains or losses of DNA segments, but affecting a
much shorter sequence of DNA (< 100 bps).
• Inversions: Chromosomal rearrangements where a DNA sequence is reversed in the
chromosome. The inversion sizes can range from tens to millions of basepairs45.
Figure 1.8: Structural variations. This figure shows the different structural varia-
tions that can be found in the genome. The arrows show the differences between the
reference and alternative alleles.
1.2.3 Linkage disequilibrium and genotyping microarrays
The alleles that lie close in a chromosome sequence tend to be inherited together more
often than distant alleles or alleles in different chromosomes46. The origin of this allele
correlation, or linkage disequilibrium (LD), is the DNA recombination that takes place dur-
ing cell meiosis. During gametogenesis, the chromosome pairs of each parent are mixed
(i.e. chromosomal recombination), leading to new chromosome sequences. This stage of
the reproductive process is crucial in increasing the genetic diversity of the next generation
of individuals. Recombination occurs at random in the chromosome, although in certain
regions, called hotspots, the probability is much higher47. Consequently, the closer two al-
leles are in a chromosome, the lower the probability that a recombination event will occur,
and therefore, the higher the probability they will be inherited together. These groups of
highly correlated alleles are also known as haplotypes48. Over multiple generations, the
original haplotype block will be shortened by successive recombination events (Figure 1.9).
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Consequently, only alleles that are very close together will have strong LD. LD is a powerful
statistical measure that can be used to determine the time at which a certain mutation ap-
peared and to study the genetic history of populations, including processes of negative and
positive selection.
Although several different LD measures have been described (D, D’, LOD)49, r2 is the most
commonly used measure to define LD in genomic studies. r2, also known as correlation
coefficient, ranges from 0 to 1. When r2 = 1 the two SNPs are in perfect LD (the genotype
of one of the SNPs can be perfectly predicted based on the genotype at the other SNP).
Figure 1.9: DNA recombination. This figure shows DNA recombination over suc-
cessive generations leading to shorter haplotype blocks. Source: www.emory.edu.
Importantly, LD patterns in the human genome can be exploited to enable genetic associa-
tion studies at the genome-wide scale. Although there are more than 40 millions of SNPs,
the correlation patterns existing between these markers (i.e. haplotype blocks) allow the
use of indirect analysis approaches. That is, for a certain LD block, it is not necessary to
genotype all SNPs in this region to detect an association with a trait, since all variants are
highly correlated, and the information can be captured by one or few SNPs (Figure 1.10)50.
These SNPs, known as tagSNPs, are the basis of most published genetic studies in complex
diseases and of all Genome-Wide Assciation Studies (GWAS). The International HapMap
project (www.hapmap.org51) is an international collaboration project, that was created to
characterize the main LD patterns present in the human genome, in order to enable large-
scale genetic studies of human traits52. The data released by the HapMap project was crucial
for the design genotyping microarrays. With only 500,000 selected markers, microarrays
are able to capture most of the common genetic variation in the human genome.
More recently, the 1000 Genomes Project (1KGP, www.1000genomes.org)53 has incorpo-
rated the new generation of sequencing technologies (i.e. Next-Gen), to produce genome-
wide sequencing data for more than 2,000 individuals. This international collaboration
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project, has therefore provided therefore an even more exhaustive mapping of the LD pat-
terns in multiple populations, as well as including less frequent genetic variants (1% < MAF
< 5%).
Figure 1.10: TagSNPs and linkage disequilibrium. This figure shows the corre-
lation patterns (i.e. LD) between adjacent SNPs. The identified haplotypes based on
these correlations are enclosed in black triangles. By selecting a reduced number of
SNPs (tagSNPs -underlined in red-) of each haplotype, most of the genetic variation
information in a genomic region can be captured.
The optimization criterion of tagSNP selection is the maximization of genomic coverage,
defined as the number of SNPs that are in high LD (i.e. r2 > 0.8) with any of the selected
tagSNPs (Figure 1.11). Since LD patterns highly depend on the studied population, the se-
lection of tagSNPs and the resulting genomic coverage might vary according to the analyzed
population.
To date, microarray genotyping platforms can genotype millions of SNPs for each individual.
The increasing drop in the costs of these genotyping technologies, has contributed to the
explosion of GWAS of human traits.
High-density genotyping microarrays have been commercialized by several companies like
Perlegen54, Affymetrix55 or Illumina56. Here we will focus on the Infinium-based beadchips
developed by Illumina (Palo Alto, California, USA). Due to its superior quality and cover-
age57, Illumina microarrays have been the platform of choice in most published GWAS in
human traits (>70%). Also, Illumina was the genotyping platform of choice used in the
IMID-Kit project (Figure 1.12).
The Illumina Infinium assays allow the multiplexed genotyping from 100,000 to 5,000,000
SNPs. Although the first microarray platforms were only based on common SNPs (MAF>5%),
the most recent microarrays have incorporated the knowledge generated by the 1KGP to
extend their coverage to more uncommon SNPs (2.5%<MAF<5%). As an example, the
Omni1-Quad microarray provides genotyping on 1,138,747 markers and covers 94%, 93%
and 78% of the common variation (MAF>5%) within the CEU (Utah residents of northern
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Figure 1.11: Genomic coverage. Comparison of the genomic coverage of multiple
genotyping microarrays. An accurate selection of the tagSNPs allows to greatly increase
the genomic coverage compared to a randomly selected set of SNPs. Max r2 refers to the
minimum LD with a tagSNP required to count a SNP as covered. Source: www.illumina.
com.
Figure 1.12: Illumina BeadChip microarrays. This figure shows the design and
evolution of Illumina genotyping platforms: from the HumanHap300 that included
317,000 probes to the HumanOmni1-Quad that included probes targeting >1,000,000
different polymorphisms. Source: www.illumina.com.
and western European ancestry), CHB+JPT (combined panel of Han Chinese from Beijing
and Japanese from Tokyo) and YRI (Yoruba from Ibadan -Nigeria-) populations, respectively.
The genotyping process of the Infinium assays is summarized as follows (Figure 1.13):
• Isolation and amplification: The genomic DNA from each individual sample is isolated
(250-700 nanograms), amplified (x 1,000-3,000) and fragmented58.
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Figure 1.13: Infinium assay. (A) Genotyping microarray; (B) Silica beads where
the DNA probes are fixed. Each SNP will have a probe pair, which will bind to each
of the two possible alleles; (C) Hybridization of probes to their corresponding SNP al-
leles; (D) Nucleotide expansion of the bound probe to generate a specific fluorescent
signal; (E) Probes bound to their corresponding alleles are scanned to detect the pres-
ence of each allele; (F) Finally, a genotyping algorithm used the observed fluorescent
patterns from the probe pairs of multiple individuals to assign the corresponding geno-
types. Source:www.illumina.com.
• Hybridization: The Illumina Infinium microarrays are designed with silica beads where
the assay DNA probes are fixed (Figure 1.13B). The probes are 50 bp long and are de-
signed to be complementary to the sequences of each SNP allele (i.e. two probes per
SNP) (Figure 1.13C).
• Enzymatic simple base extension: After the target DNA segment is hybridized with
the probe, the sequence is extended by a DNA polymerase enzyme with the use of la-
beled dideoxynucleotides (Figure 1.13C). Once linked to the primer, these dideoxynu-
cleotides act as chain finishers and DNA polymerase stops adding nucleotides. The
dideoxynucleotides corresponding to each one of the SNP alleles are labeled with dif-
ferent fluorochromes, thereby allowing the identification of each different allele with
the use of high resolution scanners (Figure 1.13E).
• Genotype calling: The fluorescence at each probe pair generates different intensity
clusters, according to the SNP genotype of each individual. Genotyping algorithms
apply clustering methods to analyze at the same time the intensity data generated from
multiple samples. The fluorescence intensities of each channel (i.e. defined as X and
Y channels that correspond to each one of the SNP alleles) are processed to model the
corresponding clusters of each one of the three possible SNP genotypes (Figure 1.13F).
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SNP clusters are characterized by the ratio between the intensities of both channels:
IX > IY homozygote samples for the first SNP allele, IX < IY homozygote samples for
the second SNP allele and IX ' IY heterozygote samples. Additionally, the intensity
data can also be used for CNV genotyping. If a probe targets a CNV, the variation
in the number of copies of the DNA segment leads to an increase or decrease of the
measured fluorescent intensities. Consequently, samples will also cluster at the total
intensity level depending on the total number of copies they carry.
1.2.4 Genome-wide association studies
GWASs are based on the simultaneous analysis of thousands of SNPs to identify genetic loci
associated to a trait of interest (Figure 1.14). During the last decade, GWASs have been
highly successful in the identification of new biological pathways associated to the risk to
develop diseases19. Despite its enormous potential, one crucial aspect for the success of
GWAS in common complex diseases, is the accurate phenotype definition and selective col-
lection of the genotyped individuals. Only with well-defined patient (and control) cohorts,
it is possible to characterize the genetic architecture of human diseases. The identification
of disease risk loci by GWAS has had two major impacts in medicine: first, the use of genetic
testing to predict disease outcomes or to guide disease therapy and, second, the identifica-
tion of new biological mechanisms associated with disease physiopathology that can lead
to the development of new, more efficient, drugs19;57.
There are two main types of GWAS designs: family-based and population-based studies.
The former is based in the analysis of related individuals such as parent-offspring trios60.
Most of the methods for analyzing family-based data use the transmission of alleles to the
offspring to assess the evidence of genetic association60. Conversely, in population-based
studies a large cohort of unrelated individuals is genotyped, and the distribution of allelic
frequencies according to the phenotypic variable is used to assess genetic association (Fig-
ure 1.15). Although family-based studies are robust against spurious associations due to
ethnicity, admixture or population stratification61, population-based studies can be more
powerful to identify risk variants since, generally, much larger samples of individuals can
be collected62;63. To date, most published GWAS are population-based60.
GWASs can be used to analyze two primary classes of phenotypes, either quantitative or
categorical. Quantitative traits are usually preferred since they can have more statistical
power to detect genetic effects65, and respond to the polygenic nature of common and
complex diseases. In many occasions, however, quantitative traits are not available. In
this case, individuals are usually classified as affected or unaffected, and analyzed using
a case-control design57. The association of each SNP to the studied trait can be analyzed
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Figure 1.14: Genome-wide association studies. GWAS studies are commonly per-
formed in two stages. During the study design stage, the phenotypes of interest are
defined, as well as the potential confounding variables (i.e. ethnicity, sex and smoking
behaviour). The individuals of the selected cohort are then genotyped using genotyping
microarrays. The resulting genotyping data is subsequently used to perform the sta-
tistical tests for each genomic variant. Once the regions in the genome that are more
significantly associated with the trait of interest are identified, they are tested in an inde-
pendent (validation) cohort. The replication step ensures that the observed association
in the discovery stage is not a false positive. Finally, the functional impact of the associ-
ated genomic variants may be further studied to explain how these variants are linked
to the studied phenotype. Source: Adapted from Kingsmore S et al59.
Figure 1.15: Population-based and family-based GWAS design. Family-based
designs are based on the co-segregation of alleles and a trait within a family, while
population-based designs are based on the differences in allele frequencies according to
the studied phenotype (i.e. case-control). Source: Adapted from Dick D et al64.
under different genetic association models. Each model implies different assumptions on
how the different variant alleles contribute to the risk (i.e. recessive, dominant, genotypic,
and allelic; Figure 1.16)66;67. The statistical tests used to analyze the association between
genetic variants and different traits will depend on the phenotype class: quantitative traits
are usually analyzed using linear regression or Analysis of Variance, while categorical or
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binary traits are usually analyzed using contingency table analysis methods (e.g. chi-square
test) or logistic regression57;67.
Figure 1.16: Genetic association models. This figure shows an example of the
distribution of genotypic and allelic data from a SNP (rs7903146) in the control and
case groups of a Type 2 Diabetes GWAS68. Between the genetic models tested, the
recessive model obtains the largest significance. Source: Barcelos G et al68.
In addition to the selection of the most appropriate genetic model of association and the
statistical analysis test, another important consideration in GWAS analysis is the multiple
testing problem (Figure 1.17). GWAS involve the analysis of thousands to millions of SNP
tests and, therefore, the probability of finding a statistically significant result by chance (i.e.,
false positive) is very high.
Several methods have been proposed to adjust for multiple testing in GWAS: Bonferroni and
Sidak corrections are simple methods that adjust for multiple testing, permutation testing
has been established as a gold standard for correcting association values67. Nevertheless,
the scientific community has increasingly acccepted α= 5·10−8 as a genome-wide threshold
for statistical significance in GWAS67;69. This means that all SNPs in a GWAS that show a
P-Value lower than α = 5 · 10−8 can be considered robust genetic associations to the trait
of interest.
In the typical GWAS approach, the set of SNPs that are selected for replication depend on
the level of statistical significance in the genome-wide analysis stage. However, recent ap-
proaches also consider SNPs with significance association values under the genome-wide
level of significance. These GWAS prioritization approaches70;71 use scoring methods that
also integrate the information of biological pathways and the functional role and other bi-
ological features of the variants.
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Figure 1.17: Manhattan plot. This type of graphic representation is usually used
to show the association results in GWASs. In this figure, each point represents a genetic
variant. The variants are plotted according to their genomic position (bp in the chromo-
some, each color represents a different chromosome) and the y-axis shows their level of
statistical association to the studied trait (−log10(P − Value)).
1.2.5 Genotyping algorithms
SNP genotyping algorithms
There are a large number of methods available to process microarray intensities and infer
the genotypes of each SNP in a given set of samples (Figure 1.18). Three of the most
commonly used algorithms in Illumina microarrays are GenCall72, GenoSNP73 and M374.
These algorithms use the intensities of X and Y channels generated by the microarray for
each SNP assay and each sample. The main differences in the genotyping algorithms are
based on the intensity normalization procedure and on the type of models used for genotype
clustering (Figure1.18).
• GenCall72: GenCall is the genotyping method provided by the microarray manufac-
turer (Illumina). In this method, intensities are normalized using an affine transfor-
mation that rotates and scales channel X and Y intensities reducing channel cross-
correlation75. This normalization procedure is performed separately for each bead
pool. Bead pools are assay groups that have been built together and are also located
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Figure 1.18: SNP genotyping. This figure shows the intensities generated by one
SNP assay using Cartesian (left) and polar (right) coordinates. Each point corresponds
to one sample and represents the measured intensities for each allele. The objective of
genotyping algorithms is to identify the clusters corresponding to each genotype (AA, AB
and BB). These clusters are mainly characterized by the intensity ratio between channels
A and B (i.e. polar coordinate θ).
close together in the BeadChip and therefore, they require specific normalizations.
Normalized intensities are then transformed to polar coordinates (R and θ) to per-
form the clustering. Using default centroid positions predefined for each assay and
a neural networks algorithm, this method re-estimates the centroids of each cluster
based on the data available for each probe and assigns a genotype to each sample
based on the new cluster estimates.
• GenoSNP73: This genotyping method (University of Oxford, USA) is characterized
by using a sample-based clustering, where each sample is independently genotyped
using the information of all the available assays. For each sample, GenoSNP first
normalizes X and Y intensities by each bead pool. Once normalized, it fits a four-
component mixture model to the log-transformed intensities. This model jointly fits
all the intensities coming from assays of the same bead pool.
• M374: This method (Yale University, USA) is a two-stage genotyping algorithm. First,
it uses an assay-based approach that fits the genotype clusters of each assay. Second,
it identifies subsets of SNPs with low MAFs (i.e. <0.05) and low genotyping quality
scores to improve their genotyping. To improve the cluster definition of these SNPs,
M3 usesthe reference clusters of high-quality SNPs with similar intensity distributions
as a prior cluster model for the low-quality SNPs.
CNV genotyping algorithms
While SNP genotyping is based on clustering at the intensity ratio level (IA > IB → AA,
IB > IA → BB and IA ' IB → AB), CNV genotyping is based on differences at the global
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Figure 1.19: SNP genotyping methods. (A) Polar intensities of one assay where each
point corresponds to one sample. GenCall assigns a genotype (i.e. color coded) using
neural networks and prior knowledge. (B) Log-normalized intensities used by GenoSNP.
The points correspond to different probes located in the same bead pool and refer to only
one sample. (C) Re-genotyped SNP (blue) using information from a reference SNP (red)
in M3 method.
intensity level. The global intensity level measured by the microarray is proportional to the
number of DNA copies.
Two of the most commonly used algorithms for CNV genotyping using Illumina microarrays
are PennCNV76 and QuantiSNP77. Both methods use sample-based approaches that analyze
the changes in total intensity measurements across adjacent genomic assays. These methods
use two features that summarize sample intensities in relation to a reference status. These
features are derived from the polar coordinates R and θ computed from the corresponding
Cartesian coordinates IA and IB (Figure 1.20):
• Log R Ratio: To compute this feature, a regression line is fitted through the centroids
of the three SNP genotyping clusters. This line provides the expected value of R (eRn)
given a θn value. The Log R Ratio is defined as the logarithm of the ratio between
the measured and the expected R values: LogRR = log RneRn . Since the most common
state (i.e. reference) is 2 copies (i.e. diploid), hemizygous deletions (i.e. 1 copy) are
expected to have LogRR = log 0.5
eRneRn = −1 and amplifications (i.e. 3 copies) LogRR =
log 1.5
eRneRn = 0.60.
• Allelic intensity ratio: The θ values corresponding to the centroid of each SNP geno-
typing cluster are assigned to 0, 0.5 and 1. From these values, the θn values of each
sample are interpolated within the range [0,1].
Using Log R Ratio and allelic intensity ratio, PennCNV and QuantiSNP apply hidden Markov
models (HMMs) to stratify genomic segments according to their estimated number of copies.
The HMMs model assumes that the observed intensities are related with an unknown copy
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Figure 1.20: Allelic frequency and LogRratio. (A) The logRratio compares the
observed intensity (Rsubject) of the sample to the expected intensity (Rexpected; gray
dot) based on the observed allelic ratio. (B) The genotype clusters (circles) are used to
convert θ values to B allele frequency. Source: Peiffer D et al75.
Figure 1.21: CNV detection. This figure shows the expected LogRratio and allelic
frequency values expected in the case of deletion (A) and amplification (B). Using this
data (upper panels) the algorithms compute the number of copies per sample (lower
panels). Source: Colella S et al77.
number state through emission distributions. HMMs also assume that the number of copies
in a single assay is highly correlated with adjacent assays (Figure 1.21).
Both PennCNV and QuantiSNP are based on a per-sample approach and use summarized
measurements relative to a reference set of samples. This type of approach has proven to
work well to genotype large CNVs. However, this approach is highly inefficient at identi-
fying short size CNVs. Also, these two approaches do not use the information generated
by the simultaneous analysis of multiple individuals, leading to high false negative rates,
particularly with small CNVs78. Therefore, there is a need for new methods that can use the
information generated by considering all samples together in order to improve the detection
of small CNVs in GWAS.
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1.3 Metabolomics
Note: Some sections of this chapter have been extracted from the article (Appendix D.1):
A. Alonso, S. Marsal and A. Julià. Analytical methods in untargeted metabolomics: state
of the art in 2015. Front. Bioeng. Biotechnol, 2015, 3:23.
DOI: 10.3389/fbioe.2015.00023.
Metabolites are the intermediates and end products of multiple enzymatic reactions and,
therefore, they are the most informative proxies of the biochemical activity in an organism.
Metabolomics is the study of the metabolite composition of a cell type, tissue, or biological
fluid. To date, metabolomics is one of the "omics" approaches that is most contributing to
the progress of challenging research areas like the personalization of treatments in medical
practice.
The current metabolomic analysis technologies have enabled the characterization of the
complete set of metabolites - the metabolome- in multiple types of biological samples79.
These applications cover diverse research areas like plant biology80, nutrition81;82, animal
breeding83, drug discovery84;85, and the study of human diseases86;87. The biomedical field
is actually one of the most active areas of development in metabolomics, and includes
the search for diagnostic and prognostic biomarkers as well as predictors of treatment re-
sponse88–90.
To date, the two main technical approaches for the generation of metabolomic data are nu-
clear magnetic resonance (NMR) and mass spectrometry (MS;91). NMR is a fast and highly
reproducible spectroscopic technique that is based on the energy absorption and re-emission
of the atom nuclei of the sample molecules due to variations in an external magnetic field
(Figure 1.22)92. Depending on the atom nuclei being targeted by the applied magnetic
field, different types of metabolomic data are generated. In biomedical studies, hydrogen is
the most commonly targeted nucleus (1H-NMR), due to its natural abundance in biological
samples. Although less frequent, other atoms like carbon (13C-NMR) and phosphorus (31P-
NMR) are also targeted by NMR, providing additional information on specific metabolite
types93.
The resulting spectral data in NMR not only allows the quantification of the concentration
of metabolites, but it also provides information about its chemical structure. The spectral
peak areas generated by each molecule are used as an indirect measure of the quantity of the
metabolite in the sample whereas the pattern of spectral peaks generated by the molecule
is used to identify the type of metabolite. The spectral data obtained with NMR techniques
can be one dimensional or two dimensional. One dimensional NMR (1D-NMR) spectra
are based on a single frequency axis, where the peaks of each molecule are placed within
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Figure 1.22: Nuclear magnetic resonance. The NMR spectral acquisition is based
on the behavior of the molecule spin under magnetic field variations. First, a constant
magnetic field is applied to the sample, aligning the spins of all their molecules (i.e. step
1). The next step consists of applying a RF pulse to generate an interfering magnetic
field which temporary misalign the molecules’ spins (i.e. step 2). Once the interfering
magnetic field disappears (i.e. step 3), the molecules’ spins relax back to their original
alignment. This spin relaxation results in a signal, FID, which can be measured and, after
applying on the FT, is transformed on a peak spectrum where each peak is characterized
by its amplitude (vertical axis) and its chemical shift (horizontal axis). The latter is
usually measured in ppm and refers to the difference between the resonance frequency
and that of a reference substance divided by the frequency of the spectrometer.
FID: Free induction decay; NMR: Nuclear magnetic resonance; ppm: Parts per million;
RF: Radio frequency; FT: Fourier transform.
its resonant frequencies (Figure 1.23)94. 1D-NMR is the most commonly used method in
high-throughput metabolomics studies. Two dimensional NMR (2D-NMR) spectra are based
on two frequency axis, and its use is generally restricted to the characterization of those
compounds that cannot be directly identified with 1D-NMR spectra. The second dimension
in 2D-NMR improves peak separation and gives additional and important information on
the chemical properties of the metabolite95. 1D- and 2D-NMR frequency axes are usually
referenced by the chemical shift expressed in parts per million (ppm). The chemical shift
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is calculated as the difference between the resonance frequency and that of a reference
substance, subsequently divided by the operating frequency of the spectrometer96.
Figure 1.23: Examples of spectra obtained with 1H-NMR and LC-MS technologies.
(A) An example of three spectra obtained with 1D 1H-NMR. (B) A zoomed view of
the spectra in (A) in the 2.66-2.74 ppm range. (C) An example of a LC-MS spectrum
with color-coded intensity and referred by the m/z and retention time axes. (D) The
sum of the LC-MS spectrum across the m/z axis. (E) The total ion chromatogram (i.e.
sum of the LC-MS spectrum across the retention time axis). The colored regions in (E)
correspond to the sum of the LC-MS spectrum limited to the m/z ranges depicted with
the same color in (D).
Untargeted metabolomic studies are characterized by the simultaneous measurement of a
large number of metabolites from each sample. This strategy, known as a top-down ap-
proach, avoids the need to define a prior specific hypothesis on a particular set of metabo-
lites and, instead, analyses the global metabolomic profile. Consequently, these studies are
characterized by the generation of large amounts of data. This data is not only characterized
by its volume but also by its complexity and, therefore, there is a need for high performance
bioinformatic tools that can efficiently extract and analyze the relevant biological informa-
tion.
Figure 1.24 shows the prototypic methodological pipeline of an untargeted metabolomic
study. This methodological pipeline starts with the processing of the spectral data to gen-
erate the sample metabolic information (i.e. metabolic features). The different methods
available to process spectral data are revised in subsection 1.3.1. Together with metabolite-
identification methods, spectral processing methods are highly dependent on the analytical
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technique used (e.g., NMR, LC-MS, or GC-MS). Once the complete set of metabolomic fea-
tures has been generated, univariant and multivariant data analysis methods can be then
applied to investigate: (a) the general structure of the metabolomics data in the dataset
and (b) how the different metabolic features are related with the phenotypic data associ-
ated with the samples. In subsection 1.3.2 we address the important technical issue that is
the identification of the metabolites underlying the observed metabolic features (i.e. peak
areas and spectral bins).
Figure 1.24: Analysis workflow in untargeted metabolomic studies. This figure
shows the different steps of the metabolomic analysis pipeline. FOCUS, the bioinfor-
matics tool developed during this Doctoral Thesis covers both Spectral processing and
Metabolite identification steps.
1.3.1 Spectral Processing
Spectral processing is a methodological approach that intends to accurately identify and
quantify the features in the sample spectra of a metabolomics study (Figure 1.25). In high-
throughput metabolomics studies, spectra are sequentially or jointly processed to obtain
a final set of feature quantifications. Spectral processing is also necessary to ensure that
each final measurement will refer to the same metabolite in all samples. The data resulting
from spectral processing is generally arranged in a feature quantification matrix (FQM) that
contains the quantification of the metabolic features of all the analyzed samples, and that
will be used as input for subsequent statistical analysis.
Spectral Pre-Processing
In order to improve the signal quality and reduce possible biases present in the raw data,
several pre-processing steps are usually applied. In NMR-based spectra, baseline correc-
tion is used to remove low frequency artifacts and differences between samples that are
generated by experimental and instrumental variation97–100. After this, the application of
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Figure 1.25: Features of spectral data. This figure shows the three different types
of features that can be extracted from spectral data and used for data analysis. First, sta-
tistical analysis can be performed using all the data points of the spectrum (i.e. spectral
intensity data); second, integrating evenly spaced regions of the spectrum (i.e. spec-
tral bins) and, third, automatically detecting the spectral peaks and integrating their
corresponding areas.
high-frequency filters may be necessary to remove the electronic noise present in the data
that is generated by the measurement equipment101.
Feature-Detection
The objective of the feature-detection step is to identify and quantify the features present
in the spectra. Peak-based methods detect the peaks across the spectrum and integrate
their areas to provide a quantification of the underlying metabolite102–104. In this approach,
spectral alignment is also generally applied either before or after peak detection. In NMR
studies, binning-based approaches have been commonly used to detect feature peaks in
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complex biological samples105. However, these methods perform poorly compared to peak-
based methods, particularly in those cases where there is significant spectral unalignment,
or in those cases where multiple peaks from different metabolites are captured by the same
spectral bin106. For these reasons, peak-based methods are increasingly being used in NMR-
based studies105. Nonetheless, there have been recent developments in binning algorithms,
particularly in the detection of the optimal binning boundaries, that have improved the
performance of this feature-detection approach107.
Peak overlap is also a common problem in NMR-based studies. Overlapping peaks are
treated as one same feature both in binning and peak-based approaches108. Consequently,
the results obtained from the analysis of these variables can be often hard to interpret since
the contribution of each peak to the total area is unknown. In order to attempt to solve this
problem, spectral deconvolution methods have been developed109. These methods, which
are based on the fitting to metabolite spectral templates, are able to extract independent
metabolite quantifications from a set of overlapping peaks. The main disadvantage of this
type of algorithms, however, is that they depend on the existence of spectral libraries of
each metabolite and, therefore, they are unable to quantify peaks arising from previously
uncharacterized metabolites.
Two main procedures are performed for feature detection: peak detection and spectral align-
ment.
• Peak detection: The most commonly used peak detection algorithms analyze each
sample spectrum independently110–112. These methods are based on two analytical
steps113. In the first step, the spectra are smoothed. For this objective, multiple differ-
ent filters are available (i.e. moving average, Gaussian, Savitzky-Golay...;113). From
these, the Wavelet transform-based filters have demonstrated a superior performance,
although at the expense of a higher computation time110;114. The performance im-
provement is mainly due to the ability of the Wavelet transform to work with unequal
peak widths, which are characteristic of metabolomic spectra. In the second step, the
different metabolite peaks are identified using one or multiple detection thresholds.
These thresholds are applied to different parameters such as the signal-to-noise ra-
tio, the intensity, or the area of each peak from the resulting filtered spectra113. In
metabolomics studies involving large numbers of samples, a frequency filter (i.e. con-
sensus peak signal), can be also applied so that only those peaks that are present in a
minimum percentage of samples are selected for downstream analysis.
• Spectral alignment: Spectral alignment is one of the main processing steps in
metabolomic studies involving multiple samples. When analyzing multiple spectra,
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the position of the peaks corresponding to the same metabolic feature may be affected
by non-linear shifts. In NMR-based studies, these shifts are observed in the ppm axis
and are usually introduced by differences in the chemical environment of the sam-
ple like ionic strength, pH, or protein content108;115. In MS-based studies, peak shifts
are mainly observed across the retention time axis, and are generally associated with
changes in the stationary phase of the chromatographic column116. Spectral align-
ment methods must be therefore applied to correct this undesired variability in the
samples that can profoundly affect the quality of the study. Spectral alignment algo-
rithms can be divided in two main groups: (i) spectral alignment methods, where the
spectral data is aligned before peak detection and (ii) peak-based alignment methods,
where spectral peaks are aligned across samples once they have been detected using
their coordinates (ppm in NMR, and m/z and retention time in LC/GC-MS).
Spectral alignment methods are classified into warping and segmenting methods.
Warping methods are based on the application of a non-linear transformation to the
ppm (in NMR spectra) or the retention time (in LC/GC-MS) axis in order to maxi-
mize the correlation between the spectra. The alignment is then performed by ei-
ther stretching or shrinking spectral segments to reach this correlation maximization.
Among these methods, correlation optimized warping (COW) and dynamic time warp-
ing (DTW) are the most commonly used. COW is a segmental alignment method that
aligns one sample spectrum toward a reference spectrum117. This is done by split-
ting the original sample and reference spectra into small segments, and by separately
aligning each pair of segments. Alignment is performed through dynamic programing
in such a way that limited changes in segment lengths are allowed. This way, the over-
all correlation between both spectra is effectively maximized. In the particular case
of crowded spectral regions with large peak shifts, COW has demonstrated to per-
form particularly well compared to other methods. An alternative to COW method,
DTW is a spectral alignment method117 that is also based on dynamic programing, and
where a warping path is computed to which the connected data points of each spec-
trum are equivalent. During this last decade, other warping approaches have been
developed118–121.
Spectral segmenting methods differ from spectral warping methods in that alignment
is performed by applying a constant shift to all the spectral points. These methods
either align the overall spectra or split the spectra into smaller segments and inde-
pendently align each resulting segment. The Icoshift algorithm122 is one of the most
commonly used segmentation methods, and is based on the convergence toward a
reference signal. This convergence is performed by applying shifts that maximize the
segment spectral correlation, which is normally computed using the fast Fourier trans-
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form (FFT) to speed up the required calculations123. Icoshift and other correlation-
based methods can also be combined with automatic segmentation methods124, which
are able to optimally split the spectra in order to improve the alignment of the result-
ing spectral segments. However, the use of a reference spectrum has several disad-
vantages such as the fact that the reference spectrum may not be representative of
the spectral diversity present in the samples or the biases produced the presence of
multiple peaks in the same alignment window. Under these conditions, the methods
based in correlation maximization are prone to align the most relevant peak of each
sample regardless of whether they correspond to the same metabolic feature or not.
Fast Fourier transform-based segmenting methods not only are able to process large
metabolomics datasets in a reduced amount of time, but also have shown to per-
form better than spectral warping methods4;122;125;126. Within the different segment-
ing methods, reference-free methods avoid the biases introduced by using reference
spectra, but at a cost of being more computationally intensive.
Of relevance, the results reported by several performance comparison studies us-
ing either NMR or MS have demonstrated that spectral alignment algorithms have
a good performance irrespective of the analytical technique that has been used (MS
or NMR;125;127. Consequently, methods that were initially developed to align NMR
spectra are also applied to align MS spectra and vice versa.
Compared to the warping and segmentation alignment methods, peak-based methods
are applied after peak detection. In these methods, peak coordinates are used to
perform the alignment. This type of method is implemented in the XCMS software128,
one of the most commonly used methods to process data from LC-MS studies. Given
that the shifts along the m/z axis are minimal and the m/z axis has a high resolution,
the data can be safely binned in m/z intervals, and peak alignment performed on each
bin along the chromatographic time. The XCMS algorithm computes the retention
time boundaries within which the observed peaks are expected to represent the same
metabolomic feature across the different samples. The computation of these retention
time boundaries is performed by using a kernel density estimator. Another common
alignment method used in MS is the RANSAC algorithm112. In this approach, the
corresponding peaks across samples are identified by using a LOESS regression on
different retention times and m/z windows.
Feature Normalization
In order to perform an accurate quantification of the features in a metabolomic analysis, a
data normalization step is generally required. The objective of normalization is to remove
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undesired systematic biases, so that only biologically relevant differences are present in the
data. This procedure is crucial when analyzing complex biofluids like blood, where the dif-
ferences in metabolite concentration between samples can be high, and the introduction
of internal standards is complicated. Although multiple statistical models have been devel-
oped for this objective129;130, the two perhaps most commonly used methods are the use
of endogenous stable metabolites (like creatinine in urine) and the use of the total spectral
area (i.e. area under the curve (AUC);108;131).
1.3.2 Metabolite Identification and Spectral Databases
Metabolite identification is one of the major challenges of high-throughput metabolomic
analysis. This step is indispensable to providea biological significanceto the associated fea-
tures in a metabolomic study. In MS-based studies, the common metabolite-identification
approach is based on querying metabolomic databases for the neutral molecular mass val-
ues of the identified peaks using a tolerance window. The neutral molecular mass is inferred
from the peak m/z value, and depends on the chemical nature of the identified peak (i.e.
ionization mode and ionization adduct). Assuming no prior knowledge, each peak m/z
value can lead to multiple plausible neutral molecular masses that can represent different
ionization adducts (i.e. H+, Na+, K+). This multiplicity often results in a high number of
false positive identifications. In order to reduce false positives, several methods have been
developed. AStream and Camera are methods designed to identify isotopic and adduct pat-
terns in order to reduce data complexity in MS experiments132;133. The PhD student was
involved in the development of the former method before starting this thesis. Using these
approaches, the chemical nature of each selected ion peak is estimated, and only one neu-
tral mass is inferred from each identified pattern (Figure 1.26). Using these methods has
the added advantage of improving the ascertainment of true biological compounds.
In NMR-based studies, automatic metabolite identification is commonly performed by match-
ing the measured NMR peaks against a set of reference metabolite patterns. Each metabo-
lite reference spectrum is defined by one or multiple peaks, which are characterized by their
ppm positions and their relative intensities. MetaboHunter is an online tool for identifying
compounds by matching the reference peak positions against the list of detected peak po-
sitions134. However, this approach can lead to high false positive rates, since it only uses
one peak parameter to match reference peaks. The MetaboHunter approach has been su-
perseded by more recent methods based on the valid cluster concept135;136. In addition to
using the ppm position, these methods include peak intensities and inter-sample intensity
correlation as parameters for matching data peaks to reference peaks. Nevertheless, these
methods do not consider the presence of missing peaks and the bias produced by spectral
overlapping.
32
Chapter 1 Section 1.3
0 1 2 3 4
-3
-2
-1
0
1
(a) Outlier scores
Qu
an
tile
s
0.1 0.2 0.3 0.4 0.5
-6
-4
-2
0
2
4
6
(b) Quantiles
Sta
nd
ard
ize
d q
ua
nti
les
0.0 0.5 1.0 1.5
0
10
0
20
0
30
0
(c) Intensity histograms
Co
un
ts
(d) Correlation Histogram
#F
ea
tur
e p
air
s
0.70 0.75 0.80 0.85 0.90 0.95 1.00
0
10
0
20
0
30
0
(e) RT differences histogram
#fe
atu
re 
pa
irs
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0
10
0
20
0
30
0
40
0
(f) M/Z differences
0
2.5
5
7.5
1012.5
1517.52022.52527.530
32.5
35
37.5
40
42.5
45
47.5
5052.55557.56062.565
67.570
72.5
75
77.5
0.5 1 1.5 2 2.5 3
Figure 1.26: AStream output. This figure shows the first output of AStream method
when analyzing a LC-MS dataset. Panels A to C show the results of the subsequent QC
steps performed by AStream. After QC, AStream computes the intensity correlation
between each pair of peaks. The resulting distribution shows enrichment for high corre-
lation values that correspond to the presence of peaks coming from the same compound
(D). These peaks are also characterized by low retention time differences (E). Finally,
AStream identifies that peak pairs that correspond to known isotopes or adducts (F).
Metabolite spectral databases are essential for metabolite identification. The quality of the
stored data as well as the number of metabolite spectra available in these databases is critical
for the performance of identification algorithms. During the last years, multiple databases
have been developed and the number of available metabolite reference spectra is continu-
ously growing137;138. The Human Metabolome Database (HMDB) is perhaps the most exten-
sive public metabolomic spectral database to date139. The HMDB stores >40,000 different
metabolite entries, with exhaustive biological metadata and MS/NMR spectral references.
In addition to spectral databases, several studies have also contributed to characterize the
metabolome of multiple types of samples. Many of these reference studies are also ex-
ceptional resources of high quality data associated with the biofluid, tissue, or cell type of
interest105;140;141.
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34
2 | Objectives of the PhD Thesis
The present PhD thesis had two main objectives. The first objective was to improve the
bioinformatics tools available for processing and analyzing data from high-throughput ge-
nomics and metabolomics studies. Like most omics sciences, genomics and metabolomics
are rapidly evolving research areas that constantly require new methods that are able to ac-
curately extract the maximum amount of biological information out of very large and com-
plex datasets. The main aim of this PhD thesis was to develop new analytical frameworks
for these two types of omics datasets, providing advances in data integration, analytical ac-
curacy as well as including new useful functionalities. Each methodological improvement
included in this work started with a comprehensive and exhaustive evaluation of the avail-
able bioinformatics tools in order to identify their limitations. Simultaneously, the unmet
needs of the researchers using these high-throughput technologies were also identified and
taken into account when planning the development of the processing pipelines.
Achieving the objectives proposed in this PhD thesis has allowed the Rheumatology Research
Group from the Vall d’Hebron Hospital to improve the analytical power of the genomic and
metabolomic studies performed within the IMID Consortium. The IMID Consortium is a
network of more than 80 clinical departments and biomedical research groups specialized
in the characterization of the molecular basis of Immune-Mediated Inflammatory Diseases
(IMIDs) through the use of high-throughput molecular data analysis ("omics") approaches.
This biomedical consortium has been funded by the Spanish Ministry of Economy and Com-
petitiveness grants (PSE-010000-2006-6 and IPT-010000-2010-36). In these two projects,
different high-throughput molecular data has been generated on large cohorts of phenotyp-
ically well-defined IMID patients and controls. Extensive genomic (>8,000 individuals) and
metabolomic (>3,000 individuals) data has been generated using DNA genotyping microar-
ray technology and proton nuclear magnetic resonance, respectively. Importantly, the new
methodologies developed in this PhD thesis have been made publicly accessible as open-
source software tools and, therefore, the entire scientific community will be also able to
benefit from these technical advances.
The second main objective of this PhD thesis was to conduct a genome-wide association anal-
ysis (GWAS) of Crohn’s disease (CD) phenotypes. CD is the most prevalent inflammatory
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bowel disease and it is characterized by a marked heterogeneity, with patients presenting
mild symptoms to patients showing a very severe affection. To date, very little is known
about the genetic basis of phenotype heterogeneity in CD. The identification of genomic
regions associated to CD clinical phenotypes is of high relevance, since it will allow a bet-
ter understanding of the biologic mechanisms relevant for this clinical heterogeneity and
it could lead to improvements in treatment personalization and the identification of more
effective drug targets. Using the genotypic and phenotypic data of the patients included in
the IMID-Kit project, the genetic risk for each phenotype has been studied, for the first time,
using a genome-wide approach. The student has applied all the experience gained through
the development of bioinformatics tools for processing genomics data to conduct the GWAS
analysis. The interaction with the clinical specialists as well as the bioinformatics team of
the IMID-Kit project has also been crucial component of the success of this study. The results
provided by this study explain how genetic variation is associated with disease heterogene-
ity in CD, and provide an invaluable resource for the identification of the physiopathological
mechanisms underlying each phenotype.
A full description of the objectives in each thesis section is presented below.
i Development of a pipeline for SNP and CNV genotyping of Illumina microarray
data for genome-wide association studies
The main objective of this section is to develop a new SNP and CNV genotyping tool that
overcomes the shortcomings of the previous methodologies. The genotyping pipeline
will be based on the Illumina microarrays which is the most commonly used GWAS geno-
typing technology. The new algorithms implemented in this tool must provide higher
genotyping call rate and accuracy in order to increase the power of high-throughput
studies. Most CNV algorithms require multiple consecutive probes in order to provide
accurate calls. The implemented methodology should be sensitive enough to perform
CNV genotyping at the single probe level, and therefore be able to identify risk CNVs of
smaller size.
The main objectives ofthe algorithms implemented in the new genotyping pipeline were:
• To develop a new SNP genotyping method that improves the SNP genotyping
performance both in terms of genotyping call rate and genotyping accuracy.
• To develop a new CNV genotyping method that increases the CNV identification
sensitivity and improves CNV genotyping call rate and accuracy.
• To perform an exhaustive algorithm benchmarking to compare the performance
of the new SNP and CNV genotyping methods against state-of-the-art methodolo-
gies.
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• To integrate SNP and CNV genotyping in a single processing pipeline. The result-
ing software tool must be user-friendly and computationally efficient in order to
genotype hundreds or thousands of samples in a reduced amount of time.
ii Development of a workflow for 1D-NMR spectra processing for high-throughput
metabolomics studies
The analysis high-throughput metabolomics studies based on NMR spectra represents a
major processing challenge due to the lack of integrated and automatic processing tools.
Although some methods cover a part of the processing workflow, some critical steps are
still performed manually due to the low accuracy of the available automatic methods.
Consequently, current high-throughput metabolomics studies are limited by the time
required to process each sample, making it almost impossible to analyze large number
of samples. The main objective of this part of the thesis was to develop a complete
data processing pipeline for 1D-NMR metabolomic studies, and to improve several of
the processing algorithms.
The specific objectives of the algorithms implemented in this processing pipeline are:
• To integrate the processing stages that are required in a typical metabolomics
NMR analysis. This automated workflow will include pre-processing, quality con-
trol, spectral alignment, peak detection, peak quantification, and metabolite iden-
tification.
• To provide a computational efficient tool that will be able to perform high-throughput
analyses (>100-1000 samples).
• To develop a spectral alignment algorithm that can deal with the large inter-
sample variance present in 1D-NMR data. The alignment algorithm will avoid the
use of a reference spectrum, which often leads to a reduction in the alignment
performance.
• To develop a metabolite identification algorithm that uses all the reference spec-
tral data available in publicly available databases. This reference data will be used
to match the peak patterns of each metabolite within the analyzed spectra and
facilitate the identification of the metabolites of interest.
• To provide a final quantification matrix ready for downstream metabolomics sta-
tistical analysis.
iii Genome-Wide Association Analysis of Crohn’s Disease Phenotypes
The identification of the biological basis of Crohn’s disease heterogeneity could have
a major impact in the development of new clinical and pharmacological approaches
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that can more efficiently control disease severity and, therefore, improve the quality of
life of patients with this inflammatory bowel disease. Although previous studies have
analyzed the association of known CD risk loci with the risk to develop different clinical
phenotypes, to date, this has not yet been investigated at a genome-wide scale. The
objective of this study was therefore to perform the first genome-wide association study
(GWAS) to identify risk loci for Crohn’s disease phenotypes. The identification of these
risk loci will demonstrate the existence of a genetic component that is specific for disease
heterogeneity. The specific objectives for this study are:
• To define the phenotypes that are of high clinical relevance in Crohn’s Disease.
To accurately define these phenotypes, the collaboration with clinical specialists
will be essential.
• To curate the clinical database and extract the phenotypes for the patients in-
cluded in the study.
• Perform the first GWAS analysis (i.e. 576,818 SNPs) for each phenotype in a well-
characterized discovery cohort of 1,090 Crohn’s disease patients from Spain.
• Select the candidate risk loci to be replicated in an independent validation cohort
of 1,296 patients from Spain.
• To identify the biological mechanisms that could explain the observed genetic
association with CD clinical phenotypes.
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3 | GStream: Improving SNP and CNV
Coverage on Genome
Wide Association Studies
Note: This chapter is an exact copy of the paper:
A. Alonso, S. Marsal, R. Tortosa, O. Canela-Xandri and A. Julià. GStream: Improving SNP
and CNV Coverage on Genome-Wide Association Studies.
PLoS ONE, 2013, 8(7), e68822. DOI: 10.1371/journal.pone.0068822.
Abstract
We present GStream, a method that combines genome-wide SNP and CNV genotyping in the
Illumina microarray platform with unprecedented accuracy. This new method outperforms
previous well-established SNP genotyping software. More importantly, the CNV calling al-
gorithm of GStream dramatically improves the results obtained by previous state-of-the-art
methods and yields an accuracy that is close to that obtained by purely CNV-oriented tech-
nologies like Comparative Genomic Hybridization (CGH). We demonstrate the superior per-
formance of GStream using microarray data generated from HapMap samples. Using the
reference CNV calls generated by the 1000 Genomes Project (1KGP) and well-known stud-
ies on whole genome CNV characterization based either on CGH or genotyping microarray
technologies, we show that GStream can increase the number of reliably detected variants
up to 25% compared to previously developed methods. Furthermore, the increased genome
coverage provided by GStream allows the discovery of CNVs in close linkage disequilibrium
with SNPs, previously associated with disease risk in published Genome-Wide Association
Studies (GWAS). These results could provide important insights into the biological mech-
anism underlying the detected disease risk association. With GStream, large-scale GWAS
will not only benefit from the combined genotyping of SNPs and CNVs at an unprecedented
accuracy, but will also take advantage of the computational efficiency of the method.
39
Chapter 3 Section 3.1
3.1 Introduction
Over the last years, Genome-Wide Association Studies (GWAS) using microarray-based tech-
nology have played an important role in the identification of common genetic variations
and their relationship with disease susceptibility18–21. Genotyping microarrays22 have en-
abled this success through the parallel genotyping of thousands of Single Nucleotide Poly-
morphisms (SNPs), capturing most of the common variation in the human genome. Very
recently, the new generation of microarrays have integrated the extensive knowledge re-
vealed by the 1KGP53 and, together with the decreasing costs of this technology, are now
allowing the use of the GWAS approach to the association of rare genetic risk variants or
more complex human traits.
In addition to SNPs, Copy Number Variants (CNVs) have shown to play an important role
in disease susceptibility26. CNVs are relatively large (> 500 bp) genomic variations and
include deletions, tandem duplications and insertions42. Recent studies based either on
specific CGH arrays or genotyping microarrays have demonstrated the importance of CNVs
due to their global contribution to the human genome variation, their functional impact and
their role in human disease24;26–30;142. Some of these reference studies have contributed
to elaborate a map of regions containing highly polymorphic CNVs called Copy Number
Polymorphisms (CNPs)24;142;143. These common variations have appeared as a significant
area of interest, since they segregate in the population at an appreciable frequency and
their analysis over big sample collections could potentially lead to significant disease risk
associations.
The development of the two mentioned technologies (CGH arrays and genotyping microar-
rays) for high throughput CNV screening has prompted the inclusion of CNVs in GWAS stud-
ies31;144–146. When comparing both technologies, genotyping microarrays offer the practical
advantage of obtaining at the same time SNP and CNV genotype data. However, there is
still a major need to develop methods that can best deal with the signal-to-noise ratio defi-
ciencies and genomic coverage of genotyping microarray data when attempting to identify
and quantify CNVs. So far, most of the commonly used methods for CNV detection and
genotyping at the genome-wide scale76;77;147 are based on independent per-sample analyses
that use summarized measurements relative to a reference set of samples. This type of ap-
proach has proven to work well for large genomic variations, but it fails to use the powerful
information generated by analyzing multiple samples, leading to high false negative rates
with small CNVs78.
In this study we present GStream, a method for SNP and CNV/CNP genotyping that is
tailored to GWAS objectives. GStream integrates a substantially improved version of our
40
Chapter 3 Section 3.2
previous CNV calling software CNstream148. Our new method achieves a superior accuracy
in both SNP and CNV genotyping compared to well-established methods. Indeed, GStream
obtains an unprecedented accuracy within CNV regions, with a performance close to that
obtained from purely CNV-oriented technologies like CGH arrays. All these improvements
have been quantitatively compared against previous state-of-the-art methods and accurately
assessed using different Illumina genotyping microarrays together with publicly available
SNP51 and CNV24;142;143 reference datasets based on Next-Generation Sequencing (NGS),
CGH array and genotyping microarray technologies. Finally, the computational efficiency
of the method has been optimized, enabling the large-scale SNP and CNV analyses to be
performed in a short amount of time.
In addition to presenting this new method and demonstrating its superior performance over
reference datasets, we have also performed different relational analyses concerning previ-
ously known risk loci. Using GStream we have been able to identify, for the first time,
several CNVs in strong linkage disequilibrium (LD) with risk-associated SNPs149 as well as
CNVs spanning disease-associated genes150. Together, these results could reveal important
insights into the causality of these disease risk associations.
3.2 Material and methods
We first introduce the Illumina BeadChip microarrays and describe the algorithms for SNP
and CNV genotyping. Next, we provide information about the datasets used in this study
and the implemented metrics for evaluating SNP and CNV genotyping accuracy. Finally, we
describe the methods used for the CNV association studies that we have run using the GWAS
catalog149 and the OMIM150 databases.
3.2.1 Illumina BeadChip Data
Illumina BeadChips have been largely used in large-scale genome-wide association studies
and are based on the Infinium assay technology56. This type of genotyping array consists
on hundreds of thousands of probe pairs designed to capture genomic variation at the SNP
and CNV level. In each probe pair, each probe has been designed to specifically bind one
of the two SNP alleles (i.e. alleles A and B) generating a pair of fluorescence intensities.
These signals are then measured and processed in order to infer the presence or absence
of these alleles in each sample. GStream software uses these raw measurements to extract
SNP and CNV genotypes for each sample at each probe pair. From here on, fluorescence
measurements of alleles A and B will be called channel A and B intensities and samples will
be categorized at each SNP as homozygotes (i.e. AA or BB) or heterozygotes (i.e. AB).
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3.2.2 GStream method for SNP genotyping
Before identifying the clusters corresponding to the AA, AB and BB genotypes at each probe,
raw intensity data of each probe must be normalized in order to equalize the overall sample
intensity distribution at each channel (Figure 3.1). This step is crucial since the sensitivity
differences of each probe and channel can lead to bias affecting the genotyping perfor-
mance. The method used by GStream is based on the scaling correction used by Peiffer et
al.75. In this method, the intensity centroids of a set of pre-computed AA and BB candidate
homozygote samples are identified and used to scale channel A and B intensities. How-
ever, GStream adds two modifications in order to improve the normalization in those cases
involving probes capturing both SNP and CNV variation. First, instead of using candidate
homozygote intensity centroids, the scaling parameter is computed by weighting the can-
didate homozygotes intensity distributions (the higher the intensity, the higher the weight)
and by finding the maximum over the resulting curve (Supplementary Figure A.1). This
modification helps GStream to better deal with the particularities of intensity distributions
coming from probes within CNV regions. The second modification introduced by GStream
uses heterozygote intensity data when no homozygote candidates are found, thus helping
to better deal with probes capturing low MAF SNPs.
Once the intensities from both A and B channels have been normalized, GStream proceeds to
identify the clusters corresponding to each SNP genotype (i.e. AA, AB and BB). Developing
an accurate SNP genotyping method is crucial not only for SNP analysis itself, but also
because GStream CNV genotyping method uses this information to improve the accuracy of
the CNV call. GStream applies the following procedure to assign a SNP genotype to each
sample at each marker:
1. Channel A and channel B intensities from the analyzed marker are transformed to B
allele frequencies (BAF) and absolute intensities75.
2. Absolute intensities are used to detect samples without any allele (homozygous dele-
tions) which are characterized by very low intensities at both channels. In order to
compute the absolute intensity threshold between homozygous deletion samples and
the other samples, the absolute intensities are sorted and then differences between
each pair of consecutive intensities are computed. If high intensity differences are
found within the expected threshold range ([0, 0.5]), the zero-threshold is fixed to
the corresponding intensities (Supplementary Figure A.2).
3. The BAF probability density function (PDF) is estimated by computing the scaled his-
togram of all the sample BAF values. Peaks over this PDF corresponding to genotype
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Figure 3.1: GStream method for SNP genotyping. This figure shows how GStream
genotyping method works on two example markers, the first one representing a typical
marker capturing a SNP (A and B) and the second one capturing both a SNP and a
CNV (C and D). The leftmost graphs show the effects of the normalization procedure
for the two markers, where the dotted blue lines enclose the ranges where candidate
homozygotes and heterozygotes are identified in order to compute the scaling factors
for each channel (black points over the axes). The rightmost graphs give an overview
of the genotyping procedure: Upper subfigures represent the scaled BAF probability
density function with the solid vertical lines setting the identified genotype centres, the
dotted vertical lines setting the genotype limits and the horizontal lines representing the
sequential search of genotype cluster peaks. Medium and lower subfigures represent
genotype calls and quality call scores respectively.
clusters will be identified sequentially starting by the peak generated by the major
allele frequency homozygote cluster. The algorithm establishes a minimum separa-
tion between peaks in order to assign them to different genotype clusters and it stops
when three peaks have been found or when no more peaks are found. Once genotype
peaks have been found, genotype limits are computed by finding the PDF minimum
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between each consecutive pair of centres (Figure 3.1). These limits will define the BAF
intervals assigned to each genotype and each sample will be genotyped accordingly
to them.
4. If the number of genotype peaks identified is less than three, each genotype cluster
is re-analyzed with a better resolution (i.e. increasing the number of histogram bins
to estimate the BAF PDF) in order to identify sub-clusters corresponding to different
genotypes. This procedure avoids common errors seen in others algorithms where,
for example, genotypes of SNPs with highly discordant sensitivities at each channel
are incorrectly assigned.
5. Finally, a global genotyping quality score and an individual score for each sample
genotype are computed (Figure 1). The global score is proportional to the standard
deviation mean of the BAF values assigned to each genotype and the individual score
corresponds to the distance between the sample BAF value and its corresponding geno-
type peak divided by the distance between genotype centres.
Both genotypes and quality control measurements for each sample are extracted by GStream
to the output files. This information is also required by the CNV genotyping method, which
is based both on the normalized channel intensities and the SNP genotype information.
Further algorithm details are given in Supplementary Text A.3.
3.2.3 GStream method for CNV genotyping
CNV identification and genotyping is one of the principal contributions of GStream to the
current state-of-the-art microarray genotyping methodology, clearly outperforming previous
approaches. Although this method has been based on our previous CNstream method148,
multiple changes have been introduced in order to improve performance and computational
efficiency.
GStream uses normalized intensities and SNP genotypes computed in the SNP genotyping
stage to identify the presence of deletions and amplifications characterized by variable clus-
tering patterns on the intensity data (i.e. high frequency CNVs) or by slight deviations from
the diploid distribution (i.e. low frequency CNVs).
One of the improvements incorporated in the algorithm is that each SNP genotype cluster is
independently analyzed taking only into account the intensity channel that carries valuable
information. This way, the CNV algorithm is divided in four parallel steps (Figure 3.2A):
1. Analysis of channel A intensities from the samples previously genotyped as AA ho-
mozygotes.
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2. Analysis of channel B intensities from the samples previously genotyped as BB ho-
mozygotes.
3. Analysis of channel A intensities from the samples previously genotyped as heterozy-
gotes (i.e. AB).
4. Analysis of channel B intensities from the samples previously genotyped as heterozy-
gotes (i.e. AB).
As well as dividing the analysis in four independent steps, the algorithm is based on the
following assumptions:
1. Homozygous deletions (0 allele copies) are previously detected during the SNP geno-
typing stage.
2. Due to the technical limitations of genotyping microarrays, the intensity measure-
ments show a saturation effect when amplifications are found. For this reason, in-
tensity clustering patterns corresponding to amplifications are very rare and hard to
detect unless they span multiple probes151.
3. Samples categorized as homozygote samples (i.e. AA and BB) can correspond to hem-
izygous deletions (i.e. A and B) or amplifications (i.e. AA+ and BB+). Due to the
saturation effect the algorithm does not stratify amplifications by the number of allele
copies.
4. Samples characterized as heterozygotes (i.e. AB) can have two or more copies (i.e. AB,
AAB, ABB...). The total number of copies can be inferred by independently computing
the number of copies of each allele and then adding the results for each sample.
Below we describe the procedure for determining the CNV genotypes from the set of channel
intensities of each one of the four analysis steps.
Model selection
For each SNP genotype, the algorithm starts identifying clusters over the channel intensi-
ties that carry the corresponding allele information (i.e. channel A for AA homozygotes,
channel B for BB homozygotes and both channels for AB heterozygotes). Due to the men-
tioned saturation effects, it is very uncommon to observe more than two intensity clusters
in microarray data and, for this reason, only two models will be fitted to the intensity data:
a one- and a two-component Gaussian mixture model (GMM). The first one will be fitted
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Figure 3.2: GStream method for CNV genotyping. (A) Each CNV analysis is di-
vided in four independent sets where the number of allele copies per channel intensity
is estimated. Here, the homozygote intensities over its respective informative channels
(upper rightmost and leftmost graphs) are fitted with a two-component model (in this
case, capturing a deletion) while heterozygote intensities over each channel are better
fitted with a one-component model (upper centre graphs). Lower graphs show the in-
tensity distributions (solid black lines) together with the corresponding copy number
score (red points) assigned to each sample. AA homozygotes are mostly classified as
deletions (scores near to 1), BB homozygotes are divided into diploids (scores∼2) and
deletions (scores∼1) while heterozygotes are classified as diploids (i.e. one allele de-
tected at each channel). (B) Final representation of the analyzed probe where points
represent samples and colour their relative copy number scores. SNP and CNV geno-
types are assigned along the BAF and the intensity axis respectively.
using the mean and the variance of all the intensities while the second one will be fitted
using the Expectation-Maximization algorithm152 (Figure 3.2A). A set of requirements in
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order to select the second model have been carefully developed and only if all of them are
accomplished, the two-component model (indicating a pattern corresponding to a common
CNV) will be selected (Figure 3.2A).
Component labelling
If the two-component model has been selected, a copy number category will be assigned
to each one of the two components. As no prior knowledge is available to assign the two
components either to a deletion pattern (i.e. CN = 1 and CN = 2) or to an amplification
pattern (i.e. CN = 2 and CN = 3), a disambiguation method is necessary. GStream bases
the component labelling both on the relative weight of each component (i.e. proportional to
the copy number frequency) and on the presence of homozygous deletions (Supplementary
Figure A.3A). When the one-component model has been selected, the component will be
labelled by default to CN = 2 (i.e. diploid), which is assumed to be the most common state.
Outlier identification and CNV scoring
Outlier identification is intended to capture low frequency CNVs that are not captured by a
two-component GMM and is based on identifying samples showing high or low deviations
from the intensity distributions defined by the selected model. CNV scoring assigns to each
sample i a score S between 0 and 3 depending on its copy number posterior probabilities
(Supplementary Figure A.3B). At the end of this step, GStream has obtained a CNV score
for all the samples that allows the identification of deletions and amplifications as well as a
quantification of the reliability of the assignment (Figure 3.2B). Additional algorithm details
are given in Supplementary Text A.3.
3.2.4 Microarray data from HapMap samples
In order to evaluate and compare the performance of GStream SNP and CNV genotyping
methods we have used raw Illumina microarray data from HapMap samples available at the
Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/)153 (Table 3.1). This
data has been also used as the input of state-of-the-art SNP and CNV genotyping algorithms
in order to extract accurate comparison measures as well as to ensure a performance assess-
ment independent from the technical biases of the raw data. Only markers having available
NCBI Build 37 mapping information were kept for further analysis.
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Platform Samples1
GEO Autosomal
Evaluation
accession2 markers
Human610-Quad 73/75/77 GSE17205/GSE17206/GSE17207 596528 568182
Human660W-Quad 89/89/89 GSE17208/GSE17209/GSE17210 638582 552529
Human1M-Duo 89/90/90 GSE16894/GSE16895/GSE16896 1141594 1058827
HumanOmni1-Quad 88/89/90 GSE17197/GSE17201/GSE17203 1103791 882445
1 Number of samples in the CEU, CHBJPT and YRI population datasets.
2 GEO accession numbers of the CEU, CHBJPT and YRI population datasets.
Table 3.1: Public microarray data used in this study. The used microarray
data comes from four diﬀerent Illumina BeadChip platforms and the sample data
comes from three HapMap populations. The total number of autosomal markers
and the number of markers used for SNP genotyping evaluation are shown.
3.2.5 SNP genotyping performance evaluation and comparison with
previous methods
Golden standard genotypes
In order to correctly evaluate the SNP genotyping algorithm performance, a set of indepen-
dent and high-quality genotype calls is required. The genotype calls of HapMap samples
have been established as a golden standard commonly used in the literature for performance
evaluation of SNP genotyping methods. These calls are available for download through the
online HapMap tool HapMart (http://hapmap.ncbi.nlm.nih.gov/biomart). For this study,
we downloaded the genotypes corresponding to the samples having available microarray
data and used them as the golden standard. SNPs used for performance evaluation were
chosen in order to fulfil three criteria: (i) to have available Build37 mapping information,
(ii) to be present both in the analyzed microarray platform and in the golden standard
HapMap dataset, and (iii) to have concordant reference alleles both in the microarray and
in the golden standard annotations (Table 3.1).
Algorithms
GStream SNP genotyping accuracy has been evaluated and compared with three methods:
(i) GenoSNP73 which is a well-known genotyping algorithm based on a within-sample ap-
proach; (ii) GenCall, which is the proprietary (Illumina, San Diego, US) algorithm72, and it
is used by the vendor genotyping software; (iii) M374, which is a recently published method
for SNP genotyping that re-analyzes the data in order to increase the accuracy over the low
MAF SNPs and has shown to have increased performance.
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3.2.6 Copy number genotyping performance evaluation
Copy number evaluation was performed at two levels: Evaluation of the GStream ability
to detect structural variation obtained from the 1000 Genomes Project53 next-generation
sequencing (NGS) data and evaluation and comparison of CNV population association re-
sults using different algorithms and golden standard calls from three recently published
studies24;142;143. Below we describe materials, methods and metrics used for this two-stage
evaluation.
Evaluation of CNV genotyping accuracy over the 1KGP Structural Variants
In order to test the ability of GStream to detect copy number variation, we have used the
HumanOmni1-Quad GStream calls and a golden standard dataset from a public release of
the 1KGP. HumanOmni1-Quad platform was chosen due to its highest coverage and res-
olution which allowed an evaluation over a major number of loci. The golden standard
dataset consisted of the last variant call files that have been released by the 1KGP (version
v3/20110521, ftp:// ftp.1000genomes.ebi.ac.uk/vol1/ ftp/ release). From all the variants in-
cluded in the 1KGP release we chose those that corresponded to structural variations (i.e.
CNVs) and we filtered out variants with a MAF lower than 2% within all the populations. The
resulting set included 2,531 structural variants (SV) with their respective calls over N=353
unrelated HapMap samples. From these 2,531 loci, 1,956 are covered by HumanOmni1-
Quad markers and GStream calls were available for 149 out of the 353 1KGP samples,
which jointly formed the final evaluation set.
The evaluation procedure consisted of finding the markers whose GStream calls are in max-
imum LD with each SV:
max
i∈Sk
{r2(CNi, SVk)} (3.1)
where Sk is the set of microarray markers within the region spanned by the SV, CNi is the
copy number genotypes assigned by GStream at marker i and SVk is the 1KGP calls for the
analyzed SV k.
Evaluation of the power to detect genome-wide associations over CNV markers and
comparison with previous methods
The objective of this section is to evaluate the power to detect CNV associations and to
compare GStream performance with other well-known methods. This comparison was per-
formed using Human1M-Duo and HumanOmni1-Quad platforms. Using these two plat-
forms also allowed an assessment of the specific platform power to detect CNV associations,
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comparing platforms with (i.e. HumanOmni1) and without (i.e. Human1M) a specific de-
sign to cover CNV.
The genome-wide association study over CNV markers was performed at the population
level aiming to identify CNVs significantly associated to specific populations and comparing
the association statistics with those obtained from golden standard datasets.
The CNV algorithms used are described below:
• PennCNV76 is one of the most frequently used methods for analyzing CNVs using Il-
lumina microarrays. This software implements a CNV estimation method based on
Hidden-Markov-Models (HMMs), in which copy number calls are performed sample
by sample by analyzing the sample LRR (i.e. absolute intensity) and BAF values at
each marker. Default settings were used in the analysis of the available HapMap sam-
ples generating the PFB file (i.e. population frequency of B allele) from their geno-
typing data.
• QuantiSNP is also one of the well-known methods for CNV analysis over Illumina
microarrays. It is based on an Objective Bayes Hidden-Markov Model that is used
to set certain hyperparameters in the HMM priors (for details see Colella et al.77).
Default settings were used in this analysis with the provided Infinum HD parameter
files and the local GC content files.
• CNstream148 was also evaluated in order to demonstrate how our new method over-
performs the previous one due to the major critical modifications introduced.
Association statistics obtained by each algorithm were compared with those obtained from
three recently published reference studies:
• The first dataset was obtained from a study published by McCarroll et al.143. In this
study a hybrid genotyping array was designed to simultaneously measure SNPs and
CNVs. Almost half (N=1,320) of the targeted CNV regions were observed in multiple
unrelated individuals and were defined as CNPs. From this set of CNPs we selected
the autosomal CNPs (N=1,292) over the 270 HapMap samples as the first golden
standard dataset.
• We used the data published by Conrad et al.24 as the second golden standard dataset.
In this study, an Agilent CGH based array was used to generate a map of CNVs greater
than 443 base pairs. For 4,978 of these CNVs reference genotypes from 450 HapMap
samples are available to download. We used the corresponding sample calls for all
the 4,899 autosomal CNVs.
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• The last dataset used for CNV performance evaluation was obtained from the results
published by Campbell et al.142. In this study a custom Agilent CGH microarray tar-
geting regions of known CNPs was designed and evaluated over HapMap samples of
diverse ethnic backgrounds. For this analysis we used the published discrete CNV calls
of polymorphic loci represented in the reference genome assembly (N=874) for the
487 HapMap samples included in the analysis.
In order to provide a measure of genome-wide association power, pairwise population-
association tests (CEU:YRI, CEU:CHBJPT and YRI:CHBJPT) were performed using the calls
from the three golden standard datasets. Loci that either were not covered by the microar-
ray platform or did not obtain significant associations (P-Value < 0.05) in any population
test (Table 3.2) were filtered out. Chi-square test P-Values were then computed at each locus
and compared to those obtained using the calls of the four methods across the markers cov-
ering the locus. For each algorithm, the marker obtaining the best result across the region
was selected for comparison.
Study Technology NCNVR
1 HumanOmni1-Quad Human1M-Duo
Coverage NASSOC
2 Coverage NASSOC
2
McCarroll Affymetrix 1292 1290 929 1288 927
Campbell Agilent CGH 874 874 962 873 962
Conrad Agilent CGH 4899 4899 3659 4899 3671
1 NCNVR refers to the number of CNV loci selected from each study.
2 NASSOC column refers to the total number of associated regions ( P-Value<0.05) for the three popu-
lation tests detected over the golden standard calls.
Table 3.2: CNV regions for each dataset and platform used
to evaluate the power to detect genome-wide associations.
Coverage with at least one marker within the CNV loci of both plat-
forms is very similar although the marker density diﬀers considerably.
3.2.7 Copy number variation and disease susceptibility
Using microarray data to accurately extract information from copy number variation can
be particularly relevant when trying to identify all the type of variants that convey risk
to disease susceptibility. Using two available catalogues of disease genomic associations
we have used two different approaches to demonstrate the joint capacity of microarray
platforms and the GStream method to identify new CNV disease associations. The two
analysis explained here have been performed using the CNV calls inferred by GStream over
the HapMap samples genotyped with the Illumina HumanOmni1-Quad platform.
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Catalog of published genome-wide association studies
Since microarray genotyping platforms became available, a large number GWAS have al-
lowed the discovery of important SNP-trait associations. However, some of these SNPs have
limited or no known functional impact. In these cases, the possibility that they act as proxies
of other types of variations (i.e. CNVs154;155) with a deeper functional impact is more likely.
In order to identify putative causal CNVs we have analyzed the LD patterns between all the
trait-associated SNPs reported by the catalog of published genome-wide association studies
(http://www.genome.gov/gwastudies)149 and the CNV microarray markers detected over
the HumanOmni1-Quad platform. Trait-associated SNP genotypes were extracted from
the 1KGP data reported previously and CNV genotypes were called with GStream. All
the HumanOmni1-Quad markers that presented a non-diploid frequency greater than 1%
(CNV markers) were included in the analysis (NCNV=90,892) together with the 7,571 trait-
associated SNPs.
The conditions used for selecting the candidate SNP-CNV pairs where the CNV could provide
new functional information on the reported association are described below:
1. Distance between the SNP and the CNV markers not greater than 50kb.
2. Correlation coefficient r2 greater than 0.7 in any of the three analyzed HapMap pop-
ulations (CEU, YRI and CHB+JPT).
3. Distance between the CNV marker and the nearest gene not greater than 100kb or CNV
marker spanning binding transcription factor regions as defined by the Transcription
Factor ChIP-seq track on the UCSC browser156.
From the 7,571 trait-associated SNPs, 382 were paired with one or more CNV markers
fulfilling these conditions. A final set of 333 SNP-CNV pairs was obtained after filtering out
repeated associations of SNPs with the same trait by different GWAS studies.
CNV overlapping analysis with disease-related genes
In this second approach, we examined the CNV variants called by GStream spanning genes
known to be involved in disease based on the OMIM database (http://www.omim.org)150.
In order to characterize CNVs with a high probability of conveying functional effects on the
disease-related OMIM genes we set multiple strict selection criteria:
1. From the initial set of CNV markers (NCNV = 90,892) only those located less than
15kb away from an OMIM gene and with at least two more CNV markers covering
this gene were selected (NCNV = 5,836).
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2. We defined CNV loci as sets of three or more nearer CNV markers (i.e. distance be-
tween them not greater than 5kb) in high LD (r2 > 0.7) spanning the same OMIM
gene. After applying this filter we obtained a final set of 212 CNV loci spanning OMIM
genes.
3. Finally, when more than one CNV locus spanned the same gene, only the one showing
the greatest r2 measurements between its CNV markers was kept for further analysis.
The final set of candidates consisted of 149 CNV loci spanning disease-related OMIM genes.
3.2.8 Software availability
An executable version of GStream along with the documentation and example data files
can be freely downloaded from our website http://www.urr.cat/GStream. This web site
also provides regularly updated results of new CNV associations within known human risk
loci identified with this method.
3.3 Results
3.3.1 Performance assessment of SNP genotyping
For each available Illumina platform, the golden standard genotype calls were compared
with the calls generated by GStream, GenoSNP, GenCall and M3 software tools. The global
accuracy results over autosomal SNPs (Table 3.3) show a moderate improvement for GStream
with respect to GenoSNP and a substantial improvement with regards to GenCall and M3
methods. GenCall performed very well when "non-called" genotypes where discarded, but
its global performance decreased due to its low call rate. M3 algorithm could only be eval-
uated over the Human610-Quad and the Human660W platforms due to code incompati-
bilities with the Human1M-Duo and the HumanOmni1-Quad platforms. Although the im-
provement of GStream SNP-genotyping method regarding its competitors may not appear
very high, they can represent a significant improvement from an absolute point of view
(i.e. the accuracy differences when using HumanOmni1-Quad would be equivalent to a
gain of 2,300 completely genotyped SNPs). Chromosome X genotyping accuracy was also
evaluated, obtaining a similar decrease in performance (∼0.5%) for all the algorithms and
maintaining the accuracy differences between algorithms.
The second performance test consisted of computing the global accuracies at different levels
of drop rate, where drop rate refers to the percentage of markers which are removed from
the accuracy computation based on low call confidence measures (as defined by Ritchie et
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Method Call rate (%)1 Accuracy (%)2 Global accuracy (%) CNstream differential (%)
Human610-Quad
GStream 99.952 99.798 99.75
GenoSNP 100 99.577 99.577 -0.173
GenCall 96.724 99.868 96.596 -3.154
M3 99.584 99.585 99.171 -0.579
Human660W-Quad
GStream 99.99 99.804 99.794
GenoSNP 100 99.65 99.65 -0.144
GenCall 95.411 99.879 95.295 -4.499
M3 99.798 99.635 99.434 -0.36
Human1M-Duo
GStream 99.97 99.768 99.738
GenoSNP 100 99.561 99.561 -0.177
GenCall 98.024 99.825 97.853 -1.885
M3 NA NA NA NA
HumanOmni1-Quad
GStream 99.971 99.671 99.643
GenoSNP 100 99.435 99.435 -0.208
GenCall 97.083 99.747 96.838 -2.805
M3 NA NA NA NA
1 Percentage of called genotypes.
2 Number of correct genotypes over the number of called genotypes.
3 Number of correct genotypes over the total number of genotypes available within the golden standard dataset.
Table 3.3: Global accuracy results for SNP genotyping.
al.157). When markers are discarded by low global marker quality score -a common filtering
procedure in GWAS quality control steps- GStream reaches the best performance for all the
evaluated drop rates (Figure 3.3). Furthermore, the difference in accuracy between low and
high drop rates is much lower on GStream, which implies a robust genotyping performance,
even for those markers with lower quality scores. The low accuracy values obtained using
GenCall at low drop rates can be explained from its low call rate (i.e. only when the drop
rate exceeds the uncall rate, GenCall performance is comparable to the other algorithms,
otherwise uncalled SNPs are included in the performance evaluation). When discarding
markers by low quality sample calls, the results show a similar pattern but with reduced
accuracy differences between the algorithms (Supplementary Figure A.4A). These results
place GStream as the best option for SNP genotyping, since its genotyping accuracy reaches
its maximum at lower drop rates compared to the other algorithms.
We also examined the performance with respect to the minor allele frequency (MAF, Fig-
ure S4B). Two key conclusions result from this analysis: First, probes capturing rare SNPs
(MAF < 0.05) showed a slight accuracy reduction (∼0.5%) on all the platforms and algo-
rithms tested and, second, GStream accuracy gain with respect to the other algorithms was
practically independent of the SNP MAF.
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Figure 3.3: Evaluating SNP genotyping performance. Plots comparing SNP geno-
typing algorithms for each microarray platform are tested. The vertical axis represents
the percentage of SNPs that are excluded from the accuracy calculation by the lowest
quality score criteria. GStream performed better at all the drop rate levels in all the plat-
forms. A high decrease in performance is observed for GenCall when drop rate values
are lower than its uncall rate (i.e. ∼2% in Human610Quad).
Finally, we tested the effect of sample size on GStream accuracy (Supplementary Figure
A.4C). The computed accuracy was compared to the accuracies obtained for the other algo-
rithms when using all the Human610-Quad samples (N=225). However, even for sample
sizes as low as N=20, the global accuracy of GStream is clearly higher than the accuracies
obtained by the other algorithms, even if the highest sample size (N=225) is used, demon-
strating the superior sensitivity of GStream genotyping algorithm.
3.3.2 Performance assessment of CNV genotyping
1KGP Structural Variants
SV calls from 1KGP for 149 unrelated HapMap samples (i.e. NC EU=32, NY RI=37 and NCHBJ PT=80)
were compared with their respective GStream calls in order to measure the ability to detect
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this type of variation using GStream on microarray data. For each SV (N=1,956), we com-
puted the CNV genotyping accuracy by finding the maximum LD measurement between its
golden standard calls and the GStream calls over the HumanOmni1-Quad markers covering
the region. The results showed a high correlation between GStream and 1KGP calls: 75.7%
of the SVs were captured by GStream with an r2>0.8, 18.3% with an r2<0.8 and only 6.0%
were not detected by GStream (Figure 3.4A).
Figure 3.4: 1KGP structural variants captured by GStream. (A) Percentage of
1KGP structural variants that are captured by GStream within different ranges of r2
between the 1KGP calls and the GStream calls over the best marker within the respective
structural variant loci. (B) Distribution of the r2 values when more than one marker is
found within the structural variant loci. Structural variants are stratified according to
the best r2 obtained by all the markers covering the loci. (C) r2 distribution stratified
by the frequency of the structural variation.
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Once demonstrated the power of GStream to capture these variants, we examined the vari-
ance of the LD measurements across the markers spanning the same SV loci. This analysis
was stratified by the maximum LD measurement of the SV as explained in the previous para-
graph. From the results (Figure 3.4B) we can conclude that the calls inferred over probes
spanning the same structural variant obtain consistent values with a slight variance due to
the quality differences across markers.
Finally, we also observed that the calling performance slightly decreases with the frequency
of the analyzed SVs due to an increment of the r2 interquartile ranges (Figure 3.4C). Nev-
ertheless, lower quartiles exceeded r2=0.7 within almost all the frequency ranges tested.
We conclude this section by stressing the power of GStream to detect structural variation
identified with more advanced technologies (i.e. NGS), obtaining CNV calls with an r2>0.8
over 75.7% of the 1KGP variants and calls with an r2>0.9 over 62.3% of the variants.
Genome-wide CNV association study
In order to evaluate the power to detect CNV associations we have performed a pairwise as-
sociation study between three HapMap populations using golden standard data from three
reference studies24;142;143. The association statistics obtained by the golden standard calls
were compared with those obtained by GStream, CNstream1, PennCNV and QuantiSNP
across two microarray platforms, HumanOmni1-Quad and Human1M-Duo. These two plat-
forms were chosen since they represent the first and the second generation of the Infinium
HD genotyping microarrays, which mainly differ by the inclusion of additional probes to ob-
tain a better coverage of CNV loci. These differences (Supplementary Figure A.5) are clearly
visible and the coverage analysis over the CNV regions defined by the three published stud-
ies showed how the marker density is doubled within these CNV regions between the first
and the second platform generations (i.e. from 10 to 20 markers/region).
The main metric used to test CNV methods was the − log10 P − Value ratio between the
association values obtained by the calls of each method and those obtained from the golden
standard calls. Under this metric, ratios near 1 represent a good performance for the method
since the obtained association P-Value is very similar to the golden standard. A performance
summary statistic was computed as the percentage of − log10 P −Value ratios giving values
between 0.9 and 1.1 over all the associated CNV loci.
Firstly, the obtained results showed a high performance decrease in the detection of CNV
associations when comparing HumanOmni1-Quad results with Human1M-Duo (Table 3.4).
This loss was common to all the methods tested but PennCNV and QuantiSNP showed a
higher percentage decrease (∼70%) than GStream and CNstream (∼40%). When compar-
ing GStream to the other state-of-the-art methods, results showed a major performance gain
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on all the golden standard sets and on both microarray platforms. Results for each platform
are described below.
Algorithm
HumanOmni1-Quad Human1M-Duo
PD1
MCarroll Campbell Conrad Mean MCarroll Campbell Conrad Mean
GStream 56.40 46.80 63.87 55.69 45.09 27.65 24.38 32.37 23.3
CNstream 31.11 30.67 30.06 30.61 29.13 17.57 13.89 20.20 10.4
PennCNV 34.66 29.94 29.57 31.39 13.70 9.36 3.73 8.93 22.5
QuantiSNP 33.80 31.50 30.86 32.05 16.50 10.08 4.37 10.32 21.7
1 Platform difference (PD) refers to the average percentage differences between both platforms.
Table 3.4: Power to detect CNP associations. Percentage of − log10 P ratios higher
than 0.9 and lower than 1.1 over the CNV population-associated regions computed for
each study.
HumanOmni1-Quad results show that GStream is able to precisely capture an average of
23.6% more associated loci than the other methods (Table 3.4) and that the number of false
negatives (Supplementary Figure A.6) decreased considerably. Examining the association
ratio distributions (Figure 3.5A), we also observed how GStream outperforms CNstream
and, to a greater extent, PennCNV and QuantiSNP: while GStream ratio distribution resem-
bles a unimodal distribution with a high kurtosis and centred around 0.95 (i.e. precisely cap-
tured loci), the rest of the distributions from CNstream, PennCNV and QuantiSNP showed a
lower kurtosis with more ratio values distributed between 0 and 0.75 (i.e. loci not or poorly
captured). To conclude, HumanOmi1-Quad comparison, we examined the association ratio
distributions stratified by the P-Value obtained by the golden standard calls (Supplementary
Figure A.7). GStream obtains very good results within all the P-Value ranges, with medi-
ans around 1 and decreasing interquartile ranges (from 0.2 to 0.02) as the P-Value ranges
decreased (i.e. greater evidence of association). Interquartile ranges obtained by the other
methods were at least twice the obtained by GStream and increased as the P-Value ranges
decreased, losing performance when comparing higher associated loci. Poorer ratio medians
were also obtained when using the other methods.
When comparing Human1M-Duo results, the performance differences between methods are
similar to the previous comparison but with an absolute decrease in performance for all the
methods due to previously referred differences on the platform design. Despite this global
performance loss, GStream was able to precisely capture three times as many associations
as PennCNV and QuantiSNP (Figure 3.5B). The number of associations not detected was
also increased by a factor of 3 with respect to HumanOmni1-Quad results (Supplementary
Figure A.6). When analyzing − log10 P−Value ratio distributions by their respective golden
standard association P-Values, ratio medians were only maintained near one when using
GStream (Supplementary Figure A.8). Instead CNstream, PennCNV and QuantiSNP showed
a significant loss with ratio medians below 0.5.
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Figure 3.5: Evaluation of the power to capture genome-wide CNP association.
Plots comparing Chi-square test P-Values obtained with the golden standard calls (i.e.
McCarroll, Campbell and Conrad datasets) with those obtained with the four tested
methods using HumanOmni1-Quad (A) and Human1M-Duo (B) platforms. Comparison
is performed by observing the distribution of the P-Value association ratios (i.e. tested
method versus golden standard). A high performance difference was obtained between
the two platforms tested (i.e. due to their high difference in coverage density) and
between GStream and the rest of algorithms tested.
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3.3.3 Copy number variation and disease susceptibility
Here we describe CNV associations that have been found by mining two available catalogues
of disease genomic associations in order to demonstrate the power of GStream to identify
new and functionally relevant CNV disease associations.
Catalog of published genome-wide association studies
A set of 333 SNP-CNV pairs have been identified when searching for CNV markers in high
LD with trait-associated SNPs reported in the GWAS catalog (Supplementary Table A.1).
From this set of paired associations, 94 spanned the HLA region, reflecting the known ge-
nomic complexity of this region. On the other hand, previously reported disease-associated
CNVs were detected using this approach (Table 3.5 and Supplementary Figure A.9) like,
for example, well-known deletions spanning IRGM, LCE3 and ARMS2 loci, which have been
respectively associated to Crohn’s disease155, psoriasis154 and age-related macular degen-
eration158. A 45 kb deletion near NEGR1 gene and a 50 kb deletion upstream of GPRC5B
gene previously associated to obesity and body mass index159 were also identified.
A thorough study of the CNVs in high LD with trait-associated SNPs revealed several inter-
esting loci. Some of these loci are described below (Table 3.5 and Supplementary Figure
A.10):
• A synonymous exonic SNP rs2240335 (PADI4 gene) has been associated to Rheuma-
toid Arthritis (RA) in a previous GWAS (P-Value=2 · 10−8) using a Japanese cohort
(1247 RA cases and 1486 controls)160. GStream found 12 CNV markers 2kb away
and spanning PADI4 intron (length = 800bp) in high LD with rs2240335 both on CEU
(r2=0.82) and CHB+JPT (r2=0.95) HapMap populations.
• An intergenic SNP rs2867125 (50kb downstream TMEM18 gene) has been associated
to body mass index in previous GWAS (P-Value=3 · 10−49)159. Two CNV loci near this
SNP have been identified by GStream in high LD (r2=1 both on CEU and CHB+JPT
populations) with this SNP.
• Levels of glycated hemoglobin have been associated to the ABCB11 intronic SNP rs552976
(P-Value=8 · 10−18)161. A deletion variant 3kb upstream of this gene showed a high
correlation (r2=0.94 CEU) with the associated SNP genotypes.
• Intronic SNP rs6815464 on MAEA gene has been associated (P-Value=2 · 10−20) with
type 2 diabetes162. This SNP has been found to be highly correlated with another
intronic deletion spanning ∼2kb.
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• 5’UTR SNP rs6904029 (HCG9 gene) has been previously associated with Vitiligo (P-
Value=1 · 10−21)163. Here we report a CNV locus spanning the 5’ region of the HCG9
gene found in high LD with this SNP.
• Intronic SNP rs3077 (HLA-DPA1 gene) has been recently associated to chronic Hep-
atitis B (P-Value=2 · 10−61) on a Japanese cohort164. A deletion potentially spanning
three HLA-DPA1 exons has been identified to be highly correlated with this SNP both
on the CHB+JPT and the YRI populations.
• A deletion highly correlated with intronic SNP rs9296736 (MLIP gene) has been iden-
tified spanning 5kb MLIP intron. This SNP has been associated with liver enzyme
levels (P-Value=3 · 10−9)165.
• Intronic SNP rs2075671 (ZAN gene) has been associated to red blood cell count (P-
Value=1 · 10−9) on a GWAS exploring erythrocyte phenotypes166. A deletion locus
spanning multiple exons of the same gene has been found with a high correlation
with the associated SNP genotypes both on the CEU (r2=0.87) and the CHB+JPT
(r2=0.91) populations.
• Finally, the 3’UTR SNP rs7247513 (ZNF490 gene), modestly associated with bipolar
disorder (P-Value=2·10−6)167, was also found in high LD with a 2kb deletion covering
ZNF490 intron.
A complete list of all the 333 associations can be consulted on Supplementary Table A.1
and, as previously mentioned, will be regularly updated in our website.
CNV overlap with disease-related genes
In this second approach we examined the CNV variants called by GStream spanning genes
known to be involved in disease. A set of 149 CNV consistent loci spanning OMIM genes
were obtained (Supplementary Table A.2) with a mean length of 6 kb and a mean number
of 7 probes per CNV loci.
In this analysis, well-known associated deletions were found. For example, a common
CFH haplotype with deletion of CFHR1 and CFHR3 genes associated with lower risk of age-
related macular degeneration168 was identified using the GStream CNV calls. A CNV span-
ning CCL3L-CCL4L genes has been extensively associated with various human immunodefi-
ciency virus-related outcomes [51] and was also identified in this analysis. SMN, GHR and
PKHD1 gene deletions respectively associated to spinal muscular atrophy169, responsiveness
to growth hormone170 and polycystic kidney disease171 were also detected using GStream
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(Supplementary Figure A.11). Besides these deletions that have already been associated to
disease risk, GStream has also allowed us to identify new exon spanning deletions within
disease-associated genes (Supplementary Table A.2). Some examples of these findings are
the deletions covering SLC2A9, DAZL and MBL2 gene exons.
In almost all these identified CNV loci, GStream calls across the probes within the loci
showed a high concordance demonstrating a high performance for a high variety of CNV
cluster intensity patterns (Supplementary Figure A.12).
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3.4 Discussion
In this study we present GStream, an integrated tool for SNP and CNV genotyping addressed
to Illumina microarray data. This new tool has been carefully designed to obtain a high
performance in genotyping accuracy when analyzing GWAS data from Illumina BeadChip
arrays. The performance of GStream has been assessed using reference data, extracted
from the latest releases of the 1KGP and the HapMap projects, as well as from reference
studies on CNV characterization. First, we show that GStream has superior SNP and CNV
genotyping performance than current state-of-the-art methods. Second, we demonstrate its
power to detect new structural variation recently identified with Next-Generation Sequenc-
ing technology. Finally, we also demonstrate the utility of GStream in the identification of
CNVs within trait risk loci as well as known disease-associated genes. The newly identified
CNV associations could help to advance in the understanding of the genetic basis of several
human traits.
In a current scenario where genotyping microarrays are decreasing in cost and widening
their spectrum of analyzed SNPs to more rare variations172, the need of developing methods
which increase SNP genotyping accuracy is even more fundamental. To this end, GStream
provides a way of facilitating this success by obtaining the best performance results com-
pared to the available state-of-the-art methods (i.e. GenCall72 and GenoSNP73). This in-
creased performance can be particularly meaningful in the case of identifying rare disease-
associated SNPs, traditionally more exposed to genotyping errors and to the subsequent
statistical bias173;174. On the other hand, the accuracy of current SNP imputation meth-
ods175, which expand the number of analyzed SNPs and also help to integrate the results
obtained with different microarray platforms (GWAS meta-analysis), also depends on the
quality of the originally genotyped SNPs. Therefore, prioritizing accurate SNP genotyping
methods is a key success factor in order to obtain reliable imputation results176.
Besides the importance of SNPs as a source of genetic variation, CNVs have also emerged
as important variations for common trait risk177 as evidenced by recent GWASs178–182. In
the present study we tested our algorithm power to detect CNV loci that have been recently
identified with the Next-Generation Sequencing technology. This NGS CNV data provided
by the 1KGP includes not only previously known CNVs (i.e. detected with CGH arrays),
but also new CNV loci that have not been previously detected. Since part of these loci
are covered by microarray probes, their detection with microarray-based technologies is
therefore possible. On the other hand, previous state-of-the-art methods for copy number
genotyping76;77 present a lack of performance when CNVs span a few number of probes
or when intensity distributions corresponding to the different copy number states partially
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overlap. The multi-component intensity distribution models implemented in GStream will
allow researchers to deeply scan the genome for additional CNVs, widening their range to
shorter, population-specific and/or previously uncharacterized CNVs.
In this study we also present a two-level comparison of the power of GStream to detect
CNV associations in a population-based study. First, we have performed a comparison be-
tween the different algorithms tested and, second, we have performed a comparison be-
tween the two genotyping microarray generations represented by the Human1M-Duo and
HumanOmni1-Quad platforms, this last one including a specific set of markers covering
known CNV loci172. On the one hand, we confirmed the improvement introduced by the new
generation microarrays as a consequence not only of their major density coverage within
predefined CNV regions, but also of their improved signal quality. The number of correctly
genotyped CNV regions (i.e. characterized in previous reference studies) increased in∼20%
when using HumanOmni1-Quad rather than Human1M-Duo, regardless of the CNV geno-
typing method being used. On the other hand, when comparing the results obtained by
each algorithm tested, GStream showed a higher performance within all the scenarios. Its
power increase for detecting and correctly genotyping CNVs (i.e. defined by three different
reference studies based either on CGH or custom genotyping arrays) ranges from 50% to
100% compared with the best scoring of the other state-of-the-art methods. Therefore, we
present GStream as an integrated SNP-CNV genotyping tool that shows a remarkable leap
in performance with respect to previous methods.
One of the most important tasks when analyzing GWAS results is to link the associated
variant to a functional effect that can explain the disease risk association. Identifying this
link is not always easy since the identified variation can act as a proxy to the underlying
causal mutation and may not be covered by the microarray platform. Actually, microarray
probe design is based on the study of the linkage disequilibrium patterns and the resulting
haplotypes that are inherited in blocks183. In this regard, we have identified several CNVs
in high LD with SNPs that have been previously associated to disease susceptibility. A clear
example of these linked CNVs are the IRGM1155 and the LCE3B/LCE3C154 deletions which
have been associated to Crohn’s Disease and Psoriasis, respectively. Furthermore, these two
deletions have been demonstrated to affect the expression of the deleted genes. In addition
to these previously known associations, we have identified additional CNVs previously not
associated with the disease that could also have functional impact. For example, several
CNVs spanning hundreds of bases of gene introns have been found to highly correlate with
disease-associated SNPs. These CNVs could provide a functional link to the associated risk
modifying, for example, RNA splicing24;184.
Furthermore, as CNV are known to span from hundreds of bases to multiple kilobases, it
is interesting to analyze not only those that correlate previously associated SNPs, but also
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those that overlap coding sequences of genes that have been previously associated to hu-
man disease (i.e. OMIM genes). The results from this analysis include several known CNV
associated loci, as those spanning CFHR1/CFHR3182, CCL3L/CCL4L185, SMN 169, GHR170 and
PKHD1171 genes. More importantly, new interesting CNV loci also appeared, as those span-
ning SLC2A9, DAZL and MBL2 disease-associated gene exons. The SLC2A9 gene (OMIM
606142) deletion has been identified by GStream within eight microarray probes span-
ning two gene exons and two gene introns (chr4:9,929,128-9,966,793). Since mutations
within this gene have been previously associated to uric acid concentration186 and to Hy-
pouricemia187, the functional effects of this deletion should be further evaluated in relation
to these traits. Indeed, GLUT9AN (resulting from alternative splicing of SLC2A9 gene) is
predominantly expressed in the kidney and expression association signals reported by Dor-
ing et al.186 link this gene to the regulation of urate concentrations. The described exon
deletion could probably imply a similar effect by modifying the resulting transcribed pro-
tein. On the other hand, DAZL (OMIM 601486) deletion was identified over 4 microarray
probes spanning 5.8 kb (chr3:16,638,525-16,644,130). This deletion could affect multiple
gene exons resulting in a drastic functional modification. Previous studies188 have linked
variants within this gene with susceptibility to spermatogenic failure and therefore, this
deletion should be evaluated in the context of this human trait. GStream also found a rele-
vant deletion spanning the last exon of the MBL2 gene. MBL2 mutations and the consequent
Mannose Binding Lectin deficit have been previously associated with cystic fibrosis189 and
recovery from infections190. This deletion could drastically modify MBL2 gene expression
and subsequently involve a Mannose Binding Lectin deficit whose association has also been
demonstrated.
In a time of rapidly evolving technologies and where Next-Generation Sequencing is be-
coming available for the study of common diseases, microarray-based technologies are still
a commonly used strategy to identify the genetic basis of human traits. First, they allow the
analysis of large sample collections at an affordable cost and, second, they have anincreas-
ing global genome coverage, expanding their analysis scope to rarer variants. Therefore,
accurate genotyping methods are basic to discover new associated loci that can be then fur-
ther studied in more detail using Next-Generation Sequencing. The tool that we present
in this study, GStream, provides an unprecedented accuracy when analyzing GWAS data
from previous and recent Illumina microarray platforms. Furthermore, our software tool
implementation allows large-scale GWAS projects to be analyzed in a very short time, pro-
viding both SNP and CNV in a single analysis. With these results, we encourage researchers
conducting GWAS on these genotyping platforms to use GStream in order to leverage the
power of their SNP and CNV loci association analyses.
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Abstract
One-dimensional 1H-NMR represents one of the most commonly used analytical techniques
in metabolomic studies. The increase in the number of samples analyzed as well as the tech-
nical improvements involving instrumentation and spectral acquisition demand increasingly
accurate and efficient high-throughput data processing workflows. We present FOCUS, an
integrated and innovative methodology that provides a complete data analysis workflow
for one-dimensional NMR-based metabolomics. This tool will allow users to easily obtain
a NMR peak feature matrix ready for chemometric analysis as well as metabolite identifi-
cation scores for each peak that greatly simplify the biological interpretation of the results.
The algorithm development has been focused on solving the critical difficulties that appear
at each data processing step and that can dramatically affect the quality of the results. As
well as method integration, simplicity has been one of the main objectives in FOCUS devel-
opment, requiring very little user input to perform accurate peak alignment, peak picking
and metabolite identification. The new spectral alignment algorithm, RUNAS, allows peak
alignment with no need of a reference spectrum and, therefore, it reduces the bias intro-
duced by other alignment approaches. Spectral alignment has been tested against previous
methodologies obtaining substantial improvements in the case of moderate or highly un-
aligned spectra. Metabolite identification has also been significantly improved, using the
positional and correlation peak patterns in contrast to a reference metabolite panel. Fur-
thermore, the complete workflow has been tested using NMR datasets from 60 human urine
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samples and 120 aqueous liver extracts, reaching a successful identification of 42 metabo-
lites from the two datasets. The open-source software implementation of this methodology
is available at http://www.urr.cat/FOCUS.
4.1 Introduction
In the last decade metabolomics has experienced an exponential growth thanks to the
development and refinement of the analytical techniques used to obtain data from the
metabolome191. At the same time, advanced bioinformatic methods have emerged in or-
der to deal with the complexity and the high dimensionality of the data generated by these
techniques. The recent advances in metabolomics, together with other omic approaches like
genomics, transcriptomics and proteomics, are increasingly leading to an integrated knowl-
edge of systems biology and to the consequent understanding of the biologic regulatory
processes that underlie metabolism and disease192–195.
Nuclear Magnetic Resonance (NMR) spectroscopy, together with chromatography-coupled
mass spectrometry (MS), are the analytical techniques that have contributed to the growth
of the metabolomic science. From the different NMR techniques, the one-dimensional (1D)
proton spectrum (1H-NMR) has been the most commonly used technique in NMR-based
metabolomics studies193. 1H-NMR is characterized by a simple and fast acquisition pro-
cess196–198, providing high repeatability spectra that cover a wide range of metabolites108;197.
However, there are several technical challenges that still need to be solved in order to make
the most of this powerful analytical method. These technical challenges affect several of the
data processing steps that are required prior to the use of any statistical analysis method.
There is actually an intense research activity on solving these technical difficulties, espe-
cially on those that more critically affect the quality of the final dataset122;134;135;196;199–203.
However, while several useful methodologies have been developed for each of the process-
ing steps, there is still a lack of a single tool that efficiently integrates the complete NMR
data processing workflow.
One first challenge on the data processing workflow is how to deal with the significant biases
in peak positions introduced by the sample chemical environment. Chemical variables like
ionic strength, pH and protein content differences between samples can produce changes
in peak positions of certain metabolites108;115. This means that, even in well-addressed
studies with uniform sample processing and randomized designs204, spectral data analysis
will require the application of complex alignment tools in order to minimize the impact of
this confounding factors205. Multiple alignment methods117;122–124;206 have been proposed
to correct this variability in chemical shifts of NMR spectra and to guarantee peak corre-
spondence across all the analyzed spectra. However, most current methods are still based
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on a reference spectrum against which each sample spectrum is aligned. This can be an
important source of bias since this reference is not always representative of all the sample
spectral diversity200. Importantly, methods based on the correlation function122;123 to com-
pute the alignment correction shifts can introduce other types of errors mainly derived from
the presence of very large peaks that account for almost all the weight of the correlation
function (despite the presence of lower peaks, where alignment is neglected).
In addition to peak position biases, another major challenge for NMR metabolomics is au-
tomatic metabolite identification. MetaboHunter134 represents an important advance and
one of the most common approaches for metabolite identification. In this method, metabo-
lite compounds are matched against a reference spectrum peak list according to the peak
positions. However, this approach can lead to a high number of false positives since it
does not use intensity and correlation measurements to refine metabolite matching. An-
other commonly used approach based on the valid cluster concept135;136 is an improvement
with respect to MetaboHunter since, it also uses peak intensities and inter-sample intensity
correlation thresholds to group peaks. However, in this method the scores used to match
reference spectra to the dataset peaks can lead to suboptimal binary identification when the
lowest reference intensity peaks are not found in the sample spectra.
Here, we present FOCUS, a complete workflow for processing large spectral NMR datasets
which covers spectral alignment, peak detection, peak quantification and metabolite iden-
tification. FOCUS output provides an accurate matrix of sample peak features ready for
chemometric analysis, as well as a metabolite identification scoring system that greatly fa-
cilitates peak data interpretation. Furthermore, FOCUS generates html-based result reports
containing exhaustive information of each analyzed peak such as quality assessment, inten-
sity correlation patterns and metabolite assignations. This integrated tool is suited for the
current large sample metabolomic studies and it incorporates several methodological ad-
vances both on peak alignment and metabolite identification. FOCUS alignment is based in
RUNA (Recursive UNreferenced Alignment) algorithm, which efficiently aligns NMR peaks
while avoiding the use of a reference spectrum. With regards to metabolite identification,
FOCUS provides a peak-based procedure that significantly speeds up this common and time-
consuming task. For each peak, FOCUS generates a list of identification scores for each pro-
cessed NMR peak, giving the researcher a powerful tool to identify the underlying metabo-
lite.
We demonstrate the improvements of FOCUS in spectral alignment and metabolite identi-
fication with respect to other existing methods using both simulated and real (i.e. human
urine and liver extract) NMR datasets. With FOCUS, researchers performing moderate to
large scale NMR studies will have a complete and powerful tool to make the most of their
metabolomic data.
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4.2 Theory
FOCUS processes raw 1D-NMR spectral datasets in an integrated and unsupervised man-
ner. As depicted in Figure 4.1, FOCUS analysis pipeline consists of four main steps namely i)
Spectral segmentation, ii) Spectral Alignment, iii) Peak detection, and iv) Metabolite Iden-
tification. Detailed information on each processing step can be found in the Supplementary
Text B.3.
4.2.1 Spectral segmentation
Raw 1D-NMR spectra are automatically divided in equally sized overlapping segments (i.e.
50% overlap) wider enough to span one or multiple peaks (see Supplementary Figure B.1
for further details). Segment overlapping guarantees that peaks falling into one segment
end will be correctly analyzed on the consecutive segment. Furthermore, this approach also
guarantees that each peak will be analyzed twice within different neighborhoods keeping
the best result for further analysis. Subsequent data processing steps concerning alignment
and peak picking are performed at the segment-level.
4.2.2 Spectral Alignment
FOCUS alignment method, RUNAS (Recursive Unreferenced Alignment of Spectra), per-
forms spectral 1H-NMR alignment using the cross-correlation function between spectra as
the alignment maximization function. In contrast to most of the currently available method-
ologies, RUNAS does not rely on the definition of a reference spectrum. Furthermore, the
alignment procedure is based on a spectral transformation (i.e. Intensity Weight Slope
Transform) that enhances peak shapes and reduces the alignment bias produced by the
presence of peaks with highly unpaired intensities. RUNAS consists of several processing
steps that are outlined below.
First, the Intensity Wight Slope Transform (IWST) is applied to all the input segment spec-
tra. Briefly, this transformation extracts the sign of the spectrum derivative at each point
and weights the resulting signal by its corresponding discretized intensity percentile across
all the spectrum points. This transformation results in multiple advantages from a spectral
alignment standpoint (see Figure 4.2A and Supplementary Figure B.2 for further details).
After this first step, RUNAS algorithm proceeds to calculate the optimal distance and the
maximal correlation for each pair of samples. The optimal distance is defined as the shift
that needs to be applied to one sample spectrum segment in order to maximize its correla-
tion with respect to another sample spectrum. This optimal distance is stored in the opti-
mized distance matrix (ODM). The correlation value between the two spectral segments at
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Figure 4.1: FOCUS workflow schema. This figure shows the FOCUS workflow anal-
ysis for processing one dimensional NMR metabolomics spectra. It starts by computing
the informative points of the spectral dataset and then splitting the whole spectra in
overlapping segments. For each segment, alignment and peak picking (i.e. peak de-
tection and quantification) are independently applied. Once the segment analysis has
finished, redundant peaks are removed and a feature matrix containing peak measure-
ments for each sample is obtained. Statistical analysis can then be performed on this
matrix and, after the peak identification procedure, the results from statistical analysis
can be interpreted.
this point is called maximal correlation and is stored in the maximized correlation matrix
(MCM). All these calculations are based on the Fast Fourier Transform (FFT)123 and are com-
puted only once. Figure 4.2B shows ODM and MCM matrices for an example segment set
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of spectra. Finally, RUNAS performs recursive alignment by iteratively shifting each sample
spectrum in order to maximize its spectral correlation with respect to all the other samples.
These shifts are calculated as the averaged optimal distances of each spectrum weighted by
their corresponding maximal correlation as detailed in equation 4.1:
δix =
∑NS
y=1 I(MCMx y ≥ CT )MCMx yODMix y
2
∑NS
y=1 I(MCMx y ≥ CT )MCMx y
,∀x ∈ [1, NS] (4.1)
where x is the spectrum being shifted, i is the algorithm iteration, MCM is the maximized
correlation matrix, ODM the optimal distance matrix and I(c) the indicator function whose
value is zero unless the comparison c is true, in which case its value is set to 1. CT refers to a
correlation threshold, so spectra that do not reach a minimal correlation with the analysed
spectrum are not taken into account in its shift computation. This threshold provides a
way to automatically align spectral segments even in those cases where the samples follow
more than one peak pattern. At the end of each iteration, the ODM is updated to take into
account the applied shifts and the previous step is repeated until convergence. This usually
occurs after 10-20 iterations (see Figure 4.2C and Supplementary Figure B.3). Figure 2D
shows how the example segment set of spectra is correctly aligned without using a reference
spectrum and how groups of different spectra are independently aligned.
Figure 4.2: FOCUS spectral alignment. This figure shows the FOCUS procedure for
spectral alignment. (A) Shows the spectral signal transformation (intensity weighted
slope transform) and how signals and peaks are equalized across samples by using this
transformation. (B) Shows the resulting MDM and ODM matrices computed before
recursive alignment. (C) Shows the matrix of applied shifts (rows representing iterations
and columns applied shifts on each sample) and the difference between the final and
the initial spectral correlation matrices. (D) Shows the aligned spectra after applying
FOCUS. It can be observed that each signal is only aligned against those signals achieving
a high degree of spectral correlation.
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4.2.3 Peak Detection
FOCUS peak detection approach is based on the computation of a consensus peak signal
(CPS) which estimates at each spectral point the frequency of samples having a peak region
spanning the considered point. For each sample spectrum, the zero-crossings of the filtered
spectrum (i.e. second derivative Gaussian filter) are used to delimitate peak regions on each
sample. The CPS is then built by computing at each spectral point the number of samples
that present a peak region spanning the considered point and scaled with respect to the
number of samples. The CPS is then an estimation of the peak frequency across the samples
at each spectral point. In this way, this method guarantees that all the samples will have
the same contribution to the definition of peak regions. Once the CPS has been computed
it is filtered using the same previous filter and the resulting signal zero-crossings delimitate
the global peak regions (see Supplementary Figure B.4A for further details). Using CPS
to delimitate peak regions also allows to take into account the residual misalignment that
may remain after peak alignment, since the residual variability on the single-spectrum peak
regions will contribute to broaden the corresponding peak on the CPS (see Supplementary
Figure B.4B).
Since input spectra are divided in consecutive overlapping segments, redundant peaks can
be generated. In order to remove this redundancy a peak reduction method based on the
sample-averaged overlapping within peak pairs extracted from consecutive windows is ap-
plied. Peak pairs having large sample-averaged overlapping correspond to redundant peaks
and the method keeps only those peaks with larger peak shape correlations.
At this point, FOCUS provides a data matrix of per-sample peak measurements that is ready
for subsequent chemometric analysis. The user can select different types of per-sample peak
features, namely i) peak areas, ii) peak maximums, and iii) peak increments (difference be-
tween the peak maximum and minimum value at the peak region limits). Furthermore,
three quality scores are provided for each peak, namely i) sample-averaged peak shape
correlation (i.e. this can be used to evaluate the peak shape correspondence between sam-
ples), ii) correlation between areas and increments (i.e. this can be useful for detecting
background interferences or overlapping peaks which might be deconvoluted) and iii) the
median peak intensity percentile with respect to all the detected peaks (i.e. this quality score
provides information about the relative concentration level of the metabolite that generates
each peak).
4.2.4 Reference-Based Metabolite Identification
FOCUS reference-based metabolite identification is based on the fact that closer NMR peaks
in one pure compound spectrum arise from the same proton and they use to show less vari-
ation across the frequency axis than peaks generated from different protons. Consequently,
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given a library of known metabolites (i.e. reference spectra) FOCUS will start by clustering
the reference peaks of each metabolite proton (see Figure 4.3A). In this way, each proton
cluster will group together peaks with close positions in the spectrum (i.e. distance between
peaks < dcluster). After this clustering step, a peak-oriented identification step is performed,
where the set of target metabolites for each dataset peak is limited to those having a close
reference peak (i.e. distance between dataset peak and reference peak < tcluster , see Fig-
ure 4.3B). For each dataset peak and a corresponding target metabolite, FOCUS proceeds
as follows:
1. Intra-cluster score: This step consists of identifying the metabolite peaks of the same
proton. For this objective, FOCUS tries to identify correlated dataset peaks (i.e. inten-
sity correlation at the sample level) at the expected positions where the other peaks
from the same proton should be located (see Figure 4.3C for further details). If a peak
from the same proton is not identified, a zero-intensity peak is assigned to it. Finally,
the correlation between the intensity levels of the correlated dataset peaks and their
respective reference peaks is computed in order to obtain the intra-cluster matching
score.
2. Inter-cluster score: This step consists of identifying the metabolite peaks of the other
reference metabolite protons (see Figure 4.3D). The inter-cluster matching score is
computed as the number of protons of the target metabolite where correlated dataset
peaks have been found, and scaled by the total number of protons. In this calculation,
the weight of each proton depends on the intensity of its reference peaks (i.e. protons
having relevant peaks will have more importance).
3. Penalization score: If correlated dataset peaks are found outside the windows defined
around the peaks of the metabolite protons, a penalization score is computed as Sp =
1−wN , where N is the number of correlated peaks outside the windows and w a user
defined weighting factor that establishes the degree of penalization.
Following this procedure, FOCUS obtains, for each detected peak, a list of candidate metabo-
lite identifications. This candidate list can be sorted by the corresponding identification
scores (i.e. average of the intra-cluster, inter-cluster and penalization scores) in order to
identify the metabolite that better represents this dataset peak. If a reference metabolite
has only one peak, the scoring is performed by averaging the penalization score with a
singlet-score, which is proportional to the closeness of the reference and dataset peaks. Af-
ter this identification step, FOCUS also creates a putative annotated feature matrix, linking
each peak with its top-scored metabolite identification.
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4.2.5 Results Report Generation
In addition to the per-sample peak feature matrix, FOCUS generates an exhaustive and
user-friendly results report which greatly facilitates the exploration of the obtained results.
This web-based report is created locally (i.e. no need of accessing an external server) and
uses JavaScript plugins to improve user navigation along the results. For each analysis, a
summary report is created with the list of detected peaks characterized by their positions,
their quality scores and the best metabolite identification. A set of group identifiers are also
provided, where each peak group refers to peaks that have been grouped due to their high
intensity correlations. Besides this summary report, each peak contains a link to another
webpage that contains detailed information such as correlated peaks and all the metabolites
that can correspond to the peak sorted by their identification scores. For further details see
Supplementary Figure B.5 and the example report available on the methodology webpage
(http://www.urr.cat/FOCUS).
4.2.6 Software
The FOCUS methodology presented here has been developed using Matlab (i.e. data pro-
cessing) and Python (i.e. automatic report generation). The Matlab package and a demo
example can be downloaded from http://www.urr.cat/FOCUS. A Python script for creating
a web-based report of the results generated by FOCUS and an example report can also be
accessed from this web.
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Figure 4.3: Metabolite identification algorithm. This figure shows the processing
steps for metabolite identification. (A) The peaks of each reference metabolite spec-
trum are grouped in clusters (i.e. putative protons) if their distance does not exceed the
maximum intra-cluster distance dcluster . (B) The reference metabolite of subfigure A is
a target metabolite for the dataset peak (red line) since one of its peaks (black lines) is
close to the dataset peak (red line). (C) Intra-cluster matching is performed by identify-
ing correlated dataset peaks (i.e. blue lines) at the positions where the other reference
proton peaks should be found (a tolerance window tpeak is defined around each expected
position). Scatter plots show the intensities of the correlated peaks (blue peaks) against
the intensity of the peak being identified (red peak). Finally, the intra-cluster score is
defined as the correlation of the mean intensity levels of the dataset peaks (blue and
red peaks) versus the library defined intensities of the target metabolite peaks (black
peaks). (D) Inter-cluster matching is defined by the number of protons having at least
a dataset related peak. Search windows are defined by the reference cluster distances
and expanded by a tolerance factor.
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4.3 Experimental section
4.3.1 Liver extract dataset
Liver extract 1H-NMR measurements of 120 samples were conducted as previously de-
scribed. Briefly, for each hepatic sample, 50 mg of tissue was removed, flash-frozen, and me-
chanically homogenized in 2 mL of H2O/CH3CN(1/1). Each homogenate was centrifuged
at 5000g for 15 min at 4◦C and the supernatant containing hydrophilic metabolites was
subsequently frozen at -80◦C. For NMR measurements, the hydrophilic extracts were re-
constituted in 600 µL D2O containing 0.5 mM trisilylpropionic acid (TSP) and transferred
to a 5 mm NMR tube. The 1D Nuclear Overhauser Effect Spectroscopy with a spoil gradi-
ent (NOESY) was used to record 1D 1H-NMR spectra using a 600.2MHz frequency Avance
III-600 Bruker spectrometer (Bruker, Germany) equipped with an inverse TCI 5 mm cry-
oprobe. A total of 256 transients were collected across 12kHz spectral width at 300K into
64k data points, and exponential line broadening of 0.3 Hz was applied before Fourier
transformation. A recycling delay time of 8s was applied between scans to ensure correct
quantification. The frequency spectra were phased, baseline corrected and then calibrated
(TSP, δ=0.0ppm) using TopSpin software (version 2.1, Bruker, Germany).
4.3.2 Human urine dataset
Control individuals were recruited as part of the Immune-Mediated Inflammatory Disease
Consortium (IMIDC)207 repository. Urine samples were obtained from 60 healthy individ-
uals attending to blood bank donations at university hospitals from different regions in
Spain in collaboration with the Spanish National DNA Bank. Urine was collected into 15
ml universal containers with clorhidric acid. All samples were processed 24 hours later, and
stored at -80◦C until analysis. After thawing, 400µL of each HCl-preserved urine sample
were aliquoted and we added 200µL of buffer phosphate (1.5 mM Na2HPO4/NaH2PO4 in
D2O with 0.62 mM of TSP, pH=6.8) to each sample. The final solution was transferred to
a 5 mm NMR tubes for subsequent 1H-NMR acquisition. We applied the same parameters
described above for spectral acquisition and processing. However, in this case the recycling
time was set to 7s.
4.3.3 Metabolite databases
When running FOCUS on the 1H-NMR liver extract and human urine datasets peaks were
annotated by using in-house metabolite databases (see Supplementary Table B.1). These
databases contain the peak positions and relative intensities of the metabolite reference
spectrum measured at pH=7.5.
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The database used for metabolite identification in the liver extract dataset contains 31 ref-
erence metabolite spectra and is based on a list of previously manually identified metabo-
lites. The database used in the human urine dataset analysis was composed of 47 reference
metabolite spectra that are commonly found within this biofluid141;196 either as endoge-
nous/exogenous metabolites or as potential sample handling contaminants.
4.3.4 Alignment Performance Evaluation
We have tested FOCUS alignment performance and compared it to two of the most com-
monly used alignment methods: Icoshift122 and Correlation Optimized Warping (COW)123.
Icoshift algorithm is based on segment-shifting by maximizing spectral correlation against
a reference signal. Like FOCUS, Icoshift uses the FFT in order to speed up calculation as
proposed by Wong et al.123. The reference spectrum is commonly computed as the average
spectrum of all the sample data and the segments in which the whole spectra are divided can
be specified by the user or otherwise determined to be regularly spaced. COW is a warping
alignment method based on dynamic programming that stretches or compresses segment
sections in order to better match the signals to be aligned. This method is also based on a
target spectrum against which sample spectra are aligned. The input data for this method
consists of the segment length and the maximum warping range in the specified segment
length.
In order to evaluate and compare these alignment methods, we first used simulated spectral
datasets under a large range of parametric scenarios. These datasets were characterized by
the presence of two and three peaks per sample, using the Lorentzian distribution108 as the
basis function for building simulated peaks (see Supplementary Text B.4 and Supplementary
Figure B.6 for details) and the different parametric scenarios have been taken into account
by jointly modifying the following parameters: (a) distance between peaks, (b) standard de-
viation of the applied shifts to unalign sample spectra, (c) scale parameter of the Lorentzian
distribution, (d) peak missingness, (e) sample size, and (f), intensity ratio between peaks.
Evaluation was performed on 973 parametric scenarios for each dataset considering all the
possible permutations. The first metric used to evaluate alignment performance was the
distance between the originally aligned spectra and the algorithmically aligned spectra cor-
relation matrices. The second metric was the correlation between the known shifts applied
to unalign the dataset and the shifts derived from the algorithmic alignment. This metric
was only computed for FOCUS and Icoshift, since COW approach does not use alignment
shifts.
In order to also test the alignment performance over a real dataset, we have also used a
human urine NMR dataset composed of 60 samples where spectral unalignment due to pH
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inter-sample variation is clearly visible. The performance was measured using the averaged
spectra correlation208 on different sample sizes (i.e. 10, 30 and 60 samples). A total of 48
informative segments were selected across the entire spectrum to perform this analysis in
order to avoid performance evaluation over uninformative segments (see Supplementary
Figure B.7).
4.4 Results and discussion
4.4.1 Alignment Performance Evaluation
Spectral alignment on the simulated spectral datasets showed a significant improvement
when using FOCUS in comparison to Icoshift and COW (see Figure 4.4 and Table 4.1). Ap-
plying FOCUS significantly reduced the correlation matrix distance between the true aligned
spectra and the algorithmic aligned spectra when compared with Icoshift (Wilcoxon test;
P-value=1e-41) and COW (Wilcoxon test; P-value=8e-38). FOCUS improvements can also
be extended to the shift correlation performance measures (see Table 4.1), where FOCUS
improved the Icoshift alignment results both on the doublet dataset (i.e. 10%) and on the
triplet dataset (i.e. 5%) when evaluating the distances between the expected and the ob-
tained correlation matrices. A more detailed analysis of the results (see Supplementary Fig-
ures B.8, B.9 and B.10) shows that COW performance was more sensitive to sample shifts
than FOCUS and Icoshift, being FOCUS the algorithm with the most stable performance
against changes in the degree of spectral unalignment, the distance between peaks, peak
width and sample size. The simulation analysis results showed the robustness of FOCUS
method against high degrees of unalignment, given that the correlation matrix distances
only increased in 2.5% (i.e. from 1.63e-3 to 1.67e-3) when doubling the standard deviation
of the applied shifts to unalign the spectra. Instead, Icoshift and COW, showed increases of
19.7% (i.e. from 2.71e-3 to 3.24e-3) and 76.9% (i.e. from 2.11e-3 to 3.74e-3), respectively.
Therefore, the RUNAS alignment algorithm implemented in FOCUS shows clearly a bet-
ter performance than the previous methodologies, making it particularly suitable to those
datasets suffering moderate to high unalignment bias either globally or in specific spectral
regions.
When evaluating spectral alignment results on the human urine spectral dataset we also
found a significant performance improvement when using FOCUS (see Figure 4.5A and
Table 4.1). FOCUS, Icoshift and COW respectively showed average spectral correlation im-
provements of 53.49% (from an initial correlation of 0.46 to 0.70), 39.38% (from 0.46
to 0.64) and 35.64% (from 0.46 to 0.62) with respect to the unaligned spectral dataset.
Reducing the number of analyzed samples (i.e. from 60 to 30 or 10 samples) produced
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Figure 4.4: Simulated datasets alignment results. This figure shows the alignment
performance measured over the simulated datasets. (A) and (C) show the distribution of
distances between real and algorithmically aligned spectral correlation matrices across
the different parametric scenarios over the doublet (X2) and triplet (X3) datasets. In
the same way, (B) and (D) show the distribution of correlation coefficients between the
true and the algorithmically computed shifts by FOCUS and Icoshift. COW method was
evaluated using a combination of different parameters (C-[segment length]/[slack]117).
only moderate performance reduction in the three methods, with consistently better results
with the FOCUS aligned dataset. When regarding per-sample correlation results, FOCUS
improvements were similar in all the spectra (see Supplementary Figure B.11). This con-
firms that FOCUS performance is superior in any sample size and does not depend on the
particular sample spectra. The effects of applying FOCUS on unaligned spectral datasets are
clearly visible on those segments which peaks are more susceptible to suffer chemical shifts.
Figure 4.5B shows a spectral segment corresponding to hippuric acid peaks that are highly
affected by unalignment. In these cases, the average spectrum clearly does not represent
the true peak distributions. FOCUS superior performance cannot only be derived from its
correlation gain but also from the increased height to width ratio of the resulting peaks
on the averaged spectrum and from the removal of peak artifacts introduced by the other
alignment methodologies (see Figure 4.5B).
4.4.2 Automated Analysis of the Human Urine Dataset
FOCUS processing workflow was applied to a set of 60 human urine spectra. The unsu-
pervised analysis was performed using the default parameter values: windows with a 50%
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Simulated dataset Human Urine dataset
Algorithm
Distance(C)1 C(Shift)2
C(Spectra)3
X2 X3 X2 X3
FOCUS 1.7e-3 1.6e-3 0.96 0.97 0.70
ICOSHIFT 3.4e-3 2.7e-3 0.87 0.92 0.64
COW 3.0e-3 2.8e-3 na na 0.62
1 Distance between the true and the algorithmically aligned correlation matrices.
2 Shift correlation between the true applied shifts and the correction shifts applied by
the algorithms.
3 Averaged spectra correlation.
Table 4.1: Performance alignment results. This table
shows the most important performance measures obtained
within the simulated and human urine datasets. Two sim-
ulated datasets were evaluated respectively presenting two
(X2) or three (X3) peaks per sample.
Figure 4.5: Human urine alignment results. This figure shows the alignment per-
formance measured over a dataset of 60 human urine NMR spectra. (A) shows the aver-
aged spectra correlation before (i.e. original) and after alignment (i.e. FOCUS, Icoshift
and COW). These performance measures were computed on the complete dataset (60
samples) but also reducing the number of analyzed samples (i.e. 30 and 10). (B) shows
a spectral segment corresponding to hippuric acid peaks and the alignment results for
the three algorithms tested. Black lines represent the averaged spectrum. These figures
show how unalignment can introduce spurious peaks that are not solved by Icoshift and
COW algorithms (red arrows).
of overlap and a length of 0.077 ppms (256 spectral data points), minimum peak width
was of 0.01 ppms and minimum sample frequency to consider a peak was 10%. The only
parameter that needed to be adapted was the minimum intensity increment to consider a
peak which depends on the intensity scale of the analyzed spectra. This minimal parameter
adaptation reflects one of the FOCUS strengths, which is its capacity to easily adapt to the
singular characteristics of different NMR datasets with very few user inputs.
After the sliding window analysis, a set of 390 peaks were obtained which was reduced to
240 peaks (i.e. 38% reduction) after applying redundancy reduction. The mean intensity
correlation between the redundant peaks was of 0.948 which confirms the accuracy of the
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redundancy reduction approach (see Supplementary Figure B.12). At this point, the NMR
data processed by FOCUS represents a quality set of per-sample peak measurements that
can be directly used to perform statistical analyses.
The correlation analysis identified 188, 168, 142 and 123 peak groups using the default
grouping correlation thresholds of 0.95, 0.90, 0.85 and 0.80, respectively. Regardless of
the correlation threshold used, 20 peak groups gathered more than two peaks, being clear
candidates for the identification step since their peaks were highly correlated between them
and uncorrelated with the remaining dataset peaks. These correlation patterns between
peaks are used by the FOCUS metabolite identification algorithm to assign to each dataset
peak the most plausible metabolite. Metabolite clusters were determined using the default
maximum intra-cluster distance of 0.05 ppm and the intensity correlation threshold to con-
sider related dataset peaks was set to 0.80. The tolerance window for matching reference
and dataset peaks and for inter-cluster peak matching was set to 0.03 ppm thus allow-
ing for a certain shift of the dataset peaks with respect to the reference metabolite peaks.
Finally, the peak tolerance window for intra-cluster matching was set to its default value
(0.005 ppm) given that the distance between peaks of the same cluster does not depend on
pH variations. This procedure obtained a set of 22 correct metabolite identifications that
were manually verified and supported by 43 peak-metabolite associations (see Table 4.2
and Supplementary Table B.2). These identifications demonstrated the good performance
of FOCUS identification procedure. For example, peaks associated to citrate, hippurate and
trigonelline obtained large identification scores (i.e. respectively 1.00, 1.00 and 0.97) due
to the presence of correlated peaks inside each cluster and between the clusters (see hip-
purate identification example on Figure 4.6). Creatinine is also another example of correct
identification based only on the inter-cluster matching since reference clusters are only com-
posed of one peak (see Supplementary Figure B.13). Furthermore, other identifications as
lactate also obtained large identification scores (i.e. 0.94) although clusters with lower in-
tensity peaks were not identified, since FOCUS prioritizes the identification of clusters with
higher intensity peaks (see Supplementary Figure B.13).
4.4.3 Automated Analysis of the Liver Extracts Dataset
FOCUS processing workflow was also applied to a set of 120 liver extract NMR spectra. Like
in the previous analysis, only the minimum intensity increment was changed with respect
to the default values. After alignment and peak detection steps, a set of 413 peaks was
obtained which was reduced to 228 (i.e. 44.8% reduction) after the redundancy reduction
step. The averaged intensity correlation between the redundant peaks was of 0.995 also
confirming the accuracy of the approach (see Supplementary Figure B.11).
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Figure 4.6: Metabolite identification. This figure shows two examples of successful
identification of metabolites on NMR datasets using FOCUS. (A) Shows the identifica-
tion results of hippurate on the human urine dataset. Hippurate reference spectrum is
characterized by four clusters (clusters are separated by thick black lines and reference
peaks are represented with black lines ended with circles proportional to the reference
peak intensities). Dataset peaks matched are represented with red lines. (B) Shows the
identification result of lactate on the liver extracts dataset.
The correlation analysis provided 112, 81, 53 and 36 peak groups using the default grouping
correlation thresholds (0.95, 0.90, 0.85 and 0.80). The number of groups gathering more
than two peaks was 15 at all the correlation thresholds, then being good candidates for the
identification step. Since this dataset shows a lower peak position variance across samples,
the tolerance window for matching reference and dataset peaks and for inter-cluster peak
matching could be reduced down to 0.01 (in comparison to the tolerance parameter used
in the human urine dataset which was of 0.03). For the same reason, grouping correlation
threshold was increased up to 0.90. The metabolite identification procedure succeeded to
correctly identify 20 metabolites on this dataset supported by 63 peak-metabolite associa-
tions rightly matched (see Table 4.2). Metabolite compounds like lactate, taurine, tyrosine
and glucose achieved high identification scores due to high intra-cluster and inter-cluster
matching scores (see lactate example on Figure 4.6). Lactate identification is a clear exam-
ple of how FOCUS is able to discriminate identification of partially overlapping metabolites
by detecting non-overlapped multiplets: in this case, both lactate and threonine have an
identical doublet on the 1.33 ppm range. Nevertheless, the identification of correlated lac-
tate peaks from another multiplet (4.08 ppm) increased the lactate score in comparison
to the threonine score (i.e. threonine related multiplets were not found). Other identifi-
83
Chapter 4 Section 4.4
Liver Extracts Dataset Urine Dataset
Metabolite Score ppm Metabolite Score ppm
Creatine 1 3.041 Citrate 1 2.692
Glucose 1 4.642 Creatinine 1 3.054
Lactate 1 4.118 Hippurate 1 7.846
Taurine 1 3.437 Dimethylamine 0.97 2.72
Acetate 0.99 1.92 Trigonelline 0.97 4.448
Choline 0.97 3.206 Choline 0.96 3.209
Fumarate 0.97 6.521 Creatine 0.96 3.939
Alanine 0.95 1.489 Alanine 0.95 1.496
Leucine 0.95 0.978 Lactate 0.94 1.347
Isoleucine 0.93 1.01 Ethanol 0.93 1.203
Tyrosine 0.92 7.205 Formate 0.93 8.468
Glycerol 0.9 3.647 Methanol 0.93 3.367
Valine 0.9 1.041 Taurine 0.92 3.418
β-hidroxybutyrate 0.88 1.208 Acetone 0.88 2.241
Glutamine 0.86 2.463 Acetylcarnitine 0.86 3.201
Creatinine 0.85 3.057 TMAO 0.85 3.288
Uridine 0.85 7.871 Glycine 0.83 3.577
ADP 0.8 8.233 Methylguanidine 0.78 2.832
Phenylalanine 0.78 7.432 Pyruvate 0.74 2.348
Glutamate 0.73 2.36 Cis-aconitate 0.74 3.107
Acetate 0.68 1.931
Phenylalanine 0.66 7.43
Table 4.2: Metabolite identiﬁcation results. This table shows the suc-
cessful metabolite identiﬁcations on the urine and the liver extracts datasets
using FOCUS.
cations, like glutamine, are good examples of the algorithmic improvements achieved by
FOCUS intra-cluster matching. This metabolite has a peak cluster between 2.39 and 2.54
ppm that groups 12 peaks. From these 12 peaks only 4 peaks have been found in this
dataset with high intensity correlations. This low ratio of cluster identified peaks would
result in low identification scores in previous methodologies. Instead, FOCUS obtains a
high identification score (i.e. 0.84), since the reference peaks that have not been identified
are characterized by low intensities with respect to the identified peaks also overlapping
with glutamate peaks (see Supplementary Figure B.14). The same can be observed on the
phenylalanine cluster between 7.32 and 7.44 ppm, where only 4 of 8 peaks were identified
but corresponded to the highest intensity reference peaks and showed the same intensity
pattern. Importantly, the identification algorithm robustness against peak position shifts
can be clearly observed in the lactate and the taurine identifications (see Figure 4.6 and
Supplementary Figure B.14). Lactate peaks on the liver spectra were found with a uniform
shift of 0.003 ppm with respect to the reference. The first taurine peak cluster showed a
perfect matching between reference and dataset peaks, while the second cluster showed a
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difference of 0.008 ppm.
Although multiple peaks have been unequivocally associated to one metabolite, other peaks
may be associated to more than one metabolite with high identification scores. Such is
the case of peak 363 at 1.754 ppm (see Supplementary Table B.3), which is located in the
overlapping region of lysine and leucine spectra and obtains identification scores of 0.83 and
0.82 for lysine and leucine, respectively. In such cases, the exploration of the correlation
patterns of the peaks of interest or the identification of non-overlapping multiplets can help
to unequivocally choose the optimal metabolite (i.e. leucine identification is reached by
identifying its triplet on 0.948 ppm). FOCUS provides an interactive tool which will allow
the users to easily navigate on the generated results for each peak, significantly facilitating
this time-consuming task.
4.4.4 Discussion on general algorithmic performance and analytical
technique limitations
Our results show a good performance of FOCUS in both synthetic and real datasets, thus
making it a suitable solution for untargeted profiling of large-scale metabolomics 1H-NMR
spectra studies. FOCUS has demonstrated to accurately handle spectral artifacts and the
most common analytical source of variances of this type of profiling studies.
Automated segmentation analysis with overlapping avoids peak detection errors when the
sample-spectrum peaks are close to the bounds of the analyzed segment, since they will be
close to the middle of the following segment. Although FOCUS has demonstrated a very
good performance handling misaligned spectra, in some rare occasions slight misalignment
errors have been observed for specific segments containing peaks with uncorrelated shift-
ing patterns. In such cases, FOCUS provides two complementary methods to reduce the
potential impact of this limitation. First, the overlapping segmentation analysis guarantees
that each peak will be analyzed twice with different neighborhoods, keeping only the best
alignment result. Second, the FOCUS peak detection method based on the CPS sets the
peak integration range accounting for the residual shift variability that may have not been
corrected by the peak alignment method. In those rare cases where these methods are not
sufficient to deal with these problems, the users can choose to set their own limits around
the peak of interest to avoid the interferences of the neighboring peaks.
FOCUS peak detection method has also shown to have a large dynamic range (i.e. 1:1000)
on the analyzed datasets. This is due to the use of a frequency threshold: true signal peak
positions are correlated while noise peaks are uncorrelated so they will rarely exceed the
frequency threshold. As previously commented, CPS signal has also demonstrated to be
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robust against residual shifts by broadening the integration area (see Supplementary Figure
B.4B).
The identification module in FOCUS attempts to assign metabolites to NMR peaks according
to a database of standard spectral references. FOCUS has been able to properly identify most
of the common metabolites present in the studied NMR spectra from biological samples.
Furthermore, FOCUS identification report includes several quality control measurements
aimed at facilitating the identification of those cases where metabolite identity assignment
can be difficult due to the inherent technical limitations of an untargeted analysis (i.e.,
heavily overlapped signals).
4.5 Conclusions
The results presented here show that FOCUS NMR analysis software addresses the main
problems that still affect to the processing of high-throughput NMR metabolomic data, FO-
CUS provides an integrated workflow that performs all the necessary processing steps re-
quired to obtain a set of spectral measurements ready for the usual chemometrics analyses.
Importantly, the FOCUS algorithm for spectral alignment (i.e. RUNAS) has demonstrated
a highly significant improvement when dealing with moderate to highly unaligned spec-
tral datasets. This behavior has been achieved by applying an innovative approach where
no reference spectra are needed and the raw spectra are mathematically transformed to
maximize peak alignment and minimize outlier artifacts. Furthermore, the peak detection
method also avoids the bias produced by outlier samples and bases its detection on the
peak-sample frequency. Additionally, FOCUS also provides a new and efficient method for
metabolite identification, facilitating this time-consuming task.
In order to demonstrate the usefulness of FOCUS we have analyzed two spectral NMR
datasets obtained from 60 human urine samples and 120 liver extracts, as well as an ex-
haustive spectral data simulation under a large number of parametric scenarios. According
to our results, FOCUS methodology is an optimal data processing workflow for 1D-NMR
analysis, and its accuracy and efficiency makes it suitable for the forthcoming large-scale
metabolomic studies.
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Abstract
BACKGROUND & AIMS: Crohn’s disease is a highly heterogeneous inflammatory bowel dis-
ease comprising multiple clinical phenotypes. Genome-wide association studies (GWASs)
have associated a large number of loci with disease risk but have not associated any specific
genetic variants with clinical phenotypes. We performed a GWAS of clinical phenotypes
in Crohn’s disease. METHODS: We genotyped 576,818 single nucleotide polymorphisms
in a well-characterized cohort of 1090 Crohn’s disease patients of European ancestry. We
assessed their association with 17 phenotypes of Crohn’s disease (based on disease loca-
tion, disease behavior, disease course, age at onset, and extra-intestinal manifestations). A
total of 57 markers with strong associations to Crohn’s disease phenotypes (P < 2 · 10−4)
were subsequently analyzed in an independent replication cohort of 1296 patients of Euro-
pean ancestry. RESULTS: We replicated the association of 4 loci with different Crohn’s
disease phenotypes. Variants in MAGI1, CLCA2, 2q24.1, and LY75 loci were associated
with a complicated stricturing disease course (Pcombined = 2.01 · 10−8), disease location
(Pcombined = 1.3 · 10−6), mild disease course (Pcombined = 5.94 · 10−7), and erythema no-
dosum (Pcombined = 2.27 · 10−6), respectively. CONCLUSIONS: In a GWAS, we associated 4
loci with clinical phenotypes of Crohn’s disease. These findings indicate a genetic basis for
the clinical heterogeneity observed for this inflammatory bowel disease.
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5.1 Introduction
Crohn’s disease (CD, OMIM(266600)) is a prevalent chronic inflammatory disease charac-
terized by segmental and transmural inflammation of the gastrointestinal tract. Beyond
clinical symptoms, persistent intestinal inflammatory activity leads to disease-related com-
plications such as intestinal stenosis, fistulas, and abscesses. These complications are rarely
managed medically and often require intestinal resection6.
Although the precise etiology of CD remains unknown, it is commonly accepted that it is
caused by the interaction of both genetic and environmental factors209. Recently, the ge-
netic basis of CD risk has been exhaustively investigated by genome-wide association studies
(GWAS). These studies have been highly successful, identifying 140 loci associated with CD
susceptibility210;211. These loci have provided valuable insights into the biological processes
involved in CD etiology, highlighting the importance of the dysregulation of the mucosal
immune system and the loss of intestinal barrier integrity in the development of CD211.
CD is known to be a highly heterogeneous disease showing different patterns of disease
location, clinical behaviour, and complications6;7. From a clinical perspective, the study
of the more severe disease phenotypes, those which require surgical intervention or anti-
TNFα therapy, is of high importance. These phenotypes have shown a significant level of
aggregation within individual families8;9, suggesting that there is a genetic basis for disease
heterogeneity. To date, several candidate gene association studies10–14 have investigated
the association of previously known CD risk loci to disease phenotypes, but only genetic
variants in NOD2 locus have been consistently validated15;16.
In the present work, we have performed the first GWAS on CD clinically relevant phenotypes.
For this objective we used a large multicenter cohort of CD patients207 of Southern European
ancestry. Using an independent cohort of CD patients of the same ancestry we performed a
replication study to validate the most significant loci associated with CD clinical phenotypes.
5.2 Patients and methods
5.2.1 Patient Subjects
A total of 1,338 patients fulfilling Lennard-Jones diagnostic criteria for CD212 were enrolled
in the discovery phase (GWAS) of this study. Patient recruitment was performed between
June 2007 and December 2010 at 15 Gastroenterology departments from different Spanish
university hospitals belonging to the Immune-Mediated Inflammatory Disease Consortium
(IMIDC)207. The IMIDC is a Spanish network of researchers investigating the genomic basis
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of immune-mediated inflammatory diseases. A cohort of 1,493 healthy individuals of the
same ancestry and previously described in Julià et al.207, was used to control for the presence
of genetic stratification and to evaluate the association to overall CD susceptibility of those
loci associated with CD phenotypes. Both CD and control cohorts were Caucasian Europeans
and all their four grandparents were born in Spain.
An independent cohort of 1,627 CD patients was used to replicate the most significant loci
associated with the different CD phenotypes in the GWAS. The clinical selection criteria were
the same as in the discovery cohort, with all patients fulfilling Lennard-Jones diagnostic
criteria. All the patients included in the replication cohort were Caucasian Europeans and
born in Spain. The patients were recruited both from the IMIDC and from the ENEIDA
project213 of the Spanish Working Group in IBD (GETECCU) repository.
An exhaustive record of epidemiological and clinical data was collected for each patient
included in the study (Table 5.1). Informed consent was obtained from all participants, and
protocols were reviewed and approved by local institutional review boards. This study was
conducted in accordance with the Declaration of Helsinki principles.
5.2.2 Crohn’s Disease Phenotypes
CD phenotypes for the GWAS were selected according to their clinical relevance and fol-
lowing the consensus criteria defined by the Montreal classification7 (Table 5.2). Associ-
ation was tested for the main phenotypic disease parameters: disease location (ileal (L1),
colonic (L2), ileocolonic (L3), and upper disease (L4)), disease behaviour (inflammatory
(B1), stricturing (B2), and penetrating (B3)), age at disease onset (early onset (≤16 years)
and late onset (>40 years)), and presence of perianal disease. We also tested for associa-
tion the more frequently reported extraintestinal manifestations: erythema nodosum and
peripheral arthropathy. When analyzing disease behaviour we restricted the control group
to those B1 patients having a follow-up time >10 years (herein defined as B1+ group). The
same restriction was applied when analyzing perianal disease (i.e. the control group was
limited to patients with no perianal disease and with >10 years of follow-up).
In addition to the phenotypes defined above, we also studied the association with addi-
tional disease outcomes related with disease severity and evolution. For this purpose we
analyzed four different complicated disease course (CDC) outcomes: stricturing, penetrat-
ing, non-luminal (defined herein as stricturing or penetrating) and perianal disease. Im-
portantly, only patients that had undergone surgery or had received anti-TNFα treatment
were included in the CDC outcomes (Table 5.2). A mild disease course (MDC) phenotype
was defined as the fulfillment of the following criteria: inflammatory behaviour, follow-up
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Variable Discovery cohort1 Replication cohort1 P-Value OR (95%CI)
Sample size (after quality
control)
1090 1296
Females 551/1090 (50.55%) 658/1296 (50.77%) 0.93 1.01 (0.86-1.19)
Age at diagnosis (years) 26.95 [21.16-35.59] 29.12 [22.49-41.24] 3.54 · 10−8 1.02 (1.01-1.02)
Follow-up time (years) 15.48 [11.80-20.54] 10.65 [6.09-16.56] 4.34 · 10−43 0.92 (0.91-0.93)
Smokers at diagnosis time 465/1090 (42.66%) 466/1296 (35.96%) 8.74 · 10−4 0.75 (0.64-0.89)
Anti-TNF 417/1090 (38.26%) 467/1102 (42.38%) 0.05 1.19 (1.00-1.41)
Ileal location (L1) 242/833 (29.05%) 324/967 (33.51%) 0.05 1.23 (1.00-1.51)
Colonic location (L2) 169/833 (20.29%) 187/967 (19.34%) 0.64 0.94 (0.74-1.20)
Ileocolonic location (L3) 422/833 (50.66%) 456/967 (47.16%) 0.14 0.87 (0.72-1.05)
Upper disease (L4) 110/746 (14.75%) 112/864 (12.96%) 0.31 0.86 (0.64-1.16)
Behaviour B1 460/974 (47.23%) 728/1245 (58.47%) 1.63 · 10−7 1.57 (1.32-1.87)
Inflammatory behaviour
(B1+)2
389/970 (40.10%) 330/1244 (26.53%) 1.60 · 10−11 0.54 (0.45-0.65)
Stricturing behaviour (B2) 340/974 (34.91%) 286/1245 (22.97%) 7.84 · 10−10 0.56 (0.46-0.67)
Penetrating behaviour (B3) 265/974 (27.21%) 280/1245 (22.49%) 0.01 0.78 (0.64-0.95)
Perianal disease 361/1067 (33.83%) 330/1277 (25.84%) 2.81 · 10−5 0.68 (0.57-0.82)
Not perianal disease2 614/1061 (57.87%) 468/1276 (36.68%) 1.27 · 10−24 0.42 (0.36-0.50)
CDC-B2 261/650 (40.15%) 213/543 (39.23%) 0.77 0.96 (0.76-1.22)
CDC-B3 196/585 (33.50%) 173/503 (34.39%) 0.8 1.04 (0.80-1.35)
CDC-Non-Luminal 382/771 (49.55%) 344/674 (51.04%) 0.6 1.06 (0.86-1.31)
CDC-Perianal 143/757 (18.89%) 100/568 (17.61%) 0.57 0.92 (0.68-1.23)
MDC 173/1013 (17.08%) 113/1019 (11.09%) 1.24 · 10−4 0.61 (0.46-0.79)
Early disease onset 75/1067 (7.03%) 96/1287 (7.46%) 0.75 1.07 (0.77-1.48)
Late disease onset 184/1067 (17.24%) 343/1287 (26.65%) 4.38 · 10−8 1.74 (1.42-2.15)
Bowel resection 403/1090 (36.97%) 335/1102 (30.40%) 1.14 · 10−3 0.74 (0.62-0.89)
EIM Erythema nodosum 85/1090 (7.80%) 54/1102 (4.90%) 6.42 · 10−3 0.61 (0.42-0.88)
EIM Arthropathy 215/1090 (19.72%) 146/1102 (13.25%) 5.32 · 10−5 0.62 (0.49-0.79)
Family history3 101/1090 (9.27%) 84/1296 (6.48%) 0.01 0.68 (0.50-0.93)
1 For categorical phenotypes n/N (%) where n is the number of patients displaying the related phenotype, N the total number of patients
and % is the percentage of patients with the phenotype. For quantitative phenotypes (e.g. age at diagnosis) M [IQR] where M is the
median value and IQR is the inter-quartile range.
2 Control groups of perianal disease and behavior phenotypes require absence of the severe outcome and follow-up time > 10 years.
3 ≥1 1st- or 2nd-degree relatives diagnosed with CD.
Table 5.1: Distribution and comparison of subphenotypes and clinical variables
on the discovery and replication cohorts. Comparison of both cohorts was conducted
using Fisher's exact test for categorical variables and logistic regression test for quantitative
variables.
time >10 years, absence of perianal disease, and without the need of surgery or starting of
anti-TNFα treatment.
After defining the most relevant disease phenotypes in CD we performed a total of 17 GWAS
(Table 5.2).
5.2.3 Genotyping in Discovery and Replication Analysis
Genome-wide genotyping was performed using the Illumina Quad610 Beadchips (Illumina,
USA) at the Centro Nacional de Genotipado (CeGen, Spain). Genotype calling was per-
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Variable Negative group1 Nneg
2 Positive group3 Npos
2
Ileal involvement L2 169/187 L1+L3 664/780
Colonic involvement L1 242/324 L2+L3 591/643
Purely ileal vs purely colonic L1 242/324 L2 169/187
Upper disease Not L4 636/752 L4 110/112
Stricturing disease B1+ 389/330 B2 340/286
Penetrating disease B1+ 389/330 B3 265/280
Age at onset Quantitative trait (1067/1285)
Early onset A2+A3 992/1191 A1 75/96
Late onset A1+A2 883/944 A3 184/343
Perianal disease Absence and Follow-up
> 10 years
614/468 Presence 361/330
CDC-B2 B1+ 389/330 B2 and [Abdominal
surgery or anti-TNFα
therapy]
261/213
CDC-B3 B1+ 389/330 B3 and [Abdominal
surgery or anti-TNFα
therapy]
196/173
CDC-Non-Luminal B1+ 389/330 [B2 or B3] and [Ab-
dominal surgery or anti-
TNFα therapy]
382/344
CDC-Perianal Absence Perianal dis-
ease and Follow-up >
10 years
614/468 Perianal disease and
[Perianal surgery or
anti-TNFα therapy]
143/100
MDC Not B1 or Perianal dis.
or Anti-TNF TNFα ther-
apy or Surgery
840/906 B1+and No surgery and
No anti-TNFα therapy
and No perianal disease
173/113
EIM Erythema Nodosum Absence 1005/1048 Presence 85/54
EIM Arthropathy Absence 875/956 Presence 215/146
1 Group used as contrast in the analysis of the indicated variable.
2 Number of samples in the negative and positive phenotype subgroups (Discovery/Validation).
3 Positive group for the indicated variable.
Table 5.2: Clinical phenotypes studied in the GWAS analyses. This Table shows
the phenotypes that were tested for in the GWAS discovery phase.
formed using the Illumina GenomeStudio software v2010.1 (Illumina, USA). A total of
576,818 markers and 1,338 samples were selected for quality control (QC) analysis (Sup-
plementary Materials and Methods C.3). Potential population stratification was evaluated
using the principal component analysis (EIGENSTRAT214; Supplementary Figure C.1). After
QC analysis, a final dataset of 539,846 SNPs and 1,090 CD patients were available for the
clinical subphenotype GWAS.
SNP imputation to further investigate associated loci in the GWASs was performed using
SHAPEIT V2-644215 and IMPUTE V2216 software. We used the data from the European
cohort from the 1,000 Genomes Project217 as the reference panel (Supplementary Materials
and Methods C.3).
The replication genotyping was performed at the HudsonAlpha Institute for Biotechnology
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(Huntsville, Alabama, USA) on an independent cohort of 1,627 CD patients. Fifty-seven
SNPs were selected for replication (Supplementary Materials and Methods C.3) and geno-
typed using the Illumina GoldenGate assay (Illumina, USA). All these SNPs had a call rate
over 97.5%. Genotyping error rate of 0.32% was estimated using a subset of samples (i.e.
5% of the total) that were genotyped twice. After excluding samples with incomplete clini-
cal data or missing rates ≥10%, a final set of 1,296 patients was available for the validation
of the phenotypic associations identified in the GWAS stage.
5.2.4 Statistical Analysis
Descriptive statistics were computed to characterize relevant epidemiological and pheno-
typical variables in the studied cohorts (i.e. discovery and replication cohorts). The distri-
butions of each variable in both cohorts were compared using Fisher’s exact test and logistic
regression test for qualitative and quantitative variables, respectively (Table 5.1). Pheno-
type co-occurrence was investigated by evaluating the association of CD phenotypes with
respect to other variables of interest (Supplementary Material and Methods C.3). Using the
final dataset of QC-filtered SNPs, the GWASs were performed using the allelic χ2 and Wald
tests implemented in PLINK software218 for binary and quantitative variables, respectively.
SNP selection for replication was performed using two criteria. First, the SNPs showing
the strongest statistical significance (P < 5 · 10−6) and representing independent loci were
automatically selected. Second, for those markers showing a moderate level of association
(defined as 5 · 10−6 < P < 5 · 10−4), we performed an evaluation of the functional/regu-
latory impact of the region harboring the SNP (Supplementary Material and Methods C.3)
and we selected those displaying biological evidence219. In order to discard the presence
of confounding effects, a multivariate analysis including gender, smoking habit as well as
the two first principal components of variation was performed on all the SNP-phenotype
associations selected for replication. For the association analysis of the replication study
we also used the allelic χ2 and Wald tests. The criteria for replication included signifi-
cance at the nominal level (P < 0.05) and same direction of effect than the observed in
the GWAS. The combined analysis of GWAS and replication cohorts was performed by test-
ing the association in the combined (GWAS and Replication) dataset. For the replicated
SNP-Phenotype associations we performed a logistic regression model adjusting by gender,
smoking habit, age at diagnosis and the phenotype’s risk factors as identified in the phe-
notype co-occurrence analysis. In order to evaluate the potential regulatory role of each
replicated loci, we used the expression quantitative trait loci (eQTL) browser (Pritchard
Lab, http://eqtl.uchicago.edu/ cgi-bin/gbrowse/eqtl, University of Chicago, USA) as well as
available regulatory data from the ENCODE project220. The NCBI GEO dataset GSE41269221
was also used to evaluate intestinal tissue (i.e. ileal biopsies) specific eQTLs related to the
SNPs with replicated phenotype associations (Supplementary Material and Methods C.3).
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In addition to the GWAS, we performed a validation study of the previously reported SNP-
phenotype associations. The validation was performed at the SNP level and at the locus
level (Supplementary Material and Methods C.3). A total of 91 candidate SNP-Phenotype
associations were identified and analyzed in the discovery cohort. Given the high relevance
of NOD2 locus in CD etiology, we also analyzed the association of the NOD2 polymorphisms
with all the clinically relevant phenotypes in CD.
In order to analyze the effects of associated SNPs in the time from diagnosis to the develop-
ment of stricturing behaviour we performed a survival analysis using Kaplan-Meier estimator
and Cox proportional hazard regression model (i.e. reported as hazard ratios (HR)). This
analysis was performed using the R package Survival222.
The remaining statistical analyses were conducted using R software for statistical computing
(version 3.0.1)223. Association graphics with linkage disequilibrium patterns were gener-
ated using the R package snp.plotter224.
5.3 Results
5.3.1 Phenotypic Characterization of the Studied Cohorts
The clinical and epidemiological characteristics of the discovery and replication patient co-
horts are shown in Table 5.1. The GWAS cohort was characterized by a markedly higher
follow-up time than the replication cohort (Median [Interquartile range]; 15.48 [11.80-
20.54] vs 10.65 [6.09-16.56] years; P = 4 · 10−43). Consequently, there was also a sta-
tistically significant higher percentage of patients with severe clinical phenotypes like B2,
B3, and perianal disease in the GWAS cohort compared to the replication cohort. However,
when looking at the CDC phenotypes, the differences between both cohorts were no longer
significant due to the normalization effect of using the follow-up time restriction. The re-
sults obtained in the phenotype co-occurrence analysis are shown in Supplementary Table
1 and Supplementary Figures C.2 to C.4.
5.3.2 Validation of Previously Associated Loci
From the total of 91 previously described genetic associations excluding NOD2 locus, we
successfully validated ATG16L1, NCF4, and FOXO3 loci associations with inflammatory be-
haviour13 (P = 0.042; OR 1.22; 95% CI 1.01-1.48), perianal disease12 (P = 0.046; OR
1.21; 95% CI 1-1.46) and aggressive disease14 (P = 0.017; OR 0.64; 95% CI 0.44-0.93),
respectively (Table 5.3 and Supplementary Tables 2 and 3). In the gene-set analysis we also
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replicated several significant phenotype associations which include IRGM 10, NLRP111, TCF-
4225, MIF 226, SMAD3227, and HNF4A228 loci (Table 5.3). Supplementary Figure C.5 shows
the loci association P-Values of the validated associations.
We also replicated several previously reported associations of NOD2 with different CD clin-
ical phenotypes (Table 5.3 and Supplementary Table 4). The most significant association
was between intronic SNP rs62029864 and bowel resection (P = 4.5 · 10−6; OR 1.58; 95%
CI 1.30-1.93; Figure 5.1).
NOD2: Phenotype associations
A1/A2 vs A3B2/B3 vs B1L1 vs L2Bowel resection
Figure 5.1: Association between CD phenotypes and NOD2 imputed variants
reaching significant values of association. The upward triangles symbolize the NOD2
variant confers risk for A3, B1, L2, or bowel resection. The downward triangles symbol-
ize the risk is conferred for A1/A3, B2/B3, L1, and absence of bowel resection.
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5.3.3 Phenotype GWAS and Replication Study
We performed 17 GWAS to identify new loci associated with clinically relevant phenotypes
in CD (Table 5.2). Principal component analysis showed no genetic ancestry differences
between the CD cohort and the control population of Southern European ancestry (Supple-
mentary Figure C.1). At the phenotype level, we found no significant correlations between
each of the analyzed clinical phenotypes and the estimated principal components of varia-
tion (Supplementary Figure C.6). Furthermore, no significant deviations from expectations
were observed on quantile-quantile plots within the results of each analyzed phenotype, dis-
carding the presence of systematic bias (Supplementary Figure C.7). SNP intensity cluster
plots were visually inspected to rule out the presence of genotyping errors (Supplementary
Figure C.8).
A total of 57 SNPs associated with clinical phenotypes in the GWAS phase (Supplementary
Figures C.9 to C.11) were selected for replication. Importantly, only 5 of these associated
SNPs mapped to a previously known susceptibility locus for CD (Supplementary Table 5).
Using an independent cohort of 1,296 CD patients, we validated the association of four
SNP-phenotype associations (P< 0.05, same direction of effect as the GWAS) (Table 5.4 and
Figure 5.2). The association of MAGI1 locus on chromosome 3p14.1 with CDC-B2 phenotype
was robustly validated in the replication cohort (rs11924265; P = 3.04·10−4; OR 2.27; 95%
CI 1.41-3.68). Combining the association evidence from the GWAS and replication cohorts,
this genetic association reached the genome-wide level of significance (P = 2.01 · 10−8;
OR 2.27; 95% CI 1.68-3.09). CLCA2 locus association with ileal involvement (rs2249296;
P = 0.033; OR 0.72; 95% CI 0.52-0.99), 2q24.1 locus association with MDC (rs1520339;
P = 0.025; OR 0.69; 95% CI 0.49-0.96) and LY75 locus association with erythema nodosum
(rs10929956; P = 0.044; OR 0.66; 95% CI 0.43-1.01) were also replicated at the nominal
level in the independent validation cohort. All the replicated phenotype associations showed
no significant variation when adjusted by potential confounding variables (Supplementary
Figure C.12) and were not associated to CD risk.
5.3.4 MAGI1 Association to Stricturing Behaviour
The SNP rs11924265, associated with CDC-B2, is located in the first intron of MAGI1 gene.
The healthy control population showed a MAF between the two patient groups (MAFcont rol =
0.092, MAFB1+ = 0.063 and MAFC DC−B2 = 0.133 in the discovery cohort). Consequently, no
significant association was found when testing for association with overall CD susceptibil-
ity. The associated SNP is located in a 46.5 Kb haplotype block inside a MAGI1 intron (from
65,748,962 to 65,795,463 pairbase in chromosome 3; Figure 5.2A and Supplementary Fig-
ure C.13). We found no evidence for regulatory function within this genomic region. In
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Figure 5.2: Association statistics for the four SNP-Phenotype validated loci.
MAGI1 (A), CLCA2 (B), LY75 (C) and 2q24.1 (D) loci associations with CDC-B2, ileal
involvement, erythema nodosum, and MDC, respectively. SNPs annotated in black are
the SNPs associated in the GWAS and validated in the replication study. Asterisks indi-
cate imputed SNPs. Green lines outline gene exon locations. Continuous and dashed
red lines indicate −log10P-Values of 0.05 and 0.01, respectively.
order to evaluate the effect of the follow-up cut-off time on MAGI1 association, we analyzed
the change in effect size (i.e. OR) when increasing the follow-up time cut-off values for B1
patients to be included in the B1+ (i.e. default >10 years) from 2 to 20 years. The results
showed an increment in OR as the follow-up time threshold increased (Figure 5.3 A).
In addition to the association with CDC-B2 phenotype, we also found a strong association of
SNP rs11924265 with B2 behaviour (Supplementary Figure C.13). The association between
this SNP and B2 behaviour was nominally significant in the GWAS cohort (P = 2.29 · 10−4;
OR, 1.99; 95% CI 1.35-2.95) and replicated in the validation cohort with a very similar effect
size (P = 6.66 · 10−4; OR, 2.09; 95% CI 1.33-3.33). In the combined cohort the association
with B2 behaviour was near to the genome-wide level of significance (P = 5.34 · 10−7; OR,
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Figure 5.3: Association results of MAGI1 locus and its role in epithelial barrier
integrity. (A) rs11924265 association to B2 depending on the follow-up cut-off value
for B1+ patients. As the cut-off value increases the number of available B1+ patients de-
crease (i.e. dark blue bars) but the association effect increases (dashed black line). This
may be due to the fact that the larger the follow-up cut-off value the smaller the number
of B1 patients that will develop strictures in the future. (B) Kaplan-Meier curves of stric-
turing onset for risk allele carriers and non-carriers. (C) Kaplan-Meier curves restricted
to CD patients that develop stricturing disease during follow-up. (D) Biological func-
tions of MAGI1 in the intestinal epithelial barrier and previously reported associations
with autoimmune diseases.
2.03; 95% CI 1.52-2.73). Survival analyses evaluating the time from diagnosis to the de-
velopment of B2 behaviour also revealed significant differences between risk allele carriers
and non-carriers (P = 6 · 10−5; HR, 1.64; 95% CI 1.30-2.08, Figure 5.3B). When restricting
this analysis to patients that developed B2 behaviour during follow-up (Figure 5.3C), we
found no significant differences between risk allele carriers and non-carriers indicating that
the risk allele is related with a major B2 prevalence but it does not predispose to an early
onset of this phenotype.
5.3.5 CLCA2, LY75 and 2q24.1 Associations to CD phenotypes
The SNP rs2249296, associated with ileal involvement, is located in the 10th intron of
CLCA2 gene (Figure 5.2B). When compared to the control cohort and to patients with ileal
involvement, patients with purely colonic involvement showed a significantly higher MAF
(MAFcont rol = 0.13, MAFL1/L3 = 0.12 and MAFL2 = 0.22 in the discovery cohort). SNP
rs2249296 lies in an 8.2 kb haplotype block that spans multiple exons of the CLCA2 gene.
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We found evidence of cis-eQTL of this SNP with the expression of ODF2L (P = 2.5 ·10−14), a
gene located at 48Kb from the SNP229. Given that NOD2 is also strongly associated with ileal
involvement, we tested for a genetic interaction (i.e. epistasis) between both genes and the
risk to develop ileal involvement. We did not find any evidence of interaction, suggesting
that the two loci are independently associated with this trait.
The SNP rs10929956, associated with erythema nodosum, is located in an intronic region of
LY75 gene. Its minor allele (T) was found to be protective against the phenotype. The MAF
in the health control cohort was similar to the MAF in the non-affected group of patients
(MAFcont rol = 0.43, MAFuna f f ec ted = 0.46, and MAFa f f ec ted = 0.28 in the discovery cohort).
The associated SNP is located in an 86kb haplotype block (Figure 5.2C) which spans multiple
LY75 exons. Importantly, one of the most strongly correlated SNPs with rs10929956 is a
nonsynonymous SNP (D807E) located in the 18th exon of LY75 gene (rs3951216; r2 =
1.00; PGWAS = 1.09 · 10−5; Supplementary Table 6). We also identified a significant ileal
tissue specific cis-eQTL (P = 1.7 ·10−4) for LY75 gene with another strongly correlated SNP
(rs10168271; r2 = 0.99; PGWAS = 9.69 ·10−6). For this analysis we used the genotyping and
expression data on ileum samples (NCBI GEO dataset GSE41269; Supplementary Table 7
and Supplementary Figure C.14).
The association between 2q24.1 locus SNP rs1520339 and MDC achieved a near genome-
wide significance in the combined dataset (Pcombined = 5.94 ·10−7; ORcombined , 0.58; 95% CI
0.47-0.72). This SNP is located in a 132 kb haplotype block in a gene desert region in the
long arm of chromosome 2 (Figure 5.2D). We found evidence of a trans-eQTL association
with the expression of PDE4D gene in ileal tissue (P = 1.4 · 10−4; Supplementary Table 7
and Supplementary Figure C.14).
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5.4 Discussion
In the present study we report, for the first time, the results of GWAS on clinically relevant
phenotypes in CD. A total of seventeen CD phenotypes of clinical importance were ana-
lyzed which included disease behaviour, disease location, complicated disease course, age
at onset, and other complications like perianal disease and extraintestinal manifestations.
Using an independent cohort of patients, we have validated the strong GWAS association of
MAGI1 with stricturing behaviour and complicated stricturing disease course. This last phe-
notype association reached the GWAS level of significance in the combined cohort. CLCA2,
LY75, and 2q24.1 loci associations with ileal involvement, erythema nodosum, and MDC
were validated at the nominal level. Finally, we also report the first confirmatory evidence
of several phenotype associations reported in previous candidate-gene studies.
MAGI1 gene encodes for the membrane-associated guanylate kinase, WW and PDZ domain-
containing protein 1230. Using survival analyses we have found that this locus predisposes
to stricturing behaviour but does not accelerate its onset. When increasing the follow-up
time threshold for the control group (B1), the association effect increased accordingly due
to the reduced number of misclassified patients in this group. This protein has been shown
to be highly involved in the tight junction of intestinal epithelial cells through the inter-
action with JAM4, a junctional adhesion transmembrane molecule231–234. This interaction
between transmembrane proteins (i.e. JAM4) and scaffolding proteins (i.e. MAGI1) is piv-
otal for the barrier function of epithelial tight junctions ensuring a highly selective barrier
permeability233;235 (Figure 5.3D). This barrier is a complex cell monolayer that separates the
intestinal lumen from the lamina propria236 and acts as a barrier against commensal bac-
teria and foreign antigens. Consequently, the disruption of its homeostasis236–238 can have
dramatic effects on the mucosal integrity, which has been shown to contribute to the devel-
opment of CD and ulcerative colitis (UC)236;237;239–241. Importantly, an increased intestinal
permeability has been described in patients with active CD as well as in their first-degree
relatives239;242–244. This evidence strongly suggests that increased intestinal permeability is
not only a consequence of intestinal inflammation occurring in CD patients, but it is rather
a risk factor for CD. Previous studies242 have shown a significant increase in intestinal per-
meability in patients with stricturing disease, while no significant differences were found
in patients with inflammatory or penetrating disease. This is consistent with the reported
association between MAGI1 and complicated stricturing disease and could contribute to an
overwhelming immune response245;246 and to the subsequent transmural inflammation of
the gastrointestinal tract (Figure 5.3D).
MAGI1 associations to immune-mediated gastrointestinal diseases including CD, UC, and
celiac disease have been previously reported247–250. MAGI1 SNP rs924022, at 54Kb of the
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SNP associated to CDC-B2 in our study, has been previously associated to medically refrac-
tory UC, a severe progressive phenotype that requires colectomy248. Also, very recently,
variation at MAGI1 locus has been associated with CD susceptibility in a candidate gene
study250. Of relevance, the low effect size reported for this locus in CD risk is likely to be
the result of combining CD patients with different behaviour phenotypes. In our patient
cohort we show that, when merging B1 and B2 patients, the joint risk allele frequency be-
comes closer to that of the control cohort, therefore leading to a non-significant association
with disease risk. This result strengthens our hypothesis that there is a genetic basis for
disease heterogeneity that is independent from overall disease susceptibility.
CLCA2 (chloride channel accessory 2) codifies for a protein that belongs to the calcium
sensitive chloride conductance protein family. High expression levels of this gene have been
previously reported251 as a characteristic feature of the follicle-associated epithelium and
M cells in mice. This specialized cell type of the intestinal epithelium is known to play
an important role in the induction of immune responses against mucosal antigens through
the antigen transcytosis mechanism252. CLCA2 gene expression has been also implicated in
colorectal cancer253 and mouse models of UC254. Of importance, SNP associated with ileal
involvement seems to have strong eQTL evidence with ODF2L (outer dense fiber of sperm
tails 2-like) gene229. Further studies are required to characterize the specific role of this
genetic variation in the development of ileal involvement.
SNP rs1520339 in the 2q24.1 locus has been associated to MDC. This marker lies in a large
intergenic region for which there is yet no functional regulatory evidence. Consequently,
functional studies analyzing relevant tissues in CD pathology (i.e. colon and ileum) are
needed to provide more insights on the biological mechanisms influenced by variation at
this locus. Nonetheless, using recent genotyping and genome-wide expression data on in-
testinal samples221, we have identified a specific trans-eQTL of this locus with the phospho-
diesterase 4D (PDE4D) gene. In this association, the allele associated with MDC is associated
with a lower expression of the PDE4D gene. Of relevance, PDE4D has been associated with
the proinflammatory activity in several autoimmune diseases and PDE4D inhibitors are ac-
tually being used for the management of Psoriatic Arthritis and Psoriasis255. At present,
the inhibitors of the PDE4 family of genes are also being studied for treating inflammatory
bowel diseases256. Future studies determining the biological mechanisms underlying the
regulatory evidence between 2q24.1 locus and this proinflammatory enzyme are therefore
warranted.
Finally, variation at LY75 (lymphocyte antigen 75) locus has been found to be associated with
the risk to develop erythema nodosum. There is evidence that SNPs in high LD with the repli-
cated SNP have strong functional effects in ileal tissue (i.e. non-synonymous SNP rs3951216
102
Chapter 5 Section 5.4
and rs10168271 with strong cis-eQTL regulation of LY75 gene expression). LY75 gene en-
codes for a C-type lectin receptor that participates in the immune system response257. LY75
protein has been shown to mediate antigen uptake and presentation, and is mainly ex-
pressed in skin and in plasmacytoid dendritic cells258;259. Importantly, erythema nodosum
is characterized by the inflammation of the subcutaneous fat cells. Additional studies aimed
at characterizing the impact of this genetic variation into protein functionality and immune
cell activity will be required to determine the implication of LY75 in the development of
erythema nodosum in CD.
In conclusion, we have performed the first GWAS for clinically relevant traits in CD and we
have found new risk loci for four different phenotypes. Importantly, these new loci have
not been previously described as risk factors for CD. Our results therefore demonstrate the
existence of a genetic component for disease heterogeneity that is independent of the genetic
variation associated with the susceptibility to CD. Further functional studies of these new
loci will provide a better understanding of the biological mechanisms that are involved in
the development of these relevant clinical phenotypes in CD.
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6 | Discussion
The methodological tools that have been developed in the course of this thesis have demon-
strated a significant improvement in the performance of the typical processing frameworks
of high-throughput genomics and metabolomics studies. All the algorithms have been tested
exhaustively and their accuracies have been evaluated against the state-of-the-art methods
using reference datasets. In addition to the methodological contributions, the GWAS of CD
phenotypes has reported very relevant results in the genetics of CD that provide new clues
for understanding the clinical heterogeneity of this disease.
6.1 GStream: High-throughput SNP and CNV genotyping
GStream solves two major methodological needs of the GWASs analytical workflow. First,
there is a lack of a bioinformatics tool that efficiently integrates both SNP and CNV geno-
typing algorithms. This integration will be crucial to streamline GWAS analyses. Second,
most of the commonly used methods for CNV genotyping at the genome-wide scale do not
use the powerful information generated by the simultaneous analysis of multiple samples
and, instead, they are based on independent, per-sample analysis. While the latter approach
has proven to work well for large genomic CNVs, it clearly fails to identify and genotype
small CNVs, therefore leading to high false negative rates. Small CNVs are highly rele-
vant when studying genome variation since their population frequency is higher than large
CNVs, and they can span important functional regions such as exons, introns and regulatory
elements260.
GStream, the method developed in this PhD thesis, efficiently uses the information gener-
ated by the SNP genotyping stage and by the analysis of multiple samples to significantly
increase the genotyping sensitivity and accuracy in Illumina genotyping microarrays. We
demonstrate that this new method clearly outperforms previous CNV genotyping method-
ologies. Additionally, GStream integrates CNV genotyping with SNP genotyping and has
been designed to be computationally efficient when performing GWASs. GStream has been
implemented in C++ as an open source tool (www.urr.cat/GStream).
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The performance of the genotyping algorithms has been assessed using well characterized
reference data generated by the HapMap project51. Although not the main objective of
this tool, GStream has outperformed previous SNP genotyping methods, providing a su-
perior call rate. When using the most recent Illumina microarray, SNP genotyping with
GStream has allowed to include the complete genotype of >2,000 additional SNPs on av-
erage. GStream obtained the best global genotyping accuracy in all the microarray platforms
tested (i.e. Human610-Quad, Human660W-Quad, Human1M-Duo, and HumanOmni1-Quad;
Table 3.3 and Figure A.3).
GStream provides a major improvement in CNV genotyping compared to previous state-of-
the art methodologies (i.e. PennCNV76, QuantiSNP77 and CNstream148). The performance
of CNV genotyping has been exhaustively evaluated using data from three reference CNV
characterization studies24;142;143, and from the 1KGP project53. The power of GStream to
detect and correctly genotype CNVs was found to be significantly higher than the previ-
ous state-of-the-art methods. GStream has also demonstrated high genotyping efficiency in
cases where the other methods have relevant limitations like, for example, in those CNVs
that span only a few number of probes, or when the intensity distributions corresponding to
the different copy number states show partial overlapping. The multi-component intensity
distribution model implemented in GStream (Figure 3.2) allows researchers to perform a
comprehensive scan of the genome for additional CNVs, broadening their detection range
to shorter, population-specific and/or previously uncharacterized CNVs (Figure 3.5).
In order to provide additional evidence of the superior performance of GStream, we have
also identified several CNVs in strong linkage disequilibrium (LD) with SNPs associated
to different traits in previous GWAS. These CNVs include several known risk loci such as
IRGM1 and LCE3B/LCE3C deletions, that have been associated to Crohn’s disease and pso-
riasis susceptibility, respectively154;155.Importantly, new strong CNV candidates have also
been detected. For example, using GStream a previously uncharacterized deletion span-
ning two exons of SLC2A9 gene was identified; this CNV is in high LD with SNPs previously
associated to uric acid concentration186. In these cases, the highly correlated CNV could be
a powerful causal candidate of the observed genetic association. Therefore, these results
could reveal important insights into the causality of these trait associations, particularly in
those studies when the reported associated SNPs are located in genomic regions with an
unknown functional impact. A complete list of the newly identified CNVs has been made
publicly accessible at www.urr.cat/GStream/SNP_CNV.
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6.2 FOCUS: 1D-NMR processing workflow for high-throughput
metabolomics studies
The second work included in this thesis has been the development and implementation
of FOCUS, a processing workflow for high-throughput NMR-based metabolomics studies.
FOCUS has been implemented using Matlab®as an open-source tool (www.urr.cat/FOCUS).
FOCUS has been developed in order to solve three main challenges in the data processing
workflow of NMR-based metabolomics studies:
• To provide a software tool that efficiently integrates all different algorithms associated
with NMR spectra processing.
• To minimize the impact of technical variability on downstream statistical analyses.
• To significantly improve automatic metabolite identification in NMR processed data
by using all the information available in the reference metabolite spectral databases.
The results provided by FOCUS have demonstrated to efficiently solve these three main chal-
lenges and to provide more accurate results than the previous methodologies. The align-
ment algorithm that has been developed, RUNAS (Recursive UNreferenced Alignment of
Spectra), performs spectral alignment using the cross-correlation function between spectra
as the alignment maximization function (Figure 4.1). In contrast to most of the currently
available methodologies, RUNAS does not rely on the definition of a reference spectrum.
The alignment procedure applies a spectral transformation that enhances peak shapes and
reduces the alignment bias produced by the presence of peaks with highly unpaired inten-
sities.
The performance of RUNAS has been assessed using simulated and real data. Using syn-
thetic data we demonstrate that FOCUS significantly reduces the correlation matrix distance
between the true aligned spectra and the spectra aligned by the algorithm compared to pre-
vious methodologies (Figure 4.4 and Table 4.1). Consequently, FOCUS provides the best
alignment performance improving the subsequent peak detection stage and reducing the
alignment-associated biases. The results of the simulation analysis also show the robust-
ness of RUNAS against high degrees of spectral unalignment. When evaluating spectral
alignment performance of FOCUS using a real human NMR dataset, we show that FOCUS is
clearly superior to other state-of-the art methodologies. FOCUS, Icoshift122 and COW117, re-
spectively, showed average spectral correlation improvements of 53.5%, 39.4%, and 35.6%
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with respect to the unaligned spectral data set (Figure 4.5). Reducing the number of ana-
lyzed samples produced only a slight reduction in alignment performance in all three meth-
ods, with consistently better results with the FOCUS aligned data set. Consequently, the
performance superiority of FOCUS is practically independent of the sample size of the study.
In order to evaluate the metabolite identification algorithm we used FOCUS on two real
spectral datasets. The first dataset consisted in NMR spectra of 60 human urine samples; in
this data, FOCUS was able to correctly identify 22 different metabolites that were manually
verified, demonstrating the good performance of the identification procedure implemented
in this algorithm. The metabolite identification procedure in the second dataset (i.e. 120
liver extract samples) correctly identified 20 metabolites, also confirming the good perfor-
mance of the identification procedure for tissue extract samples.
Finally, the peak detection method implemented in FOCUS has also demonstrated to have
a highly significant accuracy. This is due to the use of a frequency threshold that takes into
account that true signal peak positions are correlated, while noise peaks are uncorrelated.
Consequently, noise peaks will rarely exceed the frequency threshold at a given spectral
position. The results show that FOCUS provides a superior dynamic range (i.e. 1:1000)
compared to other NMR data processing methods of high-throughput metabolomics studies.
This superior sensitivity, allows FOCUS to significantly increase the power of metabolomic
studies to detect relevant metabolite associations.
Overall, FOCUS represents a major improvement in the analytical framework for high-
throughput metabolomics studies. The integration of the different processing stages in a
single tool and the improvements in spectral alignment, peak detection and metabolite
identification algorithms allow a fast and reliable data processing stage for large sample
size studies.
6.3 GWAS analysis of Crohn’s disease phenotypes
CD is a prevalent and highly heterogeneous inflammatory bowel disease that comprises mul-
tiple clinical phenotypes. The most severe CD phenotypes are of high importance since they
can lead to complicated disease progression requiring surgical intervention and involving
a drastic reduction in the patients’ quality of life. CD phenotypes have shown to have a
significant level of aggregation within families8;9, thereby indicating the presence of a ge-
netic risk basis. Although previous GWASs have identified loci associated to disease risk,
the association of specific genetic variants with clinical phenotypes has not been yet studied
at the genome-wide scale.
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During this doctoral thesis, the first GWAS to identify the genetic basis of phenotypic hetero-
geneity in CD has been performed. To date, several candidate gene studies have analyzed
the association of previously known CD risk loci with the susceptibility to develop specific
CD phenotypes (i.e. NOD2, FOXO3 and IRGM). The genomic study included in this thesis
has analyzed the whole genome variability in a large cohort of patients and has identified
new risk loci for different CD phenotypes. Importantly, these new risk loci are not associated
to disease risk, supporting the existence of an independent genetic component specific for
disease heterogeneity.
Using a two-stage GWAS design, 17 different clinical phenotypes of CD have been ana-
lyzed. In this study, we have identified and subsequently replicated four loci associated to
CD phenotypes: MAGI1, CLCA2, LY75, and 2q24.1 loci have been associated to stricturing
behaviour, ileal involvement, erythema nodosum, and mild disease course, respectively.
The association of MAGI1 to stricturing behaviour reached genome-wide significance (i.e.
P < 5 · 10−8) when combining the discovery and validation cohorts. The protein coded by
this gene is a scaffolding protein that mediates cell to cell adhesion of intestinal epithelial
cells231–234. Importantly, genetic variation in this locus has been previously associated to
severe phenotypes in autoimmune diseases of the digestive system ulcerative colitis and
celiac disease248;249. Together, its association to multiple autoimmune bowel diseases and
its regulation of cell adhesion in the intestinal epithelial tissue indicates that MAGI1 is a
powerful biological candidate to be involved in the physiopathology of these diseases.
Disease location is one of the major classification criteria for CD, where the disease can
affect the colon, the ileum or both of them7. Depending on disease location the prognostic
and the therapeutic strategy can differ considerably. The association of this phenotype with
genetic variants in the CLCA2 gene is of high relevance. High expression levels of this gene in
follicle-associated epithelium and M cells have been reported in previous studies251. These
two cell types are found in the intestinal epithelium and are known to play an important
role in the immune response against mucosal antigens. CLCA2 has also been implicated
in colorectal cancer253 and mouse models of ulcerative colitis254 confirming its implication
in bowel disorders. Together, all these evidences reveal the importance of this gene in the
immune response and common disorders of ileal tissue.
Erythema nodosum is an extraintestinal manifestation of CD characterized by the inflam-
mation of the fat cells under the skin. There is evidence that SNPs in high linkage dise-
quilibrium with the associated SNP in the LY75 gene could have strong functional effects
in ileal tissue (i.e. eQTLs and non-synonymous mutations)221. LY75 encodes for a C-type
lectin receptor that participates in the immune system response257. This protein has been
shown to mediate antigen uptake and presentation, and is expressed mainly in skin and in
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plasmacytoid dendritic cells258;259. Importantly, these cells where the resulting protein has
a clear biological function are present in the main affected tissue of erythema nodosum.
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Genomics
• Microarray-based technologies have allowed the parallel genotyping of hundreds of
thousands of genetic variants and the analysis of large sample collections at an increas-
ingly affordable cost. Illumina microarrays have been the most widely used genotyp-
ing platform to perform GWAS and identify new risk variants in common diseases.
However, there is a lack of a software tools that provide accurate methods for CNV
genotyping in this type genotyping platform. The bioinformatics tool developed dur-
ing this thesis, GStream, provides an unprecedented accuracy for both SNP and CNV
genotyping in Illumina platform microarrays. GStream has demonstrated to outper-
form state-of-the-art used methods both in terms of genotyping call rate and accuracy.
Importantly, the CNV algorithm has shown to improve the CNV detection sensitivity,
providing a major coverage of genetic variation than the commonly used algorithms.
Consequently GStream provides an unprecedented power to identify relevant genetic
associations in genome-wide SNP and CNV association analyses.
• In the present thesis work we have performed the first GWAS for clinically relevant
traits in CD. We have identified new risk loci for 4 different CD severity phenotypes.
Importantly, these new loci are not associated to disease susceptibility, thereby con-
firming the hypothesis that there is an independent genetic component that influences
disease heterogeneity in CD.
• GStream has been actually integrated into the analysis pipeline of the IMID-Consortium
GWA studies. In one of these studies, GStream has recently allowed the identification
of an intergenic deletion between ADAMTS9 and MAGI1 genes in chromosome 3 as-
sociated with psoriatic arthritis risk261. Importantly, this new CNV is one of the first
genetic risk factors specifically associated to the joint autoimmune component in Pso-
riatic Arthritis.
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Metabolomics
• The results presented in this thesis show that FOCUS NMR analysis software addresses
the main problems that affect the processing of high-throughput NMR metabolomic
data. FOCUS provides an integrated workflow that performs all the necessary pro-
cessing steps required to obtain a set of spectral measurements ready for the usual
chemometric analyses. Importantly, the algorithm for spectral alignment (RUNAS)
implemented in FOCUS, has demonstrated the best performance when processing
moderate to highly unaligned spectral data sets. This improvement is due to the use
of an innovative approach where no reference spectra are needed. The implemented
algorithm is an iterative alignment method based on the spectral correlation of each
pair of spectral samples and that uses fast Fourier transform to speed up computation.
Furthermore, the peak detection method implemented in FOCUS also avoids the bias
produced by outlier samples since it is based on the peak-sample frequency. Finally,
FOCUS also provides a new and efficient method for metabolite identification, facili-
tating this time-consuming task to spectroscopists that previously had to perform this
task manually.
• The usefulness of FOCUS has been demonstrated analyzing two spectral NMR data
sets obtained from 60 human urine samples and 120 liver extracts. We have also used
simulated spectral datasets under a large number of parametric scenarios for a better
assessment of spectral alignment accuracies. The obtained results show that FOCUS
methodology is an optimal data processing workflow for 1D-NMR data analysis. The
accuracy and efficiency of this tool makes it suitable for the forthcoming large-scale
metabolomic studies that will include very large numbers of biological samples.
• FOCUS is currently being applied in a high-throughput metabolomics study for the
identification and validation of diagnostic and activity biomarkers in IMIDs. This study
has analyzed the urine metabolome within two independent cohorts of >2,500 indi-
viduals including healthy controls and IMID patients. This study has identified and
validated significant differences in urine metabolite levels between the IMID patients
and the healthy controls. The disease activity analysis has also identified significant
associations between metabolite concentrations and the disease activity scores at sam-
ple collection time. The results of this study have been currently submitted for pub-
lication (Alonso et al. "Urine metabolome profiling in immune-mediated inflammatory
diseases").
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8.1 Research Papers in Indexed Journals
• Arnald Alonso, Sara Marsal, Raul Tortosa, Oriol Canela-Xandri and Antonio Julià.
GStream: improving SNP and CNV coverage on genome-wide association studies.
PloS one 8, no. 7 (2013): e68822.
PMID: 23844243
• Arnald Alonso, Miguel A. Rodríguez, Maria Vinaixa, Raul Tortosa, Xavier Correig, An-
tonio Julià and Sara Marsal. Focus: a robust workflow for one-dimensional NMR
spectral analysis. Analytical chemistry 86, no. 2 (2013): 1160-1169.
PMID: 24354303
• Arnald Alonso, Eugeni Domènech, Antonio Julià, Julián Panés, Valle García-Sánchez,
et al. Identification of Risk Loci for Crohn’s Disease Phenotypes Using a Genome-
wide Association Study. Gastroenterology (2014).
PMID: 25557950
8.2 Review Papers in Indexed Journals
• Antonio Julià, Arnald Alonso and Sara Marsal. Metabolomics in rheumatic diseases.
International Journal of Clinical Rheumatology 9, no. 4 (2014): 353-369.
DOI: 10.2217/ijr.14.25
• Arnald Alonso, Sara Marsal and Antonio Julià. Analytical methods in untargeted
metabolomics: state of the art in 2015. Front. Bioeng. Biotechnol. 3, no. 23
(2015).
DOI: 10.3389/fbioe.2015.00023
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8.3 Seminar and conference talks
• Identification and validation of diagnostic and activity urinary metabolomic biomark-
ers in immune-mediated inflammatory diseases. Annual European Congress of
Rheumatology (EULAR), Rome, Italy, 2015.
• Identificación de biomarcadores metabolómicos de diagnóstico y actividad en
enfermedades inflamatorias mediadas por inmunidad. Annual Congress of the
Spanish Society of Rheumatology, Santiago de Compostela, Spain, 2014.
• Identification of disease diagnostic and disease activity metabolomic biomark-
ers in immune-mediated inflammatory diseases. Annual European Congress of
Rheumatology (EULAR), Paris, France, 2014.
• Example of biomarker discovery in inflammatory diseases by NMR metabolomics.
Summer course "Metabolomics an indispensable tool for research in life sciences",
Rovira i Virgili University, Tarragona, Spain, 2014.
• ASTREAM and FOCUS: Two powerful methodologies for mass spectrometry and
nuclear magnetic resonance data analysis. 7th Scientific Conference Vall d’Hebron
Research Institute, Barcelona, Spain, 2013.
• GStream: A fast and highly accurate tool for SNP and CNV genotyping with
Illumina microarrays. 6th Scientific Conference Vall d’Hebron Research Institute,
Barcelona, Spain, 2012.
8.4 Poster presentations
• Identificación y validación de biomarcadores metabolómicos urinarios de diag-
nóstico y actividad en enfermedades inflamatorias mediadas por inmunidad me-
diante resonancia magnética nuclear. Annual Congress of the Spanish Society of
Rheumatology, Sevilla, Spain, 2015.
• ASTREAM and FOCUS: Two powerful methodologies for metabolomic data analy-
sis in high-throughput studies. 1st Scientific conference on Bioinformatics and com-
putational biology, Barcelona, Spain, 2013.
• CNStream2: a fast and highly accurate tool for SNP and CNV genotyping with
Illumina microarrays. 16th Annual International Conference on Research in compu-
tational Molecular Biology, Barcelona, Spain, 2012.
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Figure A.1: Example of raw intensity normalization. The intensity distribution of
candidate homozygote samples (i.e. AA) across its specific allele channel (i.e. channel
A) is plotted together with its centroid scaling value as computed by Peiffer et al.75.
GStream first weights this distribution and computes its maximum to scale the channel
intensities by the corresponding intensity value. This example shows a typical CNV
pattern where the error produced by the first approach is magnified.
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Figure A.2: Example of how zero-threshold is computed. (A) BAF and absolute
intensities of an example marker where some homozygous deletion samples with low
intensity values can be observed. (B) Absolute intensities are sorted and differences
between consecutive sorted intensities normalized to one. The observed peak over these
differences points to the intensity value that will be set as threshold.
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A
B
Figure A.3: CNV labelling and scoring. (A). Category disambiguation when the
two-component model is selected. The leftmost graph shows a case where the higher
intensity component (blue) is more frequent and it is assigned to the diploid state while
the lower intensity component (red) is assigned to the deletion state. This assignment is
due to the fact that high frequency amplifications are very uncommon and undetectable
with this technology. The centre graph shows a case where the higher intensity com-
ponent is less frequent and homozygous deletion samples have been found (magenta).
In this case, the higher component (blue) is assigned to the diploid state and the lower
component (red) to the deletion state fulfilling the expected Hardy-Weinberg equilib-
rium frequencies. Finally, the rightmost graph shows the last case where the higher
intensity component is less frequent and no homozygous deletion samples have been
found. In this case the higher component is assigned to the amplification state and the
lower component to the diploid state. (B) Posterior probability of each copy number
depending on the score assigned by GStream: From 0 to 0.5 samples can be categorized
as homozygous deletion, from 0.5 to 1.5 as hemizygous deletion, from 1.5 to 2.5 as
diploid and from 2.5 to 3 as amplification.
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A                                    B                                   C
Figure A.4: Genotyping performance. (A) Genotyping performance depending on
the drop rate, where calls dropped from the accuracy analysis were selected according
to the genotype call quality score. (B) Genotyping performance depending on the SNP
minor allele frequency. (C) Genotyping accuracy of GStream at different sample sizes
(i.e. N= 20, 40, 60, 80, 160 and 225) compared to the accuracies obtained by GenoSNP
and M3 with the highest sample size (N = 225).
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Figure A.5: Microarray coverage density. Coverage density of each microarray plat-
form over the CNV regions defined by each reference study. There are major differences
between the first Infinum HD platforms (Human610-Quad and Human1M-Duo) and
their succesors including specific CNV coverage (Human660W-Quad and HumanOmni1-
Quad). Both Human610-Quad and Human1M-Duo have a mean number of 10 markers
covering CNV regions, while Human660W was designed with a highest coverage ( 20
markers/region) for almost 50% of the regions. Finally, HumanOmni1-Quad increased
the global coverage to 20 markers/region.
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Figure A.6: Missed associations. Percentage of associations (i.e. P-Value<0.05 over
the golden standard dataset) that were not captured by the different methods tested
(i.e. P-Value>0.05 over the tested method).
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Figure A.7: HumanOmni1-Quad P-Value distributions. Distributions of the P-
Value association ratios depending on the golden standard dataset used for evaluation
(i.e. represented by different colours) and on the P-Value range obtained over the golden
standard calls (i.e. horizontal axis).
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Figure A.8: 1M-Duo P-Value distributions. Distributions of the P-Value association
ratios depending on the golden standard dataset used for evaluation (i.e. represented
by different colours) and on the P-Value range obtained over the golden standard calls
(i.e. horizontal axis).
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Figure A.9: Previously reported CNV associations detected by LD analysis between
GStream CNV genotypes and trait-associated SNPs. (A) LCE gene cluster deletion
associated with Psoriasis risk. (B) NEGR1 deletion associated with body mass index.
(C) IRGM deletion associated with Chrohn’s disease. (D) ARMS2 deletion associated
with age-related macular degeneration. (E) GPRC5B upstream deletion associated with
body mass index.
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Figure A.10: Interesting CNV associations detected by LD analysis between
GStream CNV genotypes and trait-associated SNPs. (A) PADI4 gene deletion asso-
ciated with Rheumatoid Arthritis. (B) TMEM18 downstream deletion associated with
body mass index. (C) 3’-deletion of gene ABCB11 associated with glycated hemoglobin
levels. (D) MAEA gene intron deletion associated with type 2 diabetes. (E) HCG9 dele-
tion associated with Vitiligo. (F) HLA-DPA1 deletion associated with Hepatitis B. (G)
MLIP intron deletion associated with liver enzyme levels. (H) ZAN gene deletion as-
sociated with red blood cell count. (I) ZNF490 intron deletion associated with bipolar
disorder.
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Figure A.11: GStream detected CNP loci spanning disease-related genes (OMIM)
where CNVs have been previously associated with disease. (A) CNP spanning CFHR1
and CFHR3 previously associated to age-related macular degeneration. (B) Deletion of
GHR exon 3 that has been previously associated with increased responsiveness to growth
hormone and Laron dwarfism. (C) Detected SMN gene deletion previously associated
with spinal muscular atrophy. (D) PKHD1 deletion associated with polycystic kidney.
(E) CCL3L1/CCL3L3 deletion previously associated with susceptibility to HIV/AIDS.
Figure A.12: GStream calls across consecutive markers spanning the same CNV
loci. These 6 microarray probes cover the same CNV loci but show very different CNV
intensity patterns. GStream is completely adapted to these types of variations and its
calling procedure is able to obtain very concordant calls when analyzing probes spanning
the same CNV.
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A.2 Supplementary tables
Online resource
doi:10.1371/journal.pone.0068822.s013
Download link
Table A.1: CNV markers in high LD with trait-associated SNPs re-
ported in the GWAS catalog.
Online resource
doi:10.1371/journal.pone.0068822.s014
Download link
Table A.2: Set of 149 CNV consistent loci spanning OMIM genes.
A.3 GStream algorithm
A.3.1 Input data
The input data required by GStream is provided by a single file and corresponds to channel
A and B intensities for each sample at each probe. Each line corresponds to one probe and
columns one to three are reserved for the probe annotation data (name, chromosome and
basepair). The following columns must contain channel A and B intensities for each sample.
Therefore the expected number of columns is Ncol = 3 + 2NS, where NS is the number of
analyzed samples. We recall that channel A and B intensities are proportional to the number
of copies of A and B alleles.
The input file can be easily generated from the Illumina GenomeStudio software by selecting
the data fields required by GStream. Figure A.13 shows the appropriate fields that have to
be used to export GenomeStudio data to GStream.
Since each probe is processed independently, the details on the algorithm will be specified
for only one probe. From here on, channels A and B will be denoted as channel X and
Y to avoid confusion between SNP genotypes (AA, AB and BB) and channel names. The
following nomenclature will be used to refer to the input data:
• Xn: Channel X intensity for sample n at the processed SNP probe
• Yn: Channel Y intensity for sample n at the processed SNP probe
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SNP n
X1     Y1      X2      Y2     X3      Y3     X4      Y4     X5      Y5     X6      Y6     X7      Y7     X8      Y8
Figure A.13: GenomeStudio screenshot. GenomeStudio data table showing the
required columns for GStream analysis.
The following sections explain in detail the algorithmic procedures integrated in GStream.
These sections follow the processing workflow of GStream (Figure A.14) and are subse-
quently and independently applied to each SNP probe:
• Normalization: This step aims to normalize channel X and Y intensity distributions in
order to redress the sensibility bias between both channels.
• SNP Genotyping: This step has the objective of assigning a SNP genotype GTn to each
sample n. Samples are clustered in three main groups: AA homozygotes, AB heterozy-
gotes and BB homozygotes (GTn ∈ AA, AB, BB).
• CNV Genotyping: This step assigns a copy number score SCn to each sample n.
A.3.2 Intensity normalization
This step performs channel intensity normalization in order to equalize both channel inten-
sity distributions. Once this normalization step is performed, a coordinate transformation
is applied to obtain the absolute intensities In and the allelic frequencies BAFn. Channel
intensity normalization is crucial since the sensibility differences of each SNP probe and
channel can lead to bias affecting the genotyping performance.
First, in order to avoid numerical overflows raw channel intensities under a sensitivity
threshold (TS) are set to the minimum allowed value TS:
X ′n =
TS, if Xn < TS;Xn, else. Y ′n =
TS, if Yn < TS;Yn, else. (A.1)
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Figure A.14: GStream workflow. This schema shows the three main stages of
GStream method.
The following step consists of the identification the two candidate homozygote groups, con-
taining the samples that have a high probability of being diploid homozygotes. The candi-
dates must fulfill two conditions:
• Having high absolute intensities (In = X ′n + Y
′
n).
• Having angular coordinates (BAFn =
2
pi arctan
Y ′n
X ′n
) next to 0 (AA homozygotes) or 1
(BB homozygotes).
n ∈ AAcand ⇔
In = X ′n + Y ′n > IminBAFn < θL n ∈ BBcand ⇔
In = X ′n + Y ′n > IminBAFn > 1− θL (A.2)
Once candidate samples are detected (Figure A.16A), the algorithm applies different pro-
cedures to compute the scaling factors depending on the candidate groups identified:
• AA and BB candidates found If both candidate groups have been detected, the algo-
rithm independently computes the scaling factors αX and αY of each channel. These
scaling factors correspond to the maximums of their respective candidate intensity-
weighted histograms HW (Figure A.15) which are computed as follows:
S(m′) = m′10 maxn∈AAcand
(In) , m′ ∈ [0 . . . 10]
W (m) = 0.5 ∗ (S(m) + S(m+ 1)), m ∈ [0 . . . 9]
HW (m) = W (m)3 ∗∑NSn=1 FI(n ∈ AAcand) ∗ FI(S(m)< In ≤ S(m+ 1))
αX = W (ar gmax
m
(HW (m)))
(A.3)
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where FI(ex pr) = 1 ↔ ex pr = True,else FI(ex pr) = 0. αY is computed in the
same way but changing AAcand → BBcand . S(m) is a vector containing the centers of
the intervals used to compute the histogram and W (m) the weighting factor. αY is
computed in the same way but changing AAcand → BBcand within eq.A.3.
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Figure A.15: Weighted intensity histogram.. In this figure two candidate homozy-
gote intensity distributions are shown with a typical CNV pattern. The most frequent
component corresponds to the two-copy component (higher intensity, left side), while
the right side corresponds to the one-copy component. The weighted intensity histogram
approach obtains scaling factors corresponding to the average intensity of the two-copy
samples.
• Only one candidate group found If only the candidate AA homozygote group is de-
tected (resp. BB), a peak detection algorithm is applied over the BAF histogram. If
only one peak is detected, the algorithm assumes that the probe does not capture al-
lelic variation and only detects AA homozygote samples (resp. BB). In that case, both
channels are normalized using the corresponding AA homozygote scaling factor αX
(resp. αY ) as computed in the previous section. If more than one peak is detected
the algorithm assumes that peaks correspond to AA homozygote and AB heterozygote
clusters (resp. BB and AB). αX (resp. αY ) is computed as in the previous section and
αY = αX Rx y (resp. αX = αY R y x) where Rx y corresponds to a cross-sensibility ratio
computed from the heterozygote sample intensities Rx y =
Y het
X het
(R y x = R−1x y).
• Neither AA nor BB candidates found
This case is uncommon. αX and αY are computed as follows:
αX = αY =
1
N
NS∑
n=1
In (A.4)
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Once scaling factors αX and αY are found, channel intensities are scaled and new BAF and
I coordinates are computed (Figure A.16B):
X ′n = X
′
n/αX
Y ′n = Y
′
n/αY
→
In = X ′n + Y
′
n
BAFn =
2
pi arctan
Y ′n
X ′n
(A.5)
Figure A.16: Normalization. (A) This figure shows an example on how homozy-
gote candidates are detected depending on the Imin and θ parameters. (B) Shows the
resulting intensities after normalization. The intensity differences between AA and BB
homozygotes have been corrected and normalized to one.
A.3.3 SNP genotyping algorithm
Once intensities have been normalized, GStream identifies the clusters corresponding to
each SNP genotype (AA, AB and BB). In this stage, specific CNV probes from Illumina mi-
croarrays are processed as the conventional SNP probes, with the singularity of commonly
having only one genotype cluster. The genotyping algorithm is divided into the following
steps:
153
Chapter A Section A.3
• Zero detection: Absolute intensities (In) are used to detect homozygous deletion sam-
ples (0 alleles) characterized by low intensities at both channels (Figure A.17). To do
that the algorithm sorts the intensities in ascending order and computes the averaged
derivative of the resulting vector:
j = f (n) |I j ≤ I j+1 , ∀n ∈ [1 . . . NS]
D( j) = I j+1 − I j
D( j) = D( j−1)+D( j)+D( j+1)3
(A.6)
Only sample intensities below the samples intensity average are taken into this cal-
culation. Once D( j) has been computed, the second stage consists of identifying its
maximum and verifying if it exceeds a predetermined threshold (Tmin). If true, the
zero threshold T0 is fixed to its corresponding intensity value:
T0 =
0.5 ∗ (Iar gmax(D( j)) + I1+ar gmax(D( j)), if max(D( j))> Tmin;0, else. (A.7)
All the samples with an intensity below T0 are excluded from the following analyses
and genotyped as homozygous deletions (GTn = 0 y SCn = 0).
• Limit detection between genotypes: The allele frequency (BAFn) probability density
function (PDF) is estimated computing its histogram HBAF(m). The histogram resolu-
tion Nres (number of bins) is adjusted depending on the number of analyzed samples
between the range 20 < Nres < 40. Once the PDF has been estimated, the maximum
peak corresponding to an homozygote cluster is identified (mp(1)). In order to label
a peak to an homozygote cluster it must be located at allelic frequencies next to 0
(AA) or 1 (BB). From this peak, a sliding window with a predefined length (L = Nres2 )
is applied over the PDF until another value within the window exceeds the first win-
dow value at a predefined distance dp. When this condition is reached, the BAF value
corresponding tho the PDF minimum within the window is set as a genotype limit Lg .
This algorithm is applied iteratively until two limits are fixed (LAA|AB y LBB|AB) or all
the BAF range ([0,1]) has been covered (Figure A.18A). The following pseudocode
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Figure A.17: Zero detection. (A) Shows sample BAF and absolute intensity dis-
tribution within a probe where homozygote deletions can be observed. (B) Absolute
intensities are sorted and peaks are detected over its averaged derivative. If the peak
exceeds a threshold, the corresponding intensity will determine the homozygous dele-
tion intensity threshold.
resumes the algorithm:
HBAF(m), m ∈ [0, 1, ...Nres]; histogram
mp(1) = argmax
m
(HBAF(m)); maximum homozygote peak
ipeak = 2;
while(ipeak < 3), stop condition 1
f or(i = (mp + 1) : Nres), sliding window starting point
mi = argmax
m∈[i...i+ Nres2 ]
(HBAF(m)) maximum within the window
i f (mi −mp(ipeak − 1)>= dp), new genotype peak
mp(ipeak) = mi; new peak position
ipeak = ipeak + 1;
Lgipeak−1 = argmin
m∈[mp(ipeak−1)...mp(ipeak)]
(HBAF(m)) genotype limit
break; search new peak
end
i f (i == Nres), break; end stop condition 2
end
end
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The limits between genotypes determine the BAF ranges assigned to each genotype
and each sample will be genotyped accordingly (Figure A.18B):
GTn =

0, if In < T0;
1, if In ≥ T0 & BAFn < LAA|AB;
2, if In ≥ T0 & LAA|AB ≤ BAFn < LBB|AB;
3, if In ≥ T0 & BAFn ≥ LBB|AB.
(A.8)
• Re-Genotyping: If the number of detected clusters is less than three, each cluster
is reanalyzed with a better resolution (increasing the number of bins used for the
PDF estimation) with the purpose of identifying subclusters corresponding to different
genotypes. This method avoids common errors seen in other algorithms where, for
example, the genotypes corresponding to probes with high discordant sensibilities
between channels are incorrectly assigned.
• Scoring: Finally, a probe quality score and an individual sample genotyping score are
computed (Figure A.18C). The global score is proportional to the average standard
deviation between the BAF values assigned to each genotype, while the individual
scores correspond to the distance between BAF sample value and its assigned genotype
cluster center normalized by the distance between genotype cluster centers.
A.3.4 CNV genotyping algorithm
GStream uses normalized intensities and SNP genotypes computed in the SNP genotyping
stage to identify the presence of deletions and amplifications. These variations are char-
acterized by variable clustering patterns on the intensity probe data (i.e. high frequency
CNVs) or by slight deviations from the diploid distribution (i.e. low frequency CNVs).
One of the improvements incorporated by the algorithm is that each SNP genotype cluster is
independently analyzed, taking only into account the intensity channel that carries valuable
information. This way, the CNV algorithm is divided in four parallel steps (Figure A.19):
• Analysis of channel A intensities from the samples genotyped as AA homozygotes
(X ′n|GTn=AA).
• Analysis of channel B intensities from the samples genotyped as BB homozygotes
(Y ′n|GTn=BB).
• Analysis of channel A intensities from the samples genotyped as AB heterozygotes
(X ′n|GTn=AB).
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Figure A.18: Limit detection between genotypes. (A) Limit detection algorithm
over the BAF probability density function. (B) Resulting genotypes assigned by GStream.
(C) Sample genotype scores.
• Analysis of channel B intensities from the samples genotyped as AB heterozygotes
(Y ′n|GTn=AB).
As well as dividing the analysis in four independent steps, the algorithm is based on the
following assumptions:
• Homozygous deletions (0 copies) are previously detected during the SNP genotyping
stage.
• Due to the technical limitations of genotyping microarrays, the intensity measure-
ments show a saturation effect when amplifications are found. For this reason, in-
tensity clustering patterns corresponding to amplifications are very rare and hard to
detect unless they span multiple probes.
• Samples categorized as homozygote samples (i.e. AA and BB) can correspond to het-
erozygous deletions (i.e. A and B) or amplifications (i.e. AA+ and BB+). Due to the
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Figure A.19: Genotype and channel independent analysis. Each SNP genotype
cluster is independently analyzed using the intensity channel that carries the informa-
tion.
saturation effect the algorithm does not stratify amplifications by the number of allele
copies.
• Samples characterized as heterozygotes (i.e. AB) can have two or more copies (i.e. AB,
AAB, ABB...). The total number of copies can be inferred by independently computing
the number of copies of each allele and then adding the results for each sample.
Below we describe the required steps for determining the CNV genotypes using the SNP
genotype data and the normalized channel intensities:
Model selection
The algorithm starts by adjusting two probabilistic models to the channel intensities that
carry the allele information corresponding to the SNP genotype cluster that is being ana-
lyzed. Due to the mentioned saturation effects, it is very uncommon to observe more than
two intensity clusters in microarray data and, for this reason, only two models will be fit-
ted to the intensity data: a one-component P1 and a two-component P2 Gaussian mixture
model (GMM):
• AA homozygotes =⇒P1(Xn|n ∈ AA) and P2(Xn|n ∈ AA)
• BB homozygotes =⇒P1(Yn|n ∈ BB) and P2(Yn|n ∈ BB)
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• AB heterozygotes =⇒P1(Xn|n ∈ AB) and P2(Xn|n ∈ AB)
• AB heterozygotes =⇒P1(Yn|n ∈ AB) and P2(Yn|n ∈ AB)
These two models will be evaluated over the intensity data to identify which fits better. The
procedure is detailed for the channel X over the cluster genotype AA but it can be easily
extrapolated to other genotypes and channels (Xn→ Yn y AA→ AB or BB).
The first model is fitted using the mean and the variance of the corresponding intensities:
µa =
1
NAA
∑
n∈AA X ′n
σ2a =
1
NAA
∑
n∈AA(X ′n −µa)2
X ′n|n∈AA ∼P1(X ) =N (µa,σ2a)
(A.9)
where NAA refers to the number of samples genotyped as AA. The second model is fitted
using the Expectation-Maximization algorithm (EM):
X ′n|n∈AA ∼P2(X ) =ω1N (µb1 ,σ2b1) +ω2N (µb2 ,σ2b2) (A.10)
The initialization of the 2-component model before applying the EM algorithm is crucial to
achieve an optimal convergence of the EM algorithm and to reduce the number of iterations
required for convergence. The following initialization method (Figure A.20A) has been
developed to ensure these results:
µb =
[med(X ′n|n∈AA)−
σa
4 , med(X
′
n|n∈AA) + 2σa], if
∑
n∈AA(X ′n −med(X ′n))> 0;
[med(X ′n|n∈AA)− 2σa , med(X ′n|n∈AA) + σa4 ], if
∑
n∈AA(X ′n −med(X ′n))≤ 0;
ωb =
[
2
3 ,
1
3], if
∑
n∈AA(X ′ni −med(X ′ni))> 0;
[13 ,
2
3], if
∑
n∈AA(X ′ni −med(X ′ni))≤ 0;
σ2b = [0.1σ
2
a , 0.1σ
2
a]
(A.11)
Once fitted the two models, a set of requirements in order to select the second model have
been carefully developed and, only if all of them are accomplished, the two-component
model (indicating a pattern corresponding to a common CNV) will be selected. Given the
2-component GMM, its probability density function is defined as follows:
P2(X ) = f1(X )+ f2(X ) = ω1q
2piσ2b1
exp (
−(x −µb1)2
2σ2b1
)+
ω2q
2piσ2b2
exp (
−(x −µb2)2
2σ2b2
) (A.12)
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Figure A.20: Model selection. (A) Shows the two-component GMM initialization
within different intensity distributions. (B) Shows how M1, M2 and C are computed.
The X values that maximize each one of the two components ( f1 y f2) and the X value that
minimizes the GMM (P2) between the two component maximums are defined as follows
(Figure A.20B):
XM1 = argmax
X
( f1(X )) −→ M1 = f1(XM1)
XM2 = argmax
X
( f2(X )) −→ M2 = f2(XM2)
XC = argmin
X∈(XM1 ,XM2 )
(P2(X )) −→ C =P2(XC)
(A.13)
Once these values are computed, the five requirements that must be accomplished for se-
lecting the 2-component model are:
• ωbi > 0.04 (0.2) , i ∈ [1, 2]
• f1(XM2)< M1 y f2(XM1)< M2
• Cmin(M1,M2) < 0.8 (0.4)
•
XM1
XM2
< 0.85
• DK L = max(
1
2(
σ2b1
σ2b2
+
(µb2−µb1 )2
σ2b2
− 1), 12(
σ2b2
σ2b1
+
(µb1−µb2 )2
σ2b1
− 1))> 2 (6)
The bracketed values refer to the requirements when analyzing intensities of heterozygote
clusters. These values are more restrictive due to their higher variance and to their lower
likelihood of having copy number patterns.
Component labeling
Once the models corresponding to each set of intensities and genotypes have been deter-
mined, the algorithm must assign a copy number label to each model component. If the
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one-component model has been selected, only one label will be required, while the two-
component model will require two:
AA Homozygotes
P1(X ) selected =⇒ CNAA(X )P2(X ) selected =⇒ CN 1AA(X ) and CN 2AA(X )
BB Homozygotes
P1(Y ) selected =⇒ CNBB(Y )P2(Y ) selected =⇒ CN 1BB(Y ) and CN 2BB(Y )
AB Heterozygotes

P1(X ) selected =⇒ CNAB(X )
P2(X ) selected =⇒ CN 1AB(X ) and CN 2AB(X )
P1(Y ) selected =⇒ CNAB(Y )
P2(Y ) selected =⇒ CN 1AB(Y ) and CN 2AB(Y )
(A.14)
This procedure applies different methods depending on the analyzed SNP genotype:
• Homozygotes
The procedure is detailed for the analysis of channel X intensities over the samples
genotyped as AA (equivalent to the analysis of channel Y intensities over the BB sam-
ples).
– P1(X ) selected: Since only one component has been detected, a unique label will
be required. The default label assigned to this case is CNAA(X ) = 2 (the common
diploid state) unless a high number of homozygous deletions have been detected.
In this case, the assigned label will be CNAA(X ) = 1 to ensure Hardy-Weinberg
equilibrium ( f (−−)> f (A−)> f (AA)).
– P2(X ) selected: Since two components have been detected, two labels will be
required and the weights of each component (ω1 and ω2) are expected to be
proportional to the frequencies of each group. Labels are assigned to ensure
Hardy-Weinberg equilibrium (Figure A.21):
[CN 1AA(X ) , CN
2
AA(X )] =

[1 , 2)], if ω1 <ω2; (Figure A.21A)
[1 , 2], if ω1 ≥ω2 and f (−−) ↑; (Figure A.21B)
[2 , 3], if ω1 ≥ω2 and f (−−) ↓; (Figure A.21C)
(A.15)
• Heterozygotes
When analyzing heterozygotes the common state is AB, which means one copy per
intensity channel. Then, when P1(X ) or P1(Y ) are selected the default labels are
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CNX = 1 or CNY = 1. When P2(X ) or P2(Y ) are selected the default labels are
[CN 1AB(X ) , CN
2
AB(X )] = [1,2] o [CN
1
AB(Y ) , CN
2
AB(Y )] = [1, 2].
A                             B                             C
Figure A.21: Component labeling. These figures show three examples of how labels
are assigned to ensure Hardy-Weinberg equilibrium.
Scoring
Sample scores will be assigned depending on their genotypes and their intensity likelihood
relative to each model component. Depending on the SNP genotype scores will be computed
as follows (Figure A.22):
• AA Homozygotes:
– P1(X ): If the one-component model has been selected, the algorithm assigns to
each sample an score proportional to its deviation with respect to the component
mean:
SCn =

CNAA(X ) +
Xn−µa
8σa
, si | Xn−µaσa |< 8;
CNAA(X ) + 1, si
Xn−µa
σa
> 8;
CNAA(X )− 1, si Xn−µaσa < −8;
(A.16)
– P2(X ): If the two-component model has been selected, each sample is scored
depending on its intensity and its relative position with respect to the mean of
162
Chapter A Section A.3
each component (µb1 and µb2):
SCn =

CN 1AA(X )− 1, si Xn < µb1 − 8σb1 ;
CN 1AA(X ) +
Xn−µb1
8σb1
, si µb1 − 8σb1 ≤ Xn < µb1;
f1(Xn)
f1(Xn)+ f2(Xn)
CN 1AA(X ) +
f2(Xn)
f1(Xn)+ f2(Xn)
CN 2AA(X ), si µb1 ≤ Xn ≤ µb2;
CN 2AA(X ) +
Xn−µb2
8σb2
, si µb2 ≤ Xn < µb2 + 8σb2 ;
CN 2AA(X ) + 1, si Xn > µb2 +
8σ
b2
;
(A.17)
• BB Homozygotes:
Same than previous but replacing: AA→ BB, X → Y and Xn→ Yn.
• AB Heterozygotes:
Para W ∈ [X , Y ]:
– P1(W ): If the one-component model has been selected, the algorithm assigns the
same score to all the samples corresponding to the component label CNAB(W ).
SCWn = CNAB(W ) , ∀n ∈ AB (A.18)
– P2(X ): If the two-component model is selected, each sample is scored depend-
ing on its intensity and its relative position with respect to the mean of each
component (µb1 and µb2):
SCWn =

CN 1AB(Z), si Zn < µb1;
f1(Zn)
f1(Zn)+ f2(Zn)
CN 1AB(Z) +
f2(Zn)
f1(Zn)+ f2(Zn)
CN 2AB(Z), si µb1 ≤ Zn ≤ µb2;
CN 2AB(Z), si µb2 ≤ Zn;
(A.19)
The final score of heterozygote samples will be computed as: SCn = SCXn + SC
Y
n
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Figure A.22: Scoring. These figures show how the scores are assigned depending on
the labels and the number of components of the selected model (red line). Blue points
show the relationship between sample intensities (horizontal axis) and sample scores
(vertical axis). The vertical cyan line represents T0, the 0-copies intensity threshold
computed in the SNP genotyping stage, while the horizontal black-dotted lines represent
the limits between discrete copy number assignments.
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B.1 Supplementary figures
Figure B.1: Moving window analysis for unsupervised analysis. This figure shows
how a whole dataset of sample spectra is divided in overlapping segments in order to
perform an unsupervised analysis. Segment length and overlap can be defined by the
user. In this case a segment overlap of 50% and a segment length of 0.08 ppm have
been defined.
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Figure B.2: Intensity-Weight Signal Transformation. This figure shows three ex-
ample spectral segments and their respective transformed segments. As described, this
transformation reduces and equalizes the intensity ratios between peaks. It also gener-
ates high intensity deltas within the signal peak positions.
Figure B.3: Recursive Unreferenced Alignment. This figure shows a segment
alignment example. Figures above represent the input segment spectra (A) and their
intensity-weight transforms (B). Figure (C) shows the shift applied to each sample at
each iteration and figure (D) the average spectra correlation of the original and trans-
formed spectra across each iteration. Finally, figures (E-F) show the set of original and
transformed spectra once they have been aligned. As showed by this alignment result,
each group of similar spectra has been independently aligned thanks to the correlation
threshold imposed on the iterative shift computation.
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Figure B.4: FOCUS peak picking. The upper figure shows the result of applying the
FOCUS peak picking algorithm to a spectral segment of the liver extracts NMR dataset.
The graphic above shows all the sample spectra (black lines) together with their respec-
tive filtered signals (red lines). Horizontal red lines show the peak regions identified on
each sample that will be used to build the consensus peak signal showed in the graphic
below. Only the peak regions exceeding the frequency threshold (i.e. 0.10) are selected
for further analysis (i.e. respectively blue and red shaded regions on the upper and
lower plots). The lower figure shows the algorithm adaptation to residual peak unalign-
ment by broadening the integration area due to the variance of the per-sample detected
peaks.
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Figure B.5: FOCUS summary report. This figure shows a part of the summary
report generated by FOCUS. Each line represents a peak, which is characterized by its
position (PPM), the segment window where it was analyzed (ID WINDOW), a set of
quality scores (QC-SC,QC-IvsA and QC-IP), a set of group identifiers depending on the
grouping correlation threshold (G-95, G-90, G-85 and G-80) and the most probable
metabolite identification.
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Figure B.6: Synthetic dataset generation. This figure shows how the resulting
synthetic spectral dataset changes when modifying one parameter while the others are
set constants.
Figure B.7: Segments for alignment performance evaluation. This figure shows
the 48 manually selected segments to evaluate alignment performance over the dataset
composed of 60 human urine spectra.
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Figure B.8: Detailed alignment results on the doublet synthetic dataset. This
figure shows the two alignment performance metrics and their dependence on each pa-
rameter. Figures at left show correlation matrix distances between the true aligned and
the algorithmically aligned spectra using Focus, Icoshift and different COW configura-
tions. Figures at right show correlation coefficients between true and algorithmically
computed shifts for Focus and Icoshift.
Figure B.9: Detailed alignment results on the triplet synthetic dataset. This figure
shows the two alignment performance metrics and their dependence on each parame-
ter. Figures at left show correlation matrix distances between the true aligned and the
algorithmically aligned spectra using Focus, Icoshift and different COW configurations.
Figures at right show correlation coefficients between true and algorithmically computed
shifts for Focus and Icoshift.
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Figure B.10: Parameter contribution on performance results. The contribution on
alignment performance of each parameter modeling the synthetic spectra is measured
for each algorithm. This has been done by using a linear regression test that sets the
distance between real and corrected correlation matrices as the dependent variable and
all the parameter values as the input variables within all the 972 simulated scenarios.
Bars show the −log10(P − Value) of each parameter for each algorithm, black lines
above the bars mean positive relation (parameter value increment causes a decrement
on the correlation matrix distances -worst alignment-) and black lines under the bars
mean negative relation (parameter value increment is related to a decrement on the
correlation matrix distances -better alignment-).
Figure B.11: Per-sample averaged spectrum correlation. This figure shows the
performance results based on the per-sample averaged spectrum correlation before and
after applying the alignment algorithms. FOCUS obtains generalized performance im-
provements across all the samples.
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A    URINE DATASET: PEAK REDUNDANCY REDUCTION   B   LIVER DATASET: PEAK REDUNDANCY REDUCTION
Figure B.12: Peak redundancy reduction. This figure shows the peak overlap
versus the intensity correlation of the peak pairs of consecutive analysis windows. A
peak overlap exceeding 0.5 represents a peak repetition and only one of the two peaks
are kept for further analysis.
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Figure B.13: Metabolite identification on the urine dataset. This figure shows two
examples of successful identifications on the urine dataset (i.e. Lactate and Creatinine).
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Figure B.14: Metabolite identification on the liver extracts dataset. This figure
shows two examples of successful identifications (i.e.Glutamine and Taurine) on the
liver extracts dataset.
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B.2 Supplementary tables
METABOLITE DATASET METABOLITE DATASET
β-hidroxyisovalerate Urine Pseudouridine Urine
3-Aminoisobutyrate Urine Pyroglutamate Urine
3-Methylhistidine Urine Serine Urine
4-Hydroxyphenylacetic Urine Succinate Urine
7-Methylxantine Urine TMAO Urine
Acetone Urine Trigonelline Urine
Acetylcarnitine Urine UMP Liver
ADP Liver Uridine Liver
Ascorbate Liver Valine Liver
Betaine Urine β-hidroxybutyrate Liver/Urine
Carnitine Liver Acetate Liver/Urine
Cis-Aconitate Urine Alanine Liver/Urine
Citrate Urine Choline Liver/Urine
Dimethylamine Urine Creatine Liver/Urine
Ethanol Urine Creatinine Liver/Urine
Ethanolamine Urine Glucose Liver/Urine
Formate Urine Glutamate Liver/Urine
Fumarate Liver Glutamine Liver/Urine
Glucose-D-1-Phosphate Liver Histidine Liver/Urine
Glycerol Liver Isoleucine Liver/Urine
Glycerophosphocholine Urine Lactate Liver/Urine
Glycine Urine Leucine Liver/Urine
Hippurate Urine Lysine Liver/Urine
Indoxylsulfate Urine Phenylalanine Liver/Urine
Methanol Urine Pyruvate Liver/Urine
Methionine Liver Taurine Liver/Urine
Methylguanidine Urine Threonine Liver/Urine
NAD Liver Tyrosine Liver/Urine
N-N-Dimethylglycine Urine Uracil Liver/Urine
Table B.1: Metabolite databases used for identiﬁcation. This table
shows the metabolites included on the databases used for the liver extract and
human urine identiﬁcation analyses.
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B.3 FOCUS methodology
B.3.1 Spectral segmentation
FOCUS algorithm performs spectral segmentation in order to independently align consecu-
tive segments within the spectra in a unsupervised way (see Figure B.1). These segments
are defined with a certain degree of overlap (i.e. 50%) so peaks near one segment edge
will be centered in the adjacent segment. A counterpart of this approach is the possibility of
having the same peak repeated across consecutive segments. Nevertheless, after the align-
ment and peak picking steps, FOCUS introduces a peak reduction method that takes this
into account to remove redundant peaks.
B.3.2 RUNAS alignment algorithm
Intensity-weighted signal transform
Previous to spectral alignment, FOCUS applies a mathematical transformation in order to
improve posterior alignment results (see Figure B.2). This transformation is applied to each
input spectrum segment and proceeds as follows:
1. Spectral segment weighting: Since FOCUS algorithm is aimed to be applied itera-
tively within overlapping segments of the entire spectrum, each segment is previously
weighted in order to reduce the weight of the segment points near the edges. There-
fore, each spectral segment is multiplied by a Tuckey window defined with a ratio of
taper to constant sections of 0.4 when segment overlap is set to 50%.
2. Moving average filtering: The resulting segment signal from the previous step is
filtered with a moving average filter in order to avoid spurious sign changes in the
signal derivative.
3. Signal derivative sign: The next step consists of computing the signal derivative
sign as follows,
s¯ti =
∂ sti
∂ x
(B.1)
where sti is the spectrum segment t of sample i once steps 1 and 2 have been applied.
4. Percentile values and limits: Given a number of percentile quantification values
(usually NQ = 10) the percentile values qi and the signal limits Li for each percentile
value are defined as follows,
qi = 100
i − 1
NQ − 1,∀i ∈ [1, NQ] (B.2)
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Li = perc(s¯
t
i , i),∀i ∈ [1, NQ] (B.3)
where perc(x , p) refers to the percentile p of signal x .
5. Percentile weighting of the signal derivative sign: The final step for transforming
the input spectrum segment applies the following formula at each segment point,
S ti (x) = s¯
t
i
NQ∑
i=1
qi I(Li−1 < s¯ti ≤ Li) (B.4)
where I(g) is the indicator function which value is 0 until the condition inside is
satisfied, in which case is set to one.
The resulting signal has multiple advantages for spectral alignment:
• increasing and decreasing spectral regions have opposite signs and, consequently, the
correlation function will be more sensitive to unalignments within peak positions
• the correlation function will also tend to match segments with the same slope sign
• the signal dynamic range (i.e. signal intensity differences between different peaks) is
reduced avoiding high contrasts on the correlation contribution of large versus small
intensity peaks
• value ranges across the different spectra are equalized.
Recursive unreferenced alignment
Given the following set of transformed segment spectra,
S ti (x)
i ∈ [1, NS]t ≡ spectral segment being aligned (B.5)
FOCUS alignment algorithm is applied in two steps (see Figure B.3):
1. MCM and ODM calculation: MCM (Maximal Correlation Matrix) stores the maximal
correlation that can be achieved between each pair of segment spectra considering all
the possible shifts. ODM (Optimal Distance Matrix) stores the shift to be applied
to each segment in order to achieve the maximal correlation with another sample
segment. These matrices are computed as follows,
ODM0i j = max
δ∈[1,LS]
(C(S ti (x −δ), S tj (x))) (B.6)
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MC Mi j = C(S
t
i (x −ODMi j), S tj (x))) (B.7)
where i and j are the pair of sample segments considered, LS is the segment length,
δ the segment shift and C(g) the correlation function. FFT is used in order to speed
up this computation.
2. Recursive alignment: Recursive alignment is based on the previous matrices and on
a correlation threshold that excludes from the shift calculation of each segment all the
other segments that do not achieve a maximal correlation above this threshold. Four
steps are recursively iterated until convergence:
(a) Shift calculation for each segment:
δki =
NS∑
j=1
I(MC Mi j ≥ CT )MC Mi jODM ki j
2
NS∑
j=1
I(MC Mi j ≥ CT )MC Mi j
,∀i ∈ [1, NS] (B.8)
where k refers to the algorithm iteration and NS to the number of segments to
be aligned.
(b) Segment shift update:
S ti (x) = S
t
i (x −δki ),∀i ∈ [1, NS] (B.9)
(c) ODM update:
ODM k+1i j = ODM
k
i j −δki +δkj (B.10)
(d) Convergence check: Recursive alignment stops either if the applied shifts to all
the spectral segments are 0 or if the number of maximal iterations has been
achieved:
stop conditions

NS∑
i=1
I(δki = 0) = NS
k > Kmax
(B.11)
B.3.3 Peak detection
Peak picking and area integration is performed by FOCUS using as input data the aligned
segment spectra defined as follows:
si(n)
i ∈ [1, NS]n ∈ [1, NP] (B.12)
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where NS is the number of sample spectra and NP the number of spectral points within the
analyzed segment.
First step consists of a per-sample peak identification and the calculation of a consensus
peak signal p(n) that stores at each segment point the global peak frequency across the
samples (see Figure B.4). This signal is computed as follows:
1. The consensus peak signal is initialized to zero: p(n) = 0,∀n
2. Peak identification at the sample spectrum level is performed as follows:
(a) The spectrum i is first filtered using a second derivative gaussian signal ΨLF(n):
s fi (n) = si(n)ΨLF(n) (B.13)
where LF refers to the filter length and its default value is 0.01 ppm.
(b) Once filtered, FOCUS obtains for each sample the zero-crossing signal d fi (n) de-
rived from s fi (n):
d fi (n) = I(s
f
i (n)> 0)− I(s fi (n− 1)> 0) (B.14)
where I(g) refers to the indicator function. The resulting signal will worth 0
unless a negative to positive (+1) or positive to negative (-1) zero-crossings are
found.
(c) For each sample, the "peak regions" are identified and delimited over d fi (n). The
peak region j delimited by points ai j and bi j must fulfill the following six criteria:
(1) ⇒ ai j < bi j (B.15)
(2) ⇒ d fi (ai j) = 1 (B.16)
(3) ⇒ d fi (bi j) = −1 (B.17)
(4) ⇒ d fi (n) = 0,∀n ∈ (ai j, bi j) (B.18)
(5) ⇒ max
n∈(ai j ,bi j)
(sni )− minn∈(ai j ,bi j)(s
n
i )≥ T 1I (B.19)
(6) ⇒ maxn∈(ai j ,bi j)(s
n
i )
minn∈(ai j ,bi j)(s
n
i )
≥ T 2I (B.20)
where i refers to the sample spectrum, j identifies the peak region, ai j − bi j de-
limit the peak region, and T 1I and T
2
I respectively refer to the minimum intensity
increment and minimum percentage increment in a region to be considered as a
peak.
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3. Once FOCUS has computed the "peak regions" for all the sample spectra, the consensus
peak signal is easily updated as follows:
p(ai j ≤ nbi j) = p(ai j ≤ nbi j) + 1
∀i ∈ [1, NS]∀ j ∈ [1, N iPR] (B.21)
where N iPR refers to the number of "peak regions" identified over the spectrum i.
4. Finally, the consensus peak signal is scaled and filtered with a moving rectangular
window ΠLF/4 of length LF/4 where LF refers to the filter length used in equation
B.13:
p(n) =
p(n)
NS
ΠLF/4(n) (B.22)
Once the consensus peak signal has been computed the overall segment peak regions can
be easily computed. The value of this consensus peak signal can be regarded as the peak
frequency on the analyzed sample spectra (i.e. p(n) = 1 means that all the samples have a
peak region spanning the spectral point n). Thus, the global peak regions that will define a
peak are identified by repeating steps 2a to 2c only over the consensus peak signal. Criteria
to consider a peak on the consensus peak signal are defined as follows:
(1) ⇒ ai j < bi j (B.23)
(2) ⇒ d fi (ai j) = 1 (B.24)
(3) ⇒ d fi (bi j) = −1 (B.25)
(4) ⇒ d fi (n) = 0,∀n ∈ (ai j, bi j) (B.26)
(5) ⇒ max
n∈(ai j ,bi j)
(p(n))≥ fT (B.27)
Finally, the global peak regions can be expanded or rejected following these two criteria:
1. If the peak region is narrower than a predefined minimal peak width (which its default
value is set to 1e-3 ppm) it is rejected.
2. The peak region is expanded to a maximum range value of 0.5 times its width unless
another peak region is found or the consensus peak signal reaches a zero.
B.3.4 Peak reduction
Before proceeding with metabolite identification, the list of peaks must be analyzed in order
to reduce their redundancy. This peak reduction method is applied to reject redundant
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peaks that have been obtained in consecutive spectral segments. This is specifically intended
for unsupervised analysis where the spectra are divided in consecutive segments with a
50% overlap. Thus, a peak can be obtained twice on two consecutive segments and this
redundancy must be avoided.
Considering two consecutive overlapping segments i and i+1 the peak reduction method
takes into account all the peaks detected within each segment:
pmi ⇒ m ∈ [1, Ni] (B.28)
pmi+1 ⇒ m ∈ [1, Ni+1] (B.29)
where pmi and p
n
i+1 respectively refer to the peaks detected in segments i and i + 1. Ni and
Ni+1 are the total number of peaks detected on each segment.
For each pair of peaks (pmi , p
n
i+1 FOCUS computes the average per-sample cross-peak overlap:
Osm,n =
max(0, min(x sR(p
m
i ), x
s
R(p
n
i+1))−max(x sL(pmi ), x sL(pmi ), x sL(pni+1)))
max(x sR(p
m
i )− x sL(pmi ), x sR(pni+1)− x sL(pni+1)) (B.30)
Om,n =
1
NS
NS∑
s=1
Osm,n (B.31)
where Osm,n is the spectral overlap between peaks (p
m
i ) and (p
n
i+1) for sample s and Om,n the
average per-sample cross-peak overlap. x sR(p) and x
s
L(p) respectively refer to the right and
left limits of peak p defined for sample s.
Peak pairs having Osm,n ≥ 0.5 are selected and the method keeps only the peak that has a
greater peak shape correlation.
B.3.5 Metabolite identification
Metabolite identification is based on matching reference spectra corresponding to each
metabolite to the set of peaks identified on the analyzed data. A metabolite reference spec-
trum is defined by its spectral peaks, which are defined by its positions (ppm) and relative
intensities (i.e. heights):
Mi ≡ {pri =
ex ri ,eI ri }, r ∈ [1 . . . Ri] (B.32)
where metabolite i(Mi) is defined by Ri peaks. ex ri refers to the reference peak position andeI ri to its relative intensity.
Before starting the identification of each dataset peak, FOCUS clusterizes each reference
metabolite spectrum obtaining a set of peak reference clusters that group close spectrum
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peaks:
|ex ri − ex si |< dclust ⇒ C ri = C si (B.33)
|ex ri − ex si | ≥ dclust ⇒ C ri 6= C si (B.34)
(B.35)
where C ri refers to the cluster identifier of the reference peak r within metabolite i.
Once all the metabolite spectra have been clusterized, the identification process for each
dataset peak begins. Given a dataset peak:
Dp

xp ≡ Dataset peak position (ppm)
I sp ≡ Dataset peak intensity for sample s
I cp = median(I
1
p . . . I
s
p . . . I
Np
p )≡ Dataset peak median intensity
(B.36)
it will be matched against all the reference metabolites that have, at least, one peak close
to the dataset peak:
|xp − ex ri | ≤ tcluster ⇒ Mi ∈ CAN Dp (B.37)
where CAN Dp refers to the set of metabolite candidates for the dataset peak p.
Given one dataset peak Dp (equation B.36) and one matched peak ri from a candidate
metabolite Mi (equation B.32) their identification score is computed as follows:
• If the candidate metabolite has only one spectral peak, the identification score will be
based on averaging the three following components:
1. The first component score is based on the distance between the reference peak
and the dataset peak. This score is scaled with respect to twice the cluster toler-
ance:
S1 = 1− min
 |xp − ex ri |, 2tcluster
2tcluster
(B.38)
2. The second component takes into account the peak quality score computed as
the per-sample average correlation of peak shapes:
S2 = QP (B.39)
3. The last component consists of the penalization score introduced to penalize the
presence of other dataset peaks highly correlated with the matched dataset peak:
S3 = max(0, 1−wN) (B.40)
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where w refers to a weighting factor and N to the number of highly correlated
dataset peaks.
• If the dataset peak has multiple spectral peaks, the identification score is based on the
three following components:
1. Intra-cluster component: If the peak reference cluster Ci has more than one peak,
a set of search windows are defined around each reference peak that belongs to
the same cluster than the matched reference peak. These search windows are
placed in a way to maintain the position pattern of the reference intra-cluster
peaks, taking also into account the distance between the matched reference and
dataset peaks. Left and right window limits are computed as follows:
∀m ∈ C ri ⇒
Lmc = xp − (ex ri − exmi )−
tpeak
2
Rmc = xp − (ex ri − exmi ) + tpeak2 (B.41)
Once these windows have been defined, the algorithm searches for all the dataset
peaks spanning them and related with the peak that is being identified by a per-
sample intensity correlation coefficient exceeding a correlation threshold. If a
search window does not identify any related dataset peak a zero-intensity peak
is assigned (i.e. it has not been found). Finally, the correlation between the
intensity levels of the related dataset peaks and their respective reference peaks
is computed in order to obtain the intra-cluster matching score:
S1 = corrcoefC ri =m,r↔p{eI ri ,eI cp} (B.42)
where m refers to the cluster identifier of the matched reference peak and r↔ p
means that dataset peak Dp (equation B.36) and reference peak p
r
i (equation
B.32) have been matched.
2. Inter-cluster component is based on the number of reference metabolite clusters
having correlated dataset peaks. Inter-cluster search windows are defined to
maintain the position distances between the reference peak matched and the
reference peaks of the other clusters. A tolerance window using tcluster is also
defined across the first and the last peak of each cluster. The final inter-cluster
score is computed as follows:
S2 =
∑
m∈Ci
Fm maxC ri =m(
eI ri )∑
m∈Ci
maxC ri =m(
eI ri ) (B.43)
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where Ci refers to the set of clusters identified for metabolite i and Fm is set to
0 unless a correlated dataset peak has been found within the search window for
cluster m.
3. The last component consists of the penalization score introduced to penalize
the presence of other dataset peaks highly correlated with the matched dataset
peak. Correlated dataset peaks outside the metabolite cluster regions are taken
into account for this calculation (see equation B.40).
Once all the three components have been computed, the final identification score for a candi-
date metabolite against a dataset peak is calculated as the average of the three components.
B.4 Alignment evaluation
B.4.1 Synthetic spectral datasets
Synthetic spectral dataset generation
In order to test the different alignment methods and both evaluate and compare their per-
formance two synthetic datasets have been generated. These datasets are characterized by
the presence of two and three peaks per sample respectively. The sample generated spec-
tra have been derived from the following formulas using the Lorentzian probability density
function (PDF) as the basis function for peak definition:
Doublet ⇒ ys(x) = Ms,1(a + As,1)
piλ(1+ ( x−Us+x0λ )2)
+
Ms,2r(a + As,2)
piλ(1+ ( x−Us−x0λ )2)
(B.44)
Triplet ⇒ Ms,1(a + As,1)
piλ(1+ ( x−Us+x0λ )2)
+
Ms,2r(a + As,2)
piλ(1+ ( x−Usλ )2)
+
Ms,3(a + As,3)
piλ(1+ ( x−Us−x0λ )2)
(B.45)
Spectra depend on deterministic (a, r, x0,λ) and random variables (M , A, U) which are de-
fined as follows:
• a: This parameter defines the mean peak intensity that is used for all the modeled
peaks
• A: Normally distributed random variable with zero mean. The standard deviation of
this variable defines the peak intensity variability across de samples.
• r: This parameter defines the intensity ratio between the generated peaks of each
spectrum.
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• M : Random binary variable ([0,1]) that accounts for the probability of a sample of
having missing peaks. Frequency of zero values (missingness) is the parameter that
controls this variable.
• λ: Scaling parameter of the Lorentzian PDF that accounts for the peak width.
• x0: This parameter defines the distance between the different peaks in the generated
spectra. This distance is 2x0 in the "doublet" dataset and x0 in the "triplet" dataset.
• U: This random variable defines the simulated unalignment between samples. It fol-
lows a zero means normal distribution which standard deviation will be proportional
to the sample unalignment degree.
In order to test alignment methods, each dataset has been simulated under a high number
of scenarios defined by the parameters above. Since the generated spectral dataset depends
on random variables, each scenario has been iterated n=10 times and the performance
measurements averaged across them. In our simulations spectra have been defined with
NX = 256 data points, a = 4 and σ(As,i) = 1.2. The different scenarios have been obtained
by permuting all the following parameter values:
• Distance between peaks: x0 ∈ [5, 10,20, 40]
• Scale parameter: ∈ [2, 5]10
• Peak intensity ratio: ∈ [1, 2,4]
• Peak missingness: f (Ms,i = 0) ∈ [0,0.2, 0.5]
• Standard deviation of unalignment shifts: σ(Us) ∈ [20,30, 40]
• Sample size: NS ∈ [25, 50,100]
Taking into account all the possible permutations, 972 scenarios were generated. Figure
B.10 shows how the resulting spectral dataset changed when modifying one parameter while
the others are set constants.
Alignment evaluation
For each simulated scenario all the true aligned spectra is known and saved before apply-
ing the artificial unalignment (U in the previous subsection). The ideal alignment method
should therefore return back the spectra to their initial known positions. In order to pro-
vide correct performance measurements we have used two metrics, which are computed as
follows:
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1. CORRELATION MATRIX DISTANCE: Since the ultimate aim of the alignment meth-
ods is to recover the relative position that each spectrum had with respect to the
others before applying unalignment, their performance is measured using the dis-
tance between the initial correlation matrix (previous to unalignment) and the final
correlation matrix (after consecutively applying the simulated unalignment and the
alignment method):
dA =
√√√√√ NS∑i=1 NS∑j=1(Ci j − Cˆi j)2
NS(NS − 1) (B.46)
where A refers to the applied algorithm, Ci j to the correlation coefficient between
spectra i and j before applying unalignment, Cˆi j to the correlation coefficient between
spectra i and j before after applying alignment algorithm A and NS to the number of
sample spectra.
2. SHIFT CORRELATION: Since Focus and Icoshift are based on shifting each spectrum
to maximize correlation their performance can be measured by comparing the cor-
rection shifts they apply with respect to the previously applied shifts to unalign the
dataset. Therefore, this performance measurement uses correlation coefficient be-
tween applied shifts to unalign the dataset and the correction shifts applied by these
two alignment methods.
B.4.2 Human urine spectral datasets
Alignment evaluation has also been tested over a complex dataset of 60 human urine spectra
where unalignment effects of chemical shifts are clearly visible. 48 informative segments
were selected across the 1H-NMR spectra in order to base the performance measures on the
alignment of relevant peaks (see Figure B.4).
The metric used for evaluation was the averaged spectra correlation matrix after and before
applying the three alignment algorithms:
CA =
NS∑
i=1
NS∑
j=1
CAi j
NS(NS − 1) (B.47)
where NS is the number of sample spectra and C
A
i j the correlation coefficient between sample
spectra i and j. A can refer to spectra before alignment or after applying FOCUS, Icoshift or
COW alignment.
188
Chapter B Section B.4
Per-sample averaged spectra correlations were also computed in order to evaluate the align-
ment at the sample level:
C iA =
NS∑
j=1, j 6=i
CAi j
NS(NS − 1) (B.48)
Finally, the number of sample spectra analyzed was varied to test the possible effect of
sample size in alignment performance. Measures were taken for the whole dataset (N=60)
but also for N=30 and N=10 samples. When evaluating the alignment over N=30 and
N=10 the results were averaged across 20 sample permutations.
189
Chapter B Section B.4
190
C | Supplementary Data of the Genome-
Wide Association Study for Crohn’s
Disease Phenotypes
C.1 Supplementary figures
191
Chapter C Section C.1
Figure C.1: Distribution of principal components 1 and 2 between the control
and CD samples included in the discovery GWAS analysis. Both cohorts obtain very
similar distributions thus discarding the need of population stratification adjustment in
our analyses. The dashed green lines correspond to 3 times the standard deviation of the
corresponding principal component scores. Samples outside these limits (n=76) were
excluded (i.e. not shown).
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Figure C.5: Association values at the previously reported phenotype susceptibility
loci. This figure shows the validated previously reported SNP-Phenotype associations.
The marker color scale indicates the LD of the SNP regarding to the reported SNP (from
1 to 0).
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Figure C.6: Distribution of principal components 1 and 2 within each phenotype
to assess population stratification. The boxplots show the distribution of principal
components 1 and 2 within each discrete phenotype (groups 1 and 2 respectively refer
to negative and positive groups as defined in Table 5.2). For continuous variables (e.g.
age at onset), a scatter plot shows any relationship between principal components and
the variable values.
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Figure C.7: Quantile-quantile plots of GWAS analyses of CD phenotypes. P-
Values for categorical phenotypes were computed using the χ2 allelic test. Continuous
phenotypes (e.g. age at onset) were evaluated using the Wald test asymptotic P-Values.
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Figure C.8: Intensity plots for the 4 successfully replicated SNPs. Channel X and
Y intensities for the samples included in the GWAS (i.e. at left) and validation (i.e. at
right) cohorts. Samples in black correspond to missing calls while blue, green and red
refers to the AA, AB and BB genotypes.
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Figure C.12: Adjusted association of replicated SNP-Phenotype associations. Un-
adjusted and adjusted P-Values for the four SNP-Phenotype validated associations.
Figure C.13: GWAS results within the imputed MAGI1 locus. GWAS association
values with structuring behaviour (B2), complicated stricturing disease course (CDC-
B2), and LD pattern within the MAGI1 locus. The upward and downward triangles
indicate that the minor allele is a risk or a protective allele, respectively.
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Figure C.14: eQTL analysis of the replicated phenotype associated SNPs. This
figure shows two relevant ileal eQTLs found for two of the associated SNPs. The NCBI
GEO GSE41269 dataset was used for this analysis.
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LOCI SUBPHENOTYPE SNP Basepair P1 LD2
q24.1 MDC rs1540803 156709593 3.69 · 10−6 0.99
q24.1 MDC rs1520339 156751921 4.94 · 10−6 1.00
q24.1 MDC rs1540804 156725938 2.64 · 10−5 0.95
q24.1 MDC rs3843321 156762304 2.92 · 10−5 0.95
q24.1 MDC rs10190879 156693033 7.21 · 10−5 0.93
MAGI1 CDC-B2 rs77617242 65751923 1.29 · 10−5 0.98
MAGI1 CDC-B2 rs114897644 65755145 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs79650565 65755317 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs77474762 65755741 2.07 · 10−5 1.00
MAGI1 CDC-B2 chr3:65759650:D 65759650 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs11924265 65760342 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs11920326 65760606 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs79032699 65761301 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs72908267 65761770 2.07 · 10−5 1.00
MAGI1 CDC-B2 rs79225788 65753811 2.07 · 10−5 0.98
LY75 Erythema nod. rs12692570 160726599 5.81 · 10−6 0.97
LY75 Erythema nod. chr2:160726952:I 160726952 6.19 · 10−6 0.97
LY75 Erythema nod. chr2:160726954:I 160726954 6.19 · 10−6 0.97
LY75 Erythema nod. rs2136977 160722850 8.54 · 10−6 0.99
LY75 Erythema nod. rs2729704 160707866 9.53 · 10−6 0.99
LY75 Erythema nod. rs10168271 160729186 9.69 · 10−6 0.99
LY75 Erythema nod. rs10929956 160714615 1.05 · 10−5 1.00
LY75 Erythema nod. rs55664214 160708059 1.06 · 10−5 1.00
CLCA2 Ileal involv. rs11161820 86900760 9.52 · 10−7 0.95
CLCA2 Ileal involv. rs1334150 86897973 1.18 · 10−6 0.92
CLCA2 Ileal involv. rs2249296 86910264 1.71 · 10−6 1.00
CLCA2 Ileal involv. rs2252313 86908149 1.82 · 10−6 1.00
CLCA2 Ileal involv. rs9433030 86901465 3.14 · 10−6 0.95
CLCA2 Ileal involv. rs2791464 86911543 4.08 · 10−6 1.00
CLCA2 Ileal involv. rs4292929 86896354 5.27 · 10−6 0.91
1 Association P-Values on imputed SNPs.
2 LD values (r2) with the originally associated SNP in the matched con-
trol population.
Bolded SNPs are the originally associated SNPs.
Table C.3: Association P-Values and LD for the imputed SNPs in the replicated
loci.
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SNP Phenotype Probe ID Position Gene P β
rs10168271 Erythema nodosum 7940580 chr11:61705366-61705469 - 3.45 · 10−05 -0.073
rs10168271 Erythema nodosum 8056113 chr2:160659872-160761247 LY75 1.70 · 10−04 -0.099
rs10168271 Erythema nodosum 8100990 chr4:74919755-74921116 PPBPL2 2.33 · 10−04 -0.068
rs10168271 Erythema nodosum 8060255 chr2:242304241-242304314 - 6.31 · 10−04 0.075
rs10168271 Erythema nodosum 8075479 chr22:31618722-31618839 - 7.26 · 10−04 0.084
rs1520339 Mild disease course 7939867 chr11:48266646-48267567 OR4X2 9.93 · 10−06 -0.12
rs1520339 Mild disease course 8067844 chr21:14982175-15013906 POTED 1.62 · 10−05 -0.076
rs1520339 Mild disease course 8058614 chr2:211295975-211341431 LANCL1 8.76 · 10−05 0.085
rs1520339 Mild disease course 8069991 chr21:33948862-33957843 TCP10L 9.86 · 10−05 -0.083
rs1520339 Mild disease course 7919208 chr1:145509235-145516076 GNRHR2 1.17 · 10−04 -0.083
rs1520339 Mild disease course 8112220 chr5:58266711-59783890 PDE4D 1.38 · 10−04 0.084
rs1520339 Mild disease course 8069836 chr21:31869142-31869472 KRTAP19-4 1.46 · 10−04 -0.099
rs1520339 Mild disease course 8115375 chr5:153371263-153418497 FAM114A2 2.48 · 10−04 0.096
rs1520339 Mild disease course 8069811 chr21:31720717-31720924 KRTAP23-1 2.53 · 10−04 -0.076
rs1520339 Mild disease course 7945956 chr11:4308729-4309175 LOC143506 2.56 · 10−04 -0.091
rs1520339 Mild disease course 7918757 chr1:115090582-115090818 DENND2C 3.62 · 10−04 -0.114
rs1520339 Mild disease course 8176910 chrY:27601452-27606322 GOLGA2P2Y 3.97 · 10−04 -0.058
rs1520339 Mild disease course 8177413 chrY:26356114-26360984 GOLGA2P2Y 3.97 · 10−04 -0.058
rs1520339 Mild disease course 7918157 chr1:108113782-108507585 VAV3 4.00 · 10−04 0.13
rs1520339 Mild disease course 7922756 chr1:183217372-183387737 NMNAT2 4.24 · 10−04 -0.082
rs1520339 Mild disease course 8178582 chr6:31680113-31681589 LY6G6E 4.42 · 10−04 -0.077
rs1520339 Mild disease course 8179810 chr6:31680113-31681589 LY6G6E 4.42 · 10−04 -0.077
rs1520339 Mild disease course 7945954 chr11:4263286-4263870 LOC143506 4.55 · 10−04 -0.078
rs1520339 Mild disease course 8075059 chr22:26360023-26360239 - 6.07 · 10−04 -0.104
rs1520339 Mild disease course 8064168 chr20:62367995-62370456 LIME1 7.41 · 10−04 -0.064
rs1520339 Mild disease course 8113073 chr5:90664541-90679121 ARRDC3 7.60 · 10−04 0.134
rs1520339 Mild disease course 7932786 chr10:28696968-28697180 - 8.43 · 10−04 -0.096
rs1520339 Mild disease course 8177083 chrY:8240142-8240212 - 9.03 · 10−04 -0.125
rs1520339 Mild disease course 8039625 chr19:57645459-57656570 ZIM3 9.32 · 10−04 -0.085
rs2249296 Ileal involvement 7929541 chr10:97759883-97792441 CC2D2B 1.21 · 10−04 0.198
rs2249296 Ileal involvement 8106098 chr5:71403118-71502853 MAP1B 1.38 · 10−04 0.152
rs2249296 Ileal involvement 8108683 chr5:140474219-140476964 PCDHB2 5.13 · 10−04 0.133
rs2249296 Ileal involvement 8172914 chrX:53559057-53713673 HUWE1 5.54 · 10−04 0.069
rs2249296 Ileal involvement 8068520 chr21:38417831-38417933 - 6.10 · 10−04 -0.114
rs2249296 Ileal involvement 8080100 chr3:51661676-51697634 RAD54L2 6.54 · 10−04 0.081
rs2249296 Ileal involvement 8126943 chr6:50011288-50016364 DEFB112 7.70 · 10−04 -0.104
rs2249296 Ileal involvement 8098289 chr4:169926400-169926493 - 9.78 · 10−04 -0.225
Table C.4: eQTL analysis of the replicated SNPs in ileal tissue (NCBI
GEO GSE40929)
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C.3 Supplementary material and methods
C.3.1 Univariate and multivariate analysis of CD phenotypic co-occurrence
Association analyses between the different CD phenotypes were performed on the cohorts
used for the GWAS and Replication analyses. The analyses were done using univariate and
multivariate logistic regression methods. In addition to the defined CD phenotypes (Tables
5.1 and 5.2), epidemiological variables such as gender, familial CD (i.e. ≥1 first- or second-
degree relative diagnosed with CD) and smoking habit (i.e. smokers at the time of diagnosis)
were also included in these analyses. The following Table C.5 shows the studied phenotypes
(i.e. dependent variables) and the set of variables included as independent variables (i.e.
risk factors or potential confounders) in the univariate and multivariate analyses.
Phenotype Variables included in the univariate analysis Variables included in the multivariate analysis
Stricturing disease (B2) Sex; Smoking habit; Perianal disease; Fa-
milial CD; Age at onset; Ileal involvement;
Colonic involvement; Ileocolonic; Upper dis-
ease
Sex; Age at onset; Smoking habit; Ileal in-
volvement; Perianal disease; Familial CD
Penetrating disease (B3) Sex; Smoking habit; Perianal disease; Fa-
milial CD; Age at onset; Ileal involvement;
Colonic involvement; Ileocolonic; Upper dis-
ease
Sex; Age at onset; Smoking habit; Ileal in-
volvement; Perianal disease; Familial CD
Complicated stricturing dis-
ease (CDC-B2)
Sex; Smoking habit; Perianal disease; Fa-
milial CD; Age at onset; Ileal involvement;
Colonic involvement; Ileocolonic; Upper dis-
ease
Sex; Age at onset; Smoking habit; Ileal in-
volvement; Perianal disease; Familial CD
Complicated penetrating dis-
ease (CDC-B3)
Sex; Smoking habit; Perianal disease; Fa-
milial CD; Age at onset; Ileal involvement;
Colonic involvement; Ileocolonic; Upper dis-
ease
Sex; Age at onset; Smoking habit; Ileal in-
volvement; Perianal disease; Familial CD
Upper disease (L4) Sex; Smoking habit; Perianal disease; Fa-
milial CD; Age at onset; Ileal involvement;
Colonic involvement; Ileocolonic
Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Ileal involvement
Ileal involvement Sex; Smoking habit; Familial CD; Age at onset Sex; Smoking habit; Familial CD; Age at onset
Colonic involvement Sex; Smoking habit; Familial CD; Age at onset Sex; Smoking habit; Familial CD; Age at onset
Ileocolonic Sex; Smoking habit; Familial CD; Age at onset Sex; Smoking habit; Familial CD; Age at onset
Perianal disease Sex; Smoking habit; Familial CD; Age at on-
set; B2; B3; Ileal involvement; Colonic in-
volvement; Ileocolonic; Upper disease
Sex; Smoking habit; Familial CD; Age at on-
set; B2; Colonic involvement
Bowel resection Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Stricturing or penetrat-
ing disease; Ileal involvement; Colonic in-
volvement; Ileocolonic
Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Stricturing or penetrat-
ing disease; Ileal involvement
Erythema nodosum Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Stricturing or penetrat-
ing disease; Ileal involvement; Colonic in-
volvement; Ileocolonic; Upper disease
Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Stricturing or penetrat-
ing disease; Ileal involvement; Upper disease
Arthropathy Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Stricturing or penetrat-
ing disease; Ileal involvement; Colonic in-
volvement; Ileocolonic; Upper disease
Sex; Smoking habit; Perianal disease; Famil-
ial CD; Age at onset; Stricturing or penetrat-
ing disease; Ileal involvement; Upper disease
Table C.5: Variables included as independent variables in the univari-
ate and multivariate analyses.
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First, the association between each phenotype of interest and its corresponding risk factors
was studied in separate univariate models. The strength of the association in these analyses
was used for selecting the variables to be included in the multivariate analysis, avoiding po-
tential colinearity due to correlated phenotypes. For example, disease behaviour phenotypes
(B2/B3/CDC-B2/CDC-B3) showed a strong association to ileal involvement. Consequently,
colonic involvement, ileocolonic location and upper disease were excluded from the multi-
variate analysis due to their strong correlation with the ileal involvement phenotype.
Subsequently, a multivariate logistic regression model was fitted for each phenotype ac-
counting for the variables previously selected from the univariate analysis.
The resulting P-Values and ORs for each multivariate analysis in the combined cohort are
given in Supplementary Table 1. Supplementary Figures C.2 to C.4 provide all the ORs and
significant associations in the univariate and multivariate analyses for each analyzed cohort
(GWAS, Replication and Combined cohorts).
C.3.2 Genotyping in Discovery and Replication Analysis
Genome-wide genotyping was performed using the Illumina Quad610 Beadchips (Illumina,
San Diego, CA, USA) at the Centro Nacional de Genotipado (CeGen, Spain). Single nu-
cleotide polymorphism genotype calling was performed using the Illumina GenomeStudio
software v2010.1 (Illumina, San Diego, CA, USA). After excluding mitochondrial, X and Y
chromosome markers or markers not mapped on the latest human assembly GRCh37/hg19
(i.e. dismissed SNPs due to changes in the human reference genomic sequences), a total of
576,818 markers from the 616,794 available markers were selected for quality control (QC)
analysis. Only SNPs that had a >95% call rate (98.1%), a minor allele frequency (MAF)
>0.01 (95.8%), and that showed Hardy-Weinberg equilibrium (99.7% of SNP, P > 0.0001
in healthy controls) were considered for further analysis. All the samples included in the ini-
tial cohort (n=1,338) showed no outlier heterozygosity rates and sex concordance between
database records and X chromosome heterozygosity. We established an inclusion thresh-
old of >95% call rate (n=1,330, 99.4% of samples passed). To evaluate potential popula-
tion stratification we performed a principal component analysis based on the EIGENSTRAT
method214 and outlier samples on this basis (>3 standard deviations above the mean on the
first or second principal component) were excluded (95.8% of samples passed; Supplemen-
tary Figure C.1). Additionally, 184 CD samples were excluded due to a high missingness on
their clinical data records. After QC analysis, a final dataset of 539,846 SNPs and 1,090 CD
patients was available for the clinical subphenotype GWAS.
Genotype imputation was used in this study to: (a) expand the number of analyzed SNPs
at the NOD2 locus, (b) identify neighboring imputed SNPs that reach higher levels of asso-
ciation than the formerly associated microarray SNPs in the GWAS stage, and, (c) to better
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estimate the limits of the genomic associated regions around each associated SNP that has
been replicated. Imputation was performed in the GWAS cohort using SHAPEIT V2-644215
and IMPUTE V2216 softwares. The reference genetic data for imputation was obtained from
the 1000 Genomes Project217. We specifically used the data of the latest release (phase 1,
version 3) from the European cohort (i.e. 379 samples). QC measures for imputed SNPs
included MAF >0.05 and a corresponding IMPUTE2 info quality metric was set to >0.8.
Fifty-seven SNPs were selected for replication and genotyped using the Illumina GoldenGate
assay (Illumina, USA). From these, nine SNPs did not exceed the minimum assay quality
score threshold. In these cases, neighboring SNPs in high linkage disequilibrium (LD) with
the original SNP (r2>0.9 on Caucasian European Hapmap samples from the 1000 Genomes
Project) and with a high quality score were finally selected. In other five cases, the originally
associated SNP was replaced by an imputed SNP at less than 50 kb that exceeded the sig-
nificance level of the originally associated SNP (≥10-fold P-value increment). All the SNPs
selected for replication had a call rate over 97.5% (average call rate was 99.61%). From the
1,627 samples, n=225 were excluded due to missing clinical data and n=106 due to low
call rates (<90%). The included samples had a missing rate below 10%, from which 90.5%
had 0%. Genotyping error rate was estimated using a subset of samples (i.e. 5% of the
total) that were genotyped twice. The concordance results between duplicates indicated a
genotyping error rate of 0.32%.
C.3.3 Criteria for selection of SNPs for replication
The selection criteria for the 57 SNPs for replication were established according to the sta-
tistical significance of the phenotype association, the biological context of the associated
SNP and the clinical relevance of the associated phenotype. This task was performed by a
multidisciplinary team of clinical and bioinformatician experts using in-house and publicly
available data. First, the most statistically significant SNPs (P < 5 · 10−6) were directly
selected (n=26 SNPs, P-Values from 5.16 ·10−8 to 4.94 ·10−6). Next, the SNP-Phenotype as-
sociations showing a moderate level of significance (5·10−6 < P < 5·10−4) were biologically
annotated based on:
1. Functional class of the associated SNP as described in the dbSNP database262 (i.e.
intronic, UTR, non-synonymous...).
2. eQTLs identified for the associated SNP, reported by previous studies or in eQTL databases229;263–268.
3. Overlap with potential regulatory regions based on the ENCODE project data269.
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4. SNPs close to genes (<100Kb) associated with Crohn’s disease or related biological
processes like inflammation. This was performed by querying PubMed database270
for articles matching "gene [gene name]" and key words such as "Crohn’s disease",
"inflammatory bowel disease", "inflammation", "immune system", "colon" and "ileum".
The returned results were manually revised.
5. SNPs close to genes (<100Kb) found to be differentially expressed in inflammatory
bowel diseases in previous studies271;272.
6. SNPs close to other SNPs (<100Kb) previously associated to inflammatory bowel dis-
eases and other auto-immune diseases as defined in the NHGRI GWAS Catalog273.
Using this annotation data, a total of n=31 additional SNPs were selected for replication.
The phenotypes of highest clinical interest (i.e. disease course, behaviour or location) were
prioritized against other less relevant or infrequent CD phenotypes (i.e. erythema nodosum
and peripheral arthropathy). The table C.6 shows the number of SNPs selected for replica-
tion according to the phenotype group.
Phenotype group Nselec ted
Age-related phenotypes 11
Behaviour-related phenotypes (including perianal disease) 13
Disease course phenotypes 17
Location phenotypes 14
Extra-intestinal manifestations 2
Total 57
Table C.6: Number of SNPs selected for replication.
Due to the high correlation between some of the phenotypes studied (i.e. ileal involvement
and colonic involvement) some of the associated loci showed moderate significance values
for multiple phenotypes. In these cases, only the SNP showing the strongest association
significance within a locus for any of the phenotypes studied was selected. We previously
verified that SNPs in the same locus showing moderate association values were in high LD
(r2>0.8) with it.
C.3.4 Validation of previously reported associations
We performed a validation study of loci previously associated with clinically relevant phe-
notypes in CD. Excluding NOD2, a total 91 SNP-phenotype associations (P < 0.05) were
identified in multiple studies (Supplementary Table 2). With the exception of the study re-
porting the FOXO3 association to mild disease course which evaluated 1,134 SNPs within 81
genes related with IL-2/IL-7 signaling pathways14, all these studies analyzed the association
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of established CD risk loci with the clinical phenotypes. Importantly, most of these genetic
associations have still not been replicated in an independent cohort of patients.
In order to evaluate these phenotype associations in our GWAS discovery cohort we per-
formed three validation analyses:
• First, we performed a validation study of the previously associated SNPs with the
clinical phenotype of interest. When the previously reported SNP was not available
in our curated microarray data, we proceeded to identify a tagSNP to evaluate the
association. tagSNPs were identified by evaluating the LD between the available SNPs
in our dataset and the previously reported missing SNP. LD was computed using the
1KGP217 data of CEU samples and the SNP with higher correlation (r2 > 0.85, at least)
with the reported SNP was selected as tagSNP.
• Second, a validation analysis exploring the association at the locus level was per-
formed. This analysis takes into account that associations at the SNP level can be
easily weakened due to differences in LD patterns when trying to replicate the associ-
ation on a different population cohort. This analysis was performed using a gene-set
based test as implemented in PLINK software218 (i.e. set-based test). This approach
maximizes the statistical power of the analysis (i.e. it takes into account the LD pat-
terns between SNPs) and provides accurate results since it is based on a permutation
procedure274. For each reported association, we created the SNP set including all the
SNPs within the locus (i.e. 50Kb around the reported SNP) and performed the analy-
sis using the standard method parameterization274 (P < 0.05, NSN Ps = 3, r2 = 0.5 and
Nperm = 1000). The results (Table 5.3 and Supplementary Table 3) provide the num-
ber of analyzed SNPs, the number of associated SNPs, the number of independently
associated SNPs and the empirical locus association P-Value.
• Finally, we also evaluated if the top-ranked association of all the SNPs within the
locus was significant after Bonferroni correction (i.e. taking into account the number
of SNPs analyzed within each locus).
NOD2 locus is the only one that has been robustly associated to multiple CD phenotypes
in previous studies16 and can therefore be also used as an internal methodological valida-
tion. In order to deeply analyze this locus we imputed all the variants within the locus
(chr16:50700642-50788313). After the QC of the imputed data a final set of 133 SNPs was
ready for analysis. The number of risk variants at rs2066844 (SNP8/R702W), rs2066845
(SNP12/G908R) and rs2066847 (SNP13/1007fs) has been the genetic variant classically as-
sociated to CD and its related subphenotypes. However, these SNPs have very low MAFs (i.e.
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0.05, 0.01 and 0.01 in the 1KGP European population) and its imputation did not withstand
the quality imputation filters. Consequently, we performed the aforementioned second (i.e.
gene-set based test) and third (i.e. Bonferroni correction) validation approaches.
C.3.5 eQTL analysis of replicated associated SNPs in ileal tissue
Specific eQTLs on ileal tissue could be investigated using the gene expression and genotyp-
ing data available in the GEO NCBI database under the accession number GSE41269221. In
this study, total RNA was extracted from 173 endoscopically and histologically normal ileal
biopsies in patients that underwent ileal pouch-anal anastomosis following colectomy. The
included patients consisted of subjects diagnosed with ulcerative colitis or familial adeno-
matous polyposis. Gene expression data was measured using the Affymetrix Human Gene
1.0 ST Array. This microarray provides the expression levels of 19,047 unique autosomal
genes listed in the NCBI database.
In our study, we restricted the eQTL analysis to the four validated loci showing CD phenotype
associations. The genotyping data for rs1520339 (i.e. associated to mild disease course)
and rs2249296 (i.e. associated to ileal involvement) was available in the GEO dataset.
A tagSNP (rs10929956) was also identified for rs10168271 (i.e. associated to Erythema
Nodosum) showing a high LD in the European 1KGP population (r2 = 0.99). However, no
tagSNPs (r2 > 0.8) were found for rs11924265 (i.e. associated to complicated stricturing
disease course) so eQTLs regarding to this SNP could not be evaluated. Table C.7 shows the
SNPs used for eQTL evaluation.
Phenotype SNP Locus SN PeQT L dd (n) Dd (n) DD (n) Model
CDC stricturing rs11924265 MAGI1 Not found - - - -
EIM Erythema nodosum rs10929956 LY75 rs101682711 38 83 48 Genotypic
Ileal involvement rs2249296 CLCA2 rs2249296 2 38 129 Recessive
MDC rs1520339 - rs1520339 7 68 94 Recessive
1 tagSNP
Table C.7: SNPs used for eQTL evaluation.
The eQTL analysis was performed fitting a linear regression model within the n=169 avail-
able samples and the n=13,785 expression probes that mapped to the human genome refer-
ence (i.e. as provided by the GEO platform annotation file GPL6244). The identified eQTLs
(P − Value < 1 · 10−3) are given in Supplementary Table 7.
215
Chapter C Section C.3
216
D | Metabolomics Review Articles
In the following sections we provide the original review articles of metabolomics:
• Section D.1: Analytical methods in untargeted metabolomics: state of the art in 2015.
• Section D.2: Metabolomics in rheumatic diseases.
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Metabolomics comprises the methods and techniques that are used to measure the small
molecule composition of biofluids and tissues, and is actually one of the most rapidly
evolving research fields.The determination of the metabolomic profile – the metabolome –
has multiple applications in many biological sciences, including the developing of new
diagnostic tools in medicine. Recent technological advances in nuclear magnetic reso-
nance and mass spectrometry are significantly improving our capacity to obtain more data
from each biological sample. Consequently, there is a need for fast and accurate statistical
and bioinformatic tools that can deal with the complexity and volume of the data gener-
ated in metabolomic studies. In this review, we provide an update of the most commonly
used analytical methods in metabolomics, starting from raw data processing and ending
with pathway analysis and biomarker identification. Finally, the integration of metabolomic
profiles with molecular data from other high-throughput biotechnologies is also reviewed.
Keywords: metabolomics, nuclear magnetic resonance, mass spectrometry, untargeted, spectral processing, data
analysis, pathway analysis, integration
INTRODUCTION
Metabolomics is the study of the metabolite composition of a cell
type, tissue, or biological fluid. The analysis of the complete set
of metabolites – the metabolome – has been present in biologi-
cal research for more than a decade (Patti et al., 2012). However,
major recent advances in the technologies used to extract and
analyze this type of molecular data have revolutionized its applica-
bility in the analysis of organisms and relevant biological processes
(Zhang et al., 2012). To date, metabolomics is envisaged as one of
the major “omics” tools that will most contribute into challeng-
ing research objectives like the personalization of treatments in
medical practice.
The metabolites are the intermediates or end products of
multiple enzymatic reactions and therefore are the most infor-
mative proxies of the biochemical activity of an organism. The
present technologies are allowing the study of tens to hundreds
of metabolites in complex biological samples (Patti et al., 2012).
One of the facts that is most contributing to the rapid growth
of metabolomics is its wide range of applications. These appli-
cations cover diverse research areas like plant biology (Qi and
Zhang,2014),nutrition (Orešicˇ, 2009; Gibbons et al.,2015),animal
breeding (Kühn, 2012), drug discovery (Robertson and Frevert,
2013; Kell and Goodacre, 2014), and the study of human diseases
(Kaddurah-Daouk et al., 2008; Mamas et al., 2011). The biomed-
ical field is actually one of the most active areas of development in
metabolomics, and includes the search for diagnostic and prognos-
tic biomarkers as well as predictors of treatment response (Meyer
et al., 2013; Armitage and Barbas, 2014; Julià et al., 2014). Also in
this field, the use of metabolomics is helping to characterize the
impact of key environmental factors on human health. In this area,
one of the most promising applications is the characterization
of gut–microbiota interactions in humans (Wikoff et al., 2009;
Nicholson et al., 2012).
To date, the two main technical approaches for the generation
of metabolomic data are nuclear magnetic resonance (NMR) and
mass spectrometry (MS; Fuhrer and Zamboni, 2015). NMR is a
fast and highly reproducible spectroscopic technique that is based
on the energy absorption and re-emission of the atom nuclei due
to variations in an external magnetic field (Bothwell and Griffin,
2011). Depending on the atom nuclei being targeted by the applied
magnetic field, different types of metabolomic data are generated.
However, in the analysis of samples of biological origin, hydro-
gen is the most commonly targeted nucleus (1H-NMR), due to its
natural abundance in biological samples. Although less frequent,
other atoms like carbon (13C-NMR) and phosphorus (31P NMR)
are also targeted by NMR, providing additional information on
specific metabolite types (Reo, 2002).
The resulting spectral data in NMR not only allows the quan-
tification of the concentration of metabolites but also provides
information about its chemical structure. The spectral peak areas
generated by each molecule are used as an indirect measure of
the quantity of the metabolite in the sample, while the pattern of
spectral peaks informing on the physical properties of the mole-
cule is used to identify the type of metabolite. The spectral data
obtained with NMR techniques can be referenced to one or two fre-
quency axes. One dimensional NMR (1D-NMR) spectra are based
on a single frequency axis, where the peaks of each molecule are
placed within its resonant frequencies (Figure 1). 1D-NMR is the
most commonly used method in high-throughput metabolomics
studies. Conversely, two dimensional NMR (2D-NMR) spectra are
based on two frequency axis, and its use is often restricted to the
characterization of those compounds that cannot be identified
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FIGURE 1 | Examples of spectra obtained with 1H-NMR and
LC-MS technologies. (A) An example of three spectra obtained with
1D 1H-NMR. (B) A zoomed view of the spectra in (A) in the
2.66–2.74 ppm range. (C) An example of a LC-MS spectrum with
color-coded intensity and referred by the m/z and retention time axes.
(D) The sum of the LC-MS spectrum across the m/z axis. (E) The total
ion chromatogram (i.e., sum of the LC-MS spectrum across the
retention time axis). The colored regions in (E) correspond to the sum
of the LC-MS spectrum limited to the m/z ranges depicted with the
same color in (D).
with 1D-NMR spectra. The second dimension in 2D-NMR allows
to separate otherwise overlapping spectral peaks and, therefore,
gives additional and important information on the chemical prop-
erties of the metabolite (Ward et al., 2007). Although 2D-NMR
generates a large number of different spectra, these can be globally
classified into homonuclear (i.e., 1H–1H-NMR) and heteronuclear
(i.e., 1H–13C or 1H–15N) spectra (Marion, 2013). There are also
different pulse sequences used to generate the 2D-NMR spectra
such as correlation spectrometry (COSY), total correlation spec-
troscopy (TOCSY), and nuclear Overhauser effect spectroscopy
(NOESY). 1D- and 2D-NMR frequency axes are usually refer-
enced by the chemical shift expressed in parts per million (ppm).
The chemical shift is calculated as the difference between the res-
onance frequency and that of a reference substance, subsequently
divided by the operating frequency of the spectrometer (Blümich
and Callaghan, 1995).
Mass spectrometry is an analytical technique that acquires
spectral data in the form of a mass-to-charge ratio (m/z) and a rel-
ative intensity of the measured compounds. For the spectrometer
to generate the peaks signals for each metabolite, the biological
sample first needs to be ionized. The resulting ionized compounds
from each molecule will then generate different peak patterns
that define the fingerprint of the original molecule. A wide range
of instrumental and technical variants are currently available for
MS spectrometry. These variants are mainly characterized by dif-
ferent ionization and mass selection methods (El-Aneed et al.,
2009). In metabolomics, MS is generally preceded by a separa-
tion step. This step reduces the high complexity of the biological
sample and allows the MS analysis of different sets of molecules
at different times. Liquid and gas chromatography columns (LC
and GC, respectively) are the most commonly used separation
techniques (Theodoridis et al., 2011). This chromatographic sep-
aration technique is based on the interaction of the different
metabolites in the sample with the adsorbent materials inside
the chromatographic column. This way, metabolites with differ-
ent chemical properties will require different amounts of time to
pass through the column. The time that each metabolite requires,
called retention time, is used together with the m/z MS values
to generate the two axes of the LC-MS and GC-MS spectral data
(Figure 1).
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In the present review, we will describe the processing and
analysis workflows that are commonly used in high-throughput
untargeted metabolomic studies. Untargeted metabolomic stud-
ies are characterized by the simultaneous measurement of a large
number of metabolites from each sample. This strategy, known
as top-down strategy, avoids the need for a prior specific hypoth-
esis on a particular set of metabolites and, instead, analyses the
global metabolomic profile. Consequently, these studies are char-
acterized by the generation of large amounts of data. This data
is not only characterized by its volume but also by its complexity
and, therefore, there is a need for high performance bioinformatic
tools. Conversely, targeted metabolomic studies are hypothesis-
driven experiments and are characterized by the measurement of
predefined sets of metabolites with a high level of precision and
accuracy. This low level of metabolite analysis is not in the scope
of this review, and interested readers are referred to other excellent
specific reviews (Roberts et al., 2012; Putri et al., 2013).
In Figure 2, we show the typical methodological pipeline of
an untargeted metabolomic study. This methodological pipeline
starts with the processing of the spectral data to generate the sam-
ple metabolic information (i.e., metabolic features). The different
methods available to process spectral data are revised in Section
“Spectral Processing.” Together with metabolite-identification
methods, spectral processing methods are highly dependent on the
analytical technique used (e.g., NMR, LC-MS, or GC-MS). Once
the complete set of metabolomic features has been generated, uni-
variant and multivariant data analysis methods can be applied
to investigate: (a) the general structure of the metabolomics data
in the dataset and (b) how the different metabolic features are
related with the phenotypic data associated with the samples.
These analysis methods are reviewed in Section “Data Analysis.”
The analysis of metabolomic data can often be used to build mod-
els that attempt to describe the observed data. Section “Biomarker
Discovery in Metabolomics” of the present review describes the
different strategies for assessing the performance of these models.
In Section “Metabolite Identification and Spectral Databases,” we
address the important technical issue that is the identification of
the metabolites underlying the observed metabolic features (i.e.,
peak areas and spectral bins). The bioinformatic methods that are
actually available for the integration of metabolomic data accord-
ing with biological knowledge are reviewed in Section “Pathway
and Network Analysis of Metabolomic Data.” Finally, the differ-
ent methodologies that allow the integration of metabolomics
data with other omics data (e.g., genomics or transcriptomics) are
reviewed in Section “Integration of Omics Data.” Table 1 shows
a list of the freely available tools that are most commonly used
in metabolomic analysis. These tools provide different method-
ological options for spectral processing, data analysis, or pathway
analysis.
SPECTRAL PROCESSING
Spectral processing is a methodological approach aimed at accu-
rately identifying and quantifying the features in the sample spec-
tra of a metabolomics study (Figure 3). Metabolomic spectra
are sequentially or jointly processed until a final set of feature
quantifications is obtained. Spectral processing is also necessary
to guarantee that each final measurement will refer to the same
metabolomic feature in all samples. The data resulting from spec-
tral processing is generally arranged in a feature quantification
matrix (FQM) that contains the quantification of the metabolic
features of all the analyzed samples and that will be used as input
for subsequent statistical analysis.
SPECTRAL PRE-PROCESSING
In order to improve the signal quality and reduce possible biases
present in the raw data, several pre-processing steps are usually
applied. In NMR- and MS-based spectra, baseline correction is
used to remove low frequency artifacts and differences between
FIGURE 2 | Analysis workflow in untargeted metabolomic studies. This figure shows the different steps of the metabolomic analysis pipeline.
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Table 1 | List of tools available for metabolomics spectral processing and data analysis.
Tool Type Target Featuresa Website Reference
MetaboAnalyst2 Web MS and NMR 1–7 http://www.metaboanalyst.ca/ Xia et al. (2012)
XCMS R MS 1–3 http://metlin.scripps.edu/xcms/ Smith et al. (2006)
MetSign MatLab MS 1–3 http://metaopen.sourceforge.net/ Lommen and Kools (2012)
XCMS online Web LC-MS 1–4 https://xcmsonline.scripps.edu/ Tautenhahn et al. (2012b)
MAVEN Application LC-MS 1–7 http://genomics-pubs.princeton.edu/mzroll Melamud et al. (2010)
mzMine2 Application LC-MS 1–5 http://mzmine.sourceforge.net/ Pluskal et al. (2010)
MAIT R LC-MS 1–5 http://b2slab.upc.edu/software-and-downloads Fernández-Albert et al. (2014)
OpenMS Application LC-MS 1–3 http://open-ms.sourceforge.net/ Sturm et al. (2008)
Metabolome express Web GC-MS 1–5 https://www.metabolome-express.org/ Carroll et al. (2010)
Metabolite detector Application GC-MS 1–4 http://md.tu-bs.de/ Hiller et al. (2009)
MetDAT Web MS 1–5 http://smbl.nus.edu.sg/METDAT2/ Biswas et al. (2010)
FOCUS MatLab NMR 1–4 http://www.urr.cat/FOCUS/ Alonso et al. (2013)
Automics Application NMR 1–2, 5 https://code.google.com/p/automics/ Wang et al. (2009)
Bayesil Web NMR 1–4 http://bayesil.ca/ Ravanbakhsh et al. (2014)
Speaq Application NMR 1–2, 5 https://code.google.com/p/speaq/ Vu et al. (2011)
MetaboLab Application NMR 1–2, 5 http://www.nmrlab.org.uk/ Ludwig and Gunther (2011)
rNMR R NMR 8 http://rnmr.nmrfam.wisc.edu/ Lewis et al. (2009)
MetaboMiner Application NMR 8 http://wishart.biology.ualberta.ca/metabominer/ Xia et al. (2008)
Muma R – 5 http://cran.r-project.org/web/packages/muma Gaude et al. (2013)
MetaXCMS R MS and NMR 5 http://metlin.scripps.edu/metaxcms/ Tautenhahn et al. (2010)
BATMAN R NMR 3–4 http://batman.r-forge.r-project.org/ Hao et al. (2012)
AStream R LC-MS 4 http://www.urr.cat/AStream/AStream.html Alonso et al. (2011)
Camera R LC-MS 4 http://metlin.scripps.edu/xcms/ Kuhl et al. (2011)
MetaboHunter Web NMR 4 http://www.nrcbioinformatics.ca/metabohunter/ Tulpan et al. (2011)
MetScape Application – 6–7 http://metscape.ncibi.org/ Gao et al. (2010)
IMPaLA Web – 6–7 http://impala.molgen.mpg.de/ Kamburov et al. (2011)
MetExplore Web – 6–7 http://metexplore.toulouse.inra.fr/ Cottret et al. (2010)
MetPA Web – 6–7 http://metpa.metabolomics.ca/ Xia and Wishart (2010a)
Cytoscape Application – 7 http://www.cytoscape.org/ Smoot et al. (2011)
Vanted Application – 7 http://vanted.ipk-gatersleben.de/ Rohn et al. (2012)
Paintomics Web – 7 http://www.paintomics.org/ García-Alcalde et al. (2011)
This table provides a complete and updated list of the open-source software that is commonly used in the untargeted analysis of metabolomic data.
aThis column refers to the features included in the tool: spectral pre-processing (1), spectral/peak alignment (2), peak detection (3), metabolite identification (4), data
analysis (5), pathway analysis (6), pathway visualization (7), and 2D-NMR analysis (8).
samples that are generated by experimental and instrumental vari-
ation (Dietrich et al., 1991; Smith et al., 2006; Xi and Rocke, 2008;
Zhang et al., 2010). After this, the application of high-frequency
filters may be necessary to remove the electronic noise present in
the data that is generated by the measurement equipment.
FEATURE-DETECTION
The objective of the feature-detection step is to identify and quan-
tify the features present in the spectra. Peak-based methods are
the most common algorithmic choice for feature-detection in MS-
based studies (Gika et al., 2014; Niu et al., 2014; Rafiei and Sleno,
2015). These methods detect the peaks across the spectrum and
integrate their areas to provide a quantification of the underlying
metabolite. In this approach, spectral alignment is also generally
applied either before or after peak detection. In NMR studies,
binning-based approaches have been commonly used to detect fea-
ture peaks in complex biological samples. However, these methods
perform poorly compared to peak-based methods, particularly in
those cases where there is significant spectral unalignment, or in
those cases where multiple peaks from different metabolites are
captured by the same spectral bin (Vu and Laukens, 2013). For
these reasons, peak-based methods are increasingly being used in
NMR-based studies (Wishart, 2008). Nonetheless, there have been
recent developments in binning algorithms, particularly in the
detection of the optimal binning boundaries that have improved
the performance of this feature-detection approach (Sousa et al.,
2013).
Peak overlap is also a common problem in NMR-based stud-
ies. Overlapping peaks are treated as one same feature both in
binning and peak-based approaches. Consequently, the results
obtained from the analysis of these variables can be often hard
to interpret. To attempt to solve this problem, spectral decon-
volution methods have been developed (Hao et al., 2014). These
methods, which are based on the fitting to metabolite spectral tem-
plates, are able to extract independent metabolite quantifications
from a set of overlapping peaks. The main disadvantage of this
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FIGURE 3 | Features of spectral data. This figure shows the different
types of features that can be extracted from spectral data and used for data
analysis.
type of algorithms, however, is that they depend on the existence
of spectral libraries of each metabolite and, therefore, they are
unable to quantify peaks arising from previously uncharacterized
metabolites.
Peak detection
The most commonly used peak detection algorithms analyze each
sample spectrum independently (Tautenhahn et al., 2008, 2012b;
Pluskal et al., 2010). These methods are based on two analytical
steps (Yang et al., 2009). In the first step, the spectra are smoothed.
For this objective, multiple different filters are available (i.e., mov-
ing average, Gaussian, Savitzky-Golay. . .; Yang et al., 2009). From
these, however, the Wavelet transform-based filters have demon-
strated a superior performance, although at the expense of a higher
computation time (Du et al., 2006; Tautenhahn et al., 2008). This
performance improvement is mainly due to the ability of the
Wavelet transform to work with the unequal peak widths that
characterize metabolomic spectra. In the second step, the differ-
ent metabolite peaks are identified using one or multiple detection
thresholds. These thresholds are applied to different parameters
such as the signal-to-noise ratio, the intensity, or the area of
each peak from the resulting filtered spectra (Yang et al., 2009).
In metabolomics studies involving large numbers of samples, a
frequency filter (i.e., consensus peak signal), can be also applied so
that only those peaks that are present in a minimum percentage of
samples are selected for downstream analysis.
Spectral alignment
Spectral alignment is one of the main processing steps in
metabolomic studies involving multiple samples. When analyz-
ing multiple spectra, the position of the peaks corresponding to
the same metabolic feature may be affected by non-linear shifts. In
NMR-based studies, these shifts are observed in the ppm axis and
are usually introduced by differences in the chemical environment
of the sample like ionic strength, pH, or protein content (Weljie
et al., 2006; Xiao et al., 2009). In MS-based studies, peak shifts are
mainly observed across the retention time axis, and are generally
associated with changes in the stationary phase of the chromato-
graphic column (Burton et al., 2008). Spectral alignment methods
must be therefore applied to correct this undesired variability in
the samples that can profoundly affect the quality of the study.
Spectral alignment algorithms can be divided in two main groups:
(i) spectral alignment methods, where the spectral data is aligned
before peak detection and (ii) peak-based alignment methods,
where spectral peaks are aligned across samples once they have
been detected using their coordinates (ppm in NMR, and m/z and
retention time in LC/GC-MS).
Spectral alignment methods are classified into warping and seg-
menting methods. Warping methods are based on the application
of a non-linear transformation to the ppm (in NMR spectra) or the
retention time (in LC/GC-MS) axis in order to maximize the cor-
relation between the spectra. The alignment is then performed by
either stretching or shrinking spectral segments to reach this cor-
relation maximization. Among these methods, correlation opti-
mized warping (COW) and dynamic time warping (DTW) are the
most commonly used. COW is a segmental alignment method that
aligns one sample spectrum toward a reference spectrum (Tomasi
et al., 2004). This is done by splitting the original sample and refer-
ence spectra into small segments, and by separately aligning each
pair of segments. Alignment is performed through dynamic pro-
graming in such a way that limited changes in segment lengths are
allowed. This way, the overall correlation between both spectra is
effectively maximized. In the particular case of crowded spectral
regions with large peak shifts, COW has demonstrated to per-
form particularly well compared to other methods. An alternative
to COW method, DTW is a spectral alignment method (Tomasi
et al., 2004) that is also based on dynamic programing, and where
a warping path is computed to which the connected data points
of each spectrum are equivalent. During this last decade, other
warping approaches have been developed (Eilers, 2003; Forshed
et al., 2003; Lee and Woodruff, 2004; Clifford et al., 2009).
Spectral segmenting methods differ from spectral warping
methods in that alignment is performed by applying a constant
shift to all the spectral points. These methods either align the
overall spectra or split the spectra into smaller segments and
independently align each resulting segment. The Icoshift algo-
rithm (Savorani et al., 2010) is one of the most commonly used
segmentation methods, and is based on the convergence toward
a reference signal. This convergence is performed by applying
shifts that maximize the segment spectral correlation, which is
normally computed using the fast Fourier transform (FFT) to
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speed up the required calculations (Wong et al., 2005). Icoshift
and other correlation-based methods can also be combined with
automatic segmentation methods (Veselkov et al., 2008), which
are able to optimally split the spectra in order to improve the
alignment of the resulting spectral segments. However, the use
of a reference spectrum has several disadvantages. Very recently,
the RUNAS algorithm implemented in the FOCUS processing
workflow (Alonso et al., 2013) has provided a spectral segmenting
method that avoids the use of a reference spectrum. Instead, the
FOCUS method uses the information from the different sample
spectra to iteratively maximize the inter-sample weighted-mean
correlation. This approach has shown that avoiding the use of a
reference spectrum is a powerful strategy to avoid many of the
analytical biases derived from its use. These biases are mainly due
to the fact that the reference spectrum may not be representative
of the spectral diversity present in the samples. FOCUS alignment
algorithm has also shown that an appropriate spectral transfor-
mation prior to alignment avoids the biases due to the presence of
multiple peaks in the same alignment window. Under these con-
ditions, the methods based in correlation maximization without
prior transformation are more prone to align the most relevant
peak of each sample regardless of whether they correspond to the
same metabolic feature or not.
Fast Fourier transform-based segmenting methods such as
RAFFT, Icoshift, and FOCUS not only are able to process large
metabolomics datasets in a reduced amount of time, but also
have shown to perform better than spectral warping methods
(Giskeødegård et al., 2010; Savorani et al., 2010; Alonso et al.,
2013; Jiang et al., 2013). Within the different segmenting meth-
ods, reference-free methods avoid the biases introduced by using
reference spectra, but at a cost of being more computationally
intensive.
Of relevance, the results reported by several performance com-
parison studies using either NMR or MS have demonstrated that
spectral alignment algorithms have a good performance irrespec-
tive of the analytical technique that has been used (MS or NMR;
Van Nederkassel et al., 2006; Giskeødegård et al., 2010). Con-
sequently, methods that were initially developed to align NMR
spectra are also applied to align MS spectra and vice versa.
Compared to the warping and segmentation alignment meth-
ods, peak-based methods are applied after peak detection. In these
methods, peak coordinates are used to perform the alignment.
This type of method is implemented in the XCMS software (Taut-
enhahn et al., 2012b), one of the most commonly used methods
to process data from LC-MS studies. Given that the shifts along
the m/z axis are minimal and the m/z axis has a high resolution,
the data can be safely binned in m/z intervals, and peak align-
ment performed on each bin along the chromatographic time.
The XCMS algorithm computes the retention time boundaries
within which the observed peaks are expected to represent the
same metabolomic feature across the different samples. The com-
putation of these retention time boundaries is performed by using
a kernel density estimator. Another common alignment method
used in MS is the RANSAC algorithm (Pluskal et al., 2010). In this
approach, the corresponding peaks across samples are identified
by using a LOESS regression on different retention times and m/z
windows.
FEATURE NORMALIZATION
In order to perform an accurate quantification of the features
in a metabolomic analysis, a data normalization step is generally
required. The objective of normalization is to remove undesired
systematic biases, so that only biologically relevant differences
are present in the data. This procedure is crucial when analyzing
complex biofluids like blood, where the differences in metabolite
concentration between samples can be high, and the introduction
of internal standards is complicated. Although multiple statistical
models have been developed for this objective (Craig et al., 2006;
Kohl et al., 2012), the two perhaps most commonly used methods
are the use of endogenous stable metabolites (like creatinine in
urine) and the use of the total spectral area [i.e., area under the
curve (AUC); Weljie et al., 2006; Rasmussen et al., 2011].
DECONVOLUTION METHODS IN TARGETED ANALYSIS
One of the main limitations for the quantification of metabolomic
features is the overlap between peaks from different metabolites.
NMR and GC-MS spectra are particularly prone to this type of
bias. In order to deal with this technical issue, several method-
ological approaches have been developed. These approaches are
based on spectral deconvolution (Chylla et al., 2011; Astle et al.,
2012; Du and Zeisel, 2013; Hao et al., 2014), a signal processing
technique that estimates the relative area corresponding to each
individual peak when multiple peaks overlap within the same
spectral region (Figure 4). However, an important limitation of
deconvolution methods is that prior knowledge of the compounds
FIGURE 4 | Spectral deconvolution. This figure shows how spectra (gray
shaded area) can be decomposed (i.e., deconvoluted) in multiple
components corresponding to different metabolite compounds.
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present in the mixture is required. Additionally, the use of these
methods in untargeted metabolite studies is yet not possible due
to computational intractability (Hao et al., 2014).
The usual input data for these methods is the spectral data from
the study and at template library containing the reference peak
patterns of each metabolite. Currently, there are multiple methods
available for spectral deconvolution of NMR data (Chylla et al.,
2011; Zheng et al., 2011; Astle et al., 2012; Hao et al., 2014) and
they are mostly based on Bayesian model selection. Among them,
BATMAN (Hao et al., 2012) is one of the most frequently used,
providing a rich and user-friendly interface and a complete pro-
tocol to perform this type of analysis (Hao et al., 2014). BATMAN
is an open-source software and its performance has been demon-
strated to be very similar to that of the NMR Suite software package
(Chenomx Inc., Edmonton, AB, Canada; Weljie et al., 2006), a
proprietary software that is considered a gold standard for NMR
metabolomics (Chenomx Inc., Edmonton, AB, Canada; Weljie
et al., 2006). The NMR Suite itself provides a semi-automated tool
for spectral deconvolution which allows interactive fitting of the
metabolite peaks to the reference metabolite spectra. The major
disadvantage of this tool is the large amount of time required to
process large sample datasets and the need of highly skilled data
analysis specialists.
GC-MS methods for spectral deconvolution are mostly based
on unsupervised approaches that do not require the prior knowl-
edge of the compounds presents in the sample (Stein, 1999; Hiller
et al., 2009; Ni et al., 2012). These approaches are mainly based
on three steps, namely: (a) noise analysis for selecting the spectral
segments to be deconvoluted, (b) component perception for iden-
tification of the individual components present in each segment,
and (c) deconvolution for fitting the individual components to
the overall spectral shape. Du et al. provide an extensive review of
these methods (Du and Zeisel, 2013).
DATA ANALYSIS
Once the metabolite features are robustly quantified, there are
multiple univariate and multivariate statistical methods that can
be used to perform the desired study analysis. These groups of
techniques are commonly known as chemometric methods (Mad-
sen et al., 2010) and usually require some degree of expertise to
be conveniently applied. In the following sections, we define the
most commonly used metabolomic features, and we describe the
most commonly used chemometric methods.
METABOLOMIC FEATURES
After applying the adequate pre-processing methods,metabolomics
data is usually reduced to a FQM. In this data representation, rows
correspond to the samples and columns correspond to the different
metabolomic features. Each metabolomic feature is intrinsically
related to the concentration of a particular metabolite. Depending
on the analytical technique and the spectral processing workflow
that have been used, different metabolomic features are used as
input for data analysis (Figure 3):
• Spectral peak areas: one of the most commonly used features
in high-throughput metabolomics data (NMR-based or MS-
based). They are computed through the integration of the peaks
identified and aligned using the methods described in the pre-
vious section (see Spectral Pre-Processing to Deconvolution
Methods in Targeted Analysis). Once this data has been analyzed,
the identification of the metabolites representing the relevant
peaks is required in order to provide biological meaning to
the results. Metabolite-identification methods are reviewed in
Section “Metabolite Identification and Spectral Databases.”
• Metabolite concentrations: in contrast to the previous features,
metabolite identification can be performed prior to data analysis
in order to obtain absolute or relative metabolite concentra-
tions to be used as input for data analysis (Wishart, 2008; Zhou
et al., 2012). This type of features allow both to reduce the
high redundancy of peak areas (i.e., one metabolite is often
represented by multiple spectral peaks), and to provide biolog-
ical significance to all the analyzed features. The most com-
mon metabolite-identification methods are reviewed in Section
“Metabolite Identification and Spectral Databases.”
• Spectral bin areas: in addition to peak areas and metabolite con-
centrations, spectral bins (or also buckets) are also commonly
used features in NMR-based studies. This technique consists of
dividing the spectra into evenly spaced regions that are later inte-
grated to obtain the corresponding spectral bin areas. In order
to mitigate problems such as peaks lying in two consecutive
integration regions, some methods have implemented uneven
binning algorithms like dynamic adaptative binning (Ander-
son et al., 2011), Gaussian binning (Anderson et al., 2008),
and adaptative intelligent binning (De Meyer et al., 2008). This
feature estimation approach has, however, some inherent disad-
vantages produced by the presence of uninformative features in
the spectra (i.e., spectral areas without spectral peaks) and the
lack of inter-sample feature correspondence when spectra are
heavily affected by unalignment (e.g., urine samples with large
pH variability).
UNIVARIATE ANALYSIS METHODS
Univariate methods analyze metabolomic features independently.
They are common statistical analysis approaches and, therefore,
their main advantage is their ease of use and interpretation. How-
ever, their main disadvantage is that they do not take into account
the presence of interactions between the different metabolic fea-
tures. The metabolomic data obtained from biological samples is
often very complex with the presence of correlations between fea-
tures from the same metabolite and correlations between metabo-
lites from the same pathway. Also, the effect of potential confound-
ing variables like gender, diet, or body mass index is not taken into
account by these analysis methods, increasing the probability of
obtaining false positive or false negative results (Winnike et al.,
2009; Rasmussen et al., 2011; Townsend et al., 2013).
Several univariate analysis methods are available for
metabolomic data analysis. The selection of the method will
depend on the statistical properties of the feature distribution
(Broadhurst and Kell, 2006; Vinaixa et al., 2012). For example,
when assessing differences between two or more groups, para-
metric tests such as Student’s t -test and ANOVA are commonly
applied, provided that normality assumptions are conveniently
verified. The latter can be confirmed using the Kolmogorov–
Smirnov normality test or Bartlett’s homogeneity of variances
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test. In those cases where normality of the data cannot be
assumed, non-parametric tests such as Mann–Whitney U test or
Kruskal–Wallis one-way analysis of variance are preferable.
In addition to choose the most appropriate statistical analysis
test, another important consideration in metabolomic data analy-
sis is the multiple testing problem. In most metabolomic studies,
a large number of metabolomic features are analyzed simulta-
neously and, therefore, the probability of finding a statistically
significant result by chance (i.e., false positive) is high. In order to
control for this multiple testing issue, several correction methods
are available. Each method is characterized by a particular balance
between avoiding false metabolite associations (i.e., false positives)
and prevents discarding true associations (i.e., false negatives).
Depending on the study design, researchers might decide to use a
more or less conservative approach. The Bonferroni correction is
perhaps the most conservative multiple test correction approach,
where the number of type I errors (false positives) regarding to
the total number of hypotheses tested [i.e., defined as familywise
error rate (FWER)] is minimized at the expense of increasing type
II errors (false negatives). In the Bonferroni correction, the signif-
icance level for one hypothesis (i.e., alpha value), is divided by the
number of hypotheses tested simultaneously. Although a very con-
servative approach, especially when the hypotheses tested are not
independent, many researchers advocate its use in metabolomic
studies (Broadhurst and Kell, 2006). Recently, Chadeau-Hyam
et al. assessed the metabolome-wide significance level (MWSL)
for biomarker identification in urine using a permutation-based
method to estimate the correct FWER (Chadeau-Hyam et al.,
2010). Their method took into account metabolite collinearity and
reported that a conservative estimate of the independent number
of tests is 35% of the performed tests. This result indicates that
the Bonferroni multiple test correction method might be over
conservative.
Other less conservative multiple test correction methods are
however available and are mostly based on the minimization of
the false-discovery rate (FDR; Benjamini and Hochberg, 1995).
While Bonferroni and other FWER-based methods minimize the
probability of at least one false positive in the overall set of tests,
FDR-based methods minimize the expected proportion of false
positives on the total number of positives (Van Den Oord, 2008).
Most of these methods have been extensively used for the analy-
sis of gene-expression microarray data, where thousands of genes
are tested in parallel (Reiner et al., 2003; Jung, 2005; Xie et al.,
2005). In untargeted metabolomic studies, where large numbers
of metabolites are simultaneously analyzed, and where it is also
expected that more than one or two of these biomarkers will be
associated, the use of less strict multiple correction methods like
FDR methods might be more useful.
MULTIVARIATE ANALYSIS METHODS
In contrast to univariate methods, multivariate analysis methods
take into account all the metabolomic features simultaneously
and, consequently, they can identify relationship patterns between
them. These pattern-recognition methods can be classified into
two groups: supervised and unsupervised methods. In unsuper-
vised analysis methods, the similarity patterns within the data are
identified without taking into account the type or class of the
study samples. In supervised methods, the sample labels are used
in order to identify those features or features combinations that are
more associated with a phenotype of interest. Supervised methods
are also the basis for building prediction models.
Unsupervised methods
Unsupervised methods are often applied to summarize the com-
plex metabolomic data. They provide an effective way to detect
data patterns that are correlated with experimental and/or biolog-
ical variables. Principal component analysis (PCA) is the most
commonly used unsupervised method in metabolomic studies
(Wold et al., 1987; Bro and Smilde, 2014). PCA is based on the
linear transformation of the metabolic features into a set of lin-
early uncorrelated (i.e., orthogonal) variables known as principal
components. This decomposition method maximizes the variance
explained by the first component while the subsequent compo-
nents explain increasingly reduced amounts of variance. At the
same time, PCA minimizes the covariance between these compo-
nents (i.e., they are independent of each other). After applying
the PCA method, a set of loading vectors and score vectors are
obtained. The loading vectors represent the principal components,
and each vector coefficient corresponds to the individual contribu-
tion of each variable to the principal component. The score vectors
represent the projection of each sample onto the new orthogonal
basis. Plotting these sample scores over the first principal com-
ponents is a convenient way of summarizing the global dataset,
since normally these first principal components capture most of
the variability in the dataset. PCA is also used in metabolomics
studies to assess data quality, since it can identify sample outliers
or reveal hidden biases in the study. For example, PCA has been
used in several studies to determine the impact of technical varia-
tion in the analysis of metabolic profiles (Gika et al., 2008; Winnike
et al., 2009; Rasmussen et al., 2011; Yin et al., 2013).
Other unsupervised methods like hierarchical clustering analy-
sis (HCA) and self-organizing maps (SOMs) have also been
applied to metabolomic data. These methods can be particularly
suitable to detect non-linear trends in the data that are not conve-
niently covered by PCA. SOMs have been used in metabolomics
studies to visualize metabolic phenotypes and feature patterns as
well as to prioritize the metabolites of interest based on their sim-
ilarity (Kohonen et al., 2000; Meinicke et al., 2008; Mäkinen et al.,
2008; Goodwin et al., 2014). HCA is also a powerful clustering and
visualization tool that provides a clustering procedure at the fea-
ture and sample levels according to a predefined distance measure
(Brauer et al., 2006; Sreekumar et al., 2009).
Supervised methods
Supervised methods are used to identify metabolic patterns that
are correlated with the phenotypic variable of interest while down-
weighting the other sources of variance. These methods are also
the basis for building classifiers based on metabolomic features
(Xia et al., 2013). Partial least squares (PLS; Fonville et al., 2010) is
one of the most widely used supervised method in metabolomics.
It can be used either as a regression analysis (i.e., quantitative
variable of interest) or as a binary classifier (PLS-DA; i.e., binary
variable of interest). Unlike PCA, PLS components do not maxi-
mize the explained dataset variance but the covariance between
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the variable of interest and the metabolomic data. Therefore,
the feature coefficients (loadings) of PLS components represent
a measure of how much a feature contributes to the discrimi-
nation of the different sample groups. However, one weakness
of PLS is that some metabolic features that are not correlated
with the variable of interest can influence the results. In order to
deal with this problem, orthogonal PLS (O-PLS; Trygg and Wold,
2002) were developed. O-PLS models evolved from PLS mod-
els and factorize the data variance into two components: a first
component which is correlated with the variable of interest and
a second uncorrelated component (i.e., orthogonal). Classifica-
tion of metabolomics samples is commonly performed by fitting
the discriminant analysis versions of PLS and O-PLS models (i.e.,
PLS-DA, O-PLS-DA; Kemsley, 1996; Bylesjö et al., 2006).
The performance of PLS and O-PLS models has been exten-
sively compared but, to date, there is no agreement as to which
of the two methods is superior (Tapp and Kemsley, 2009). In the
last years, however, a progressive move from the use of PLS mod-
els to O-PLS models has been observed in the metabolomics field
(Fonville et al., 2010).
Support vector machines (SVMs) are another class of super-
vised analysis methods to build classifiers based on metabolomic
data (Mahadevan et al., 2008; Kim et al., 2010; Luts et al., 2010).
Although classifiers based on SVM are harder to interpret, they are
able to manage the presence of non-linear relations between the
metabolomic data and the variable of interest.
Multiway methods for longitudinal metabolomic data
There is also a wide range of methods that are designed to provide
a comprehensive interpretation of the metabolic changes accord-
ing to the organization of the analyzed samples (i.e., samples from
different tissues or corresponding to time series in a longitudi-
nal study). These methods decompose the original multiway (i.e.,
multi-dimensional) data matrix into a set of easily interpretable
factors. In NMR studies, two of the most commonly used meth-
ods are parallel factor analysis (PARAFAC) and multivariate curve
resolution (MCR). The input data for these methods is commonly
a three dimensional (3D) matrix with coefficients cijk (where i
represents a metabolic feature, j the analyzed individual, and k
the tissue from which the sample was extracted or the sample
extraction time-point). The PARAFAC analysis of a 3D matrix
generates three loading matrices that capture the contributions
of each metabolic feature, of each individual, and of each tissue
type or time-point. Alternatively, MCR analysis decomposes the
3D matrix into a set of two factors which contain the contribu-
tions of each metabolic feature and each analyzed sample. To do
this, the 3D matrix must be fitted in a 2D matrix, where the differ-
ent metabolic features are arranged on the first dimension while
the each individual and tissue/time-point are arranged on the sec-
ond dimension (Peré-Trepat et al., 2007; Karakach et al., 2009;
Montoliu et al., 2009; Martin et al., 2010).
BIOMARKER DISCOVERY IN METABOLOMICS
One of the most promising applications of metabolomics in
the medical sciences is the identification of biomarkers. New
metabolomic biomarkers are usually determined using supervised
analysis models since they are capable to aggregate the evidence of
multiple metabolites. The usefulness of the resulting classification
models must be then evaluated in order to consider their use in
real clinical settings. Performance assessment and model valida-
tion are crucial analytical steps for the evaluation of metabolomic
classification models.
PERFORMANCE ASSESSMENT
Performance assessment measures how well the outcome predicted
by our model matches the real outcome. Several complemen-
tary measures are available to assess the classifier performance:
predictive accuracy (percentage of correctly classified subjects),
sensitivity (percentage of true positives that are correctly classi-
fied), and specificity (percentage of true negatives that are correctly
classified). These three measures allow the assessment of the classi-
fier performance given a fixed decision boundary. However, these
performance measures tend to be dependent on the outcome
prevalence and on the decision boundary chosen (Xia et al., 2013).
The receiver operating characteristic (ROC) curve avoids this type
of bias and is the most used performance assessment method.
ROC curve estimation is a non-parametric procedure consisting
of the comparison of specificity against sensitivity according to
a specific decision boundary. ROC curves are often summarized
by the AUC metric. The AUC metric gives the probability that a
classifier will rank a randomly chosen positive sample higher than
a randomly chosen negative one. Therefore, a perfect classifier will
obtain AUC= 1 while a random classifier will obtain AUC close to
0.5. An AUC >0.7 is often considered the minimal performance
for a biomarker test to be considered clinically useful (Xia et al.,
2013). In addition to the overall performance assessment using
the AUC metric, the ROC curves can also be used to determine
the optimal decision boundary for the classifier (Xia et al., 2013).
ROC curve estimation is a common analysis and therefore, multi-
ple tools are available for ROC-based performance evaluation like
the R packages ROCR (Sing et al., 2005) and pROC (Robin et al.,
2011), as well as the ROCCET (Xia et al., 2013) web application.
MODEL VALIDATION
When designing classification models, a validation step is required
to estimate how well the classification model will perform when
applied to new samples. This step is particularly important when
using small sample sizes in order to discard model overfitting.
Two main approaches are available for performing this task:
permutation testing and cross-validation (Westerhuis et al., 2008).
The aim of the permutation-based validation is to measure the
performance of the predictor model by determining the probabil-
ity of observing an equal or better performance by pure chance.
This analysis is performed by estimating the null distribution of
the performance measures (i.e., AUC) under the assumption that
no differences exist between sample groups. This is done by ran-
domly permuting multiple times the sample group classes (e.g.,
case-control) and calculating the statistic under each permuted
dataset. Once computed, the performance measures of the true
model (i.e., based on the real sample status) should lie outside
the chosen confidence intervals (e.g., 95 or 99%) of the estimated
null distributions in order to be considered significant. In contrast
with the permutation approach, cross-validation approaches esti-
mate the predictive performance of a classifier using an iterative
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approach. At each round of cross-validation, the total sample is
split into a training group and a testing group. In the former
group, the predictor model is built using a specific set of para-
meters. The performance of this model is then evaluated using
the remaining group of samples. This procedure is repeated sev-
eral times so that all the samples have been used once as a testing
group. Averaging these results we will obtain an unbiased esti-
mate of the performance of the predictor. The size of the testing
sample can be composed by several samples (i.e., n-fold cross-
validation) or can be as small as a single individual (i.e., leave-one
out cross-validation). This approach provides a good measure of
how data overfitting affects to the computed model. When the
used models require optimization (i.e., optimal number of PLS/O-
PLS components to be used) a double cross-validation schema is
usually required: a first cross-validation step is applied to opti-
mize the model and a second step for assessing the model quality
(Westerhuis et al., 2008; Szymanska et al., 2012). The double cross-
validation schema requires the dataset to be iteratively split in two
sets S1 and S2. In the first step, the S1 set is randomly divided into
two subsets S11 and S12, where S11 is used to compute models
with different number of components and the S12 set is used to
evaluate the prediction power of each model. This procedure is
repeated until all the samples in S1 have been once in the S12
set, and the model with the lowest prediction error is selected. In
the second step, the S2 set is used to assess the performance of the
optimal model as computed in step one. This global analysis is per-
formed recursively by randomly splitting the global dataset in sets
S1 and S2 until all the samples have been once in S1. Further details
on the different types of cross-validations are described in more
detail elsewhere (Westerhuis et al., 2008; Szymanska et al., 2012).
METABOLITE IDENTIFICATION AND SPECTRAL DATABASES
Metabolite identification is one of the major challenges of high-
throughput metabolomic analysis. This step is indispensable
to confer a biological meaning to the associated features in a
metabolomic study. In MS-based studies, the common metabolite-
identification approach is based on querying metabolomic data-
bases for the neutral molecular mass values of the identified peaks
using a tolerance window. The neutral molecular mass is inferred
from the peak m/z value, and depends on the chemical nature of
the identified peak (i.e., ionization mode and ionization adduct).
Assuming no prior knowledge, each peak m/z value can lead to
multiple plausible neutral molecular masses that can represent
different ionization adducts (H+, Na+, K+, . . .). This multiplicity
often results in a high number of false positive identifications. In
order to reduce false positives, several methods have been devel-
oped. AStream and Camera are methods designed to identify
isotopic and adduct patterns in order to reduce data complexity
in MS experiments (Alonso et al., 2011; Kuhl et al., 2011). Using
these approaches, the chemical nature of each selected ion peak is
estimated, and only one neutral mass is inferred from each iden-
tified pattern. Using these methods has the added advantage of
improving the ascertainment of true biological compounds.
In NMR-based studies, automatic metabolite identification is
commonly performed by matching the measured NMR peaks
against a set of reference metabolite patterns. Each metabolite
reference spectrum is defined by one or multiple peaks, which are
characterized by their ppm positions and their relative intensities.
MetaboHunter is an online tool for identifying compounds by
matching the reference peak positions against the list of detected
peak positions (Tulpan et al., 2011). However, this approach can
lead to high false positive rates, since it only uses one peak para-
meter to match reference peaks. The MetaboHunter approach has
been superseded by more recent methods based on the valid clus-
ter concept (Mercier et al., 2011; Jacob et al., 2013). In addition
to using the ppm position, these methods include peak intensities
and inter-sample intensity correlation as parameters for matching
data peaks to reference peaks. The NMR analysis workflow imple-
mented in FOCUS follows this same metabolite-identification
approach, with the added advantage that it also accounts for
the presence of missing peaks generated by spectral overlapping
(Alonso et al., 2013).
Metabolite spectral databases are essential for metabolite iden-
tification. The quality of the stored data as well as the number of
metabolite spectra available in these databases is critical for the
performance of identification algorithms. During the last years,
multiple databases have been developed (Table 2) and the number
of available metabolite reference spectra is continuously growing
(Ellinger et al., 2013; Fukushima and Kusano, 2013). The Human
Metabolome Database (HMDB) is perhaps the most extensive
public metabolomic spectral database to date (Wishart et al.,
2013). The HMDB stores >40,000 different metabolite entries,
with exhaustive biological metadata and MS/NMR spectral ref-
erences. In addition to spectral databases, several studies have
also contributed to characterize the metabolome of multiple types
of samples. Many of these reference studies are also exceptional
resources of high quality data associated with the biofluid, tissue,
or cell type of interest (Wishart et al., 2008; Psychogios et al., 2011;
Bouatra et al., 2013).
PATHWAY AND NETWORK ANALYSIS OF METABOLOMIC
DATA
Pathway and network analysis approaches increase the informa-
tion generated by metabolomic studies. Both approaches exploit
the relational properties present in metabolomic data. Pathway
analysis uses prior biological knowledge to analyze metabolite
patterns from an integrative point of view. Alternatively, net-
work analysis uses the high degree of correlation existing in
metabolomics data to build metabolic networks that character-
ize the complex relationships existing in the set of measured
metabolites.
PATHWAY ANALYSIS
Until very recently, when analyzing metabolomic data no prior
knowledge regarding metabolite relationships could be assumed.
During the last years, however, the biological knowledge avail-
able for metabolomics studies has been constantly increasing.
Metabolic pathways are groups of metabolites that are related
to the same biological process, and that are directly or indirectly
connected by one or multiple enzymatic reactions. Biological data-
bases such as Kyoto Encyclopedia of Genes and Genomes (KEGG;
Kanehisa et al., 2012), small molecule pathway database (SMPDB;
Jewison et al., 2014), EHMN (Ma et al., 2007), WikiPathways
(Kelder et al., 2012), and MetaCyc (Caspi et al., 2008) provide
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Table 2 | Spectral databases available for metabolite identification.
Database Spectral
data
Website Statistics Reference
HMDB MS/NMR http://www.hmdb.ca 41,806 metabolite entries and 1,579 metabolites
with spectra (1H-NMR, LC-MS, GC-MS . . .)
Wishart et al. (2013)
LMSD MS http://www.lipidmaps.org 37,500 lipid structures with MS/MS spectra Sud et al. (2007)
METLIN MS http://metlin.scripps.edu 240,516 metabolite entries and 12,057 metabolites
with MS/MS spectra
Tautenhahn et al. (2012a)
TOCCATA
COLMAR
NMR http://spin.ccic.ohio-state.edu Multiple spectral NMR datasets: 1H- and 13C-NMR,
2D 13C–13C TOCSY (n=463), 2D 1H–1H TOCSY
and 13C–1H HSQC-TOCSY (n=475), and 2D
13C–1H HSQC (n=555)
Robinette et al. (2008),
Bingol et al. (2012, 2014,
2015)
MassBank MS http://www.massbank.jp 2,337 metabolites and 40,889 spectra (LC-MS,
GC-MS . . .)
Horai et al. (2010)
Golm metabolome GC-MS http://gmd.mpimp-golm.mpg.de 2,019 metabolites with GC-MS spectra Hummel et al. (2007)
BMRB NMR http://www.bmrb.wisc.edu 9,841 biomolecules with 1H, 13C, or 15N spectra Ulrich et al. (2008)
Madison NMR http://mmcd.nmrfam.wisc.edu 794 compounds with spectra including 1H, 13C,
1H–1H, 1H–13C . . .
Cui et al. (2008)
NMRShiftDB NMR http://nmrshiftdb.nmr.uni-koeln.de 42,840 structures and 50,897 measured spectra Steinbeck et al. (2003)
RIKEN MS/NMR http://prime.psc.riken.jp 1,589 metabolites (Arabidopsis) Akiyama et al. (2008),
Sakurai et al. (2013)
Birmingham
Metabolite Library
NMR http://www.bml-nmr.org 208 metabolites and 3,328 1D- and 2D-NMR
spectra
Ludwig et al. (2012)
This table shows a list of the spectral databases that are most commonly used in current metabolomics studies to characterize the associated metabolite features.
exhaustive information of a large number of metabolic pathways
(Table 3). The availability of this data is therefore enabling the
use of pathway-based approaches in metabolomics. These meth-
ods are currently referred as metabolite set enrichment analysis
(MSEA), and are methodologically based on the gene set enrich-
ment analysis (GSEA) approach, designed for pathway analysis of
gene-expression data (Khatri et al., 2012).
To date, three different approaches have been developed to
perform MSEA (Xia and Wishart, 2010b):
• Overrepresentation analysis (ORA): Given a list of metabolite
pathways or groups of metabolites of interest, a hypergeomet-
ric test or a Fisher’s Exact test is used to evaluate whether the
metabolites of these groups are represented more than expected
by chance. When the input metabolite list is defined as the set
of metabolites which are differentially expressed in the analyzed
phenotypes, the ORA results may identify metabolic pathways
that are globally associated to these phenotypes.
• Quantitative enrichment analysis (QEA): Unlike ORA, the input
data for this method is a set of metabolite concentrations
from multiple samples. Enriched pathways can be identified
using different approaches like globaltest (Goeman et al., 2004),
globalAncova (Hummel et al., 2008), or the Wilcoxon-based
test (Adjaye et al., 2005). Enriched pathways include pathways
where a few number of compounds are significantly changed or
pathways where a large number of metabolites are slightly but
consistently changed (Xia and Wishart, 2010b).
• Single-sample profiling (SSP): While the two previous methods
are suited for studies involving large numbers of samples, this
approach can be used at the sample level. The input data for SSP
analysis is an input list of normalized metabolite concentrations
in a common biofluid, tissue, or cell type and a database with the
normal concentration ranges of these metabolites in the sample.
From this input data, SSP identifies the set of metabolites show-
ing levels significantly different from the normal concentration
ranges.
In order to improve the interpretability of pathway analysis
results, MSEA results can be combined with pathway topologi-
cal measures. These measures allow the assessment of impact of
the unbalanced metabolites within the overrepresented pathway.
First, single impacts are evaluated using the degree and between-
ness network centrality measures of each metabolite (Aittokallio
and Schwikowski, 2006). Subsequently, the overall impact (i.e.,
pathway impact; Xia and Wishart, 2010a) is calculated as the sum
of the single impact measures of the unbalanced metabolites nor-
malized by the sum of the impact measures of all the metabolites
within the pathway.
Metabolomics researchers currently have a wide variety of soft-
ware tools to analyze metabolomic data at the pathway level.
Applications such as Paintomics (García-Alcalde et al., 2011),
Vanted (Rohn et al., 2012), and Cytoscape (Smoot et al., 2011)
provide different pathway visualization tools. In these tools, the
metabolites are mapped on predefined metabolic pathways, and
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Table 3 | Biological databases for pathway analysis.
Database Description Website Reference
Kyoto Encyclopedia of Genes and
Genomes (KEGG)
466 pathways, 17,333 metabolites, and 9,764
biochemical reactions
http://www.genome.jp/kegg/ Kanehisa et al. (2012)
MetaCyc 2260 pathways from 2600 different organisms http://metacyc.org/ Caspi et al. (2008)
The small molecule pathway database
(SMPDB)
1,594 metabolites mapping 727 small molecule
pathways found in humans
http://www.smpdb.ca/ Jewison et al. (2014)
WikiPathways 1,910 pathways http://wikipathways.org/ Kelder et al. (2012)
Plant metabolic network
(PMN/PlantCyc)
Multi-species pathway database for plant
metabolomics
http://www.plantcyc.org/ Chae et al. (2014)
This table describes the main databases that provide biological information on metabolites and metabolic pathways.
allow a high level of interaction with the data. In addition to
visualization tools, Impala (Kamburov et al., 2011) and MetScape2
(Karnovsky et al., 2012) are software tools that also implement spe-
cific MSEA methods. Finally, Metaboanalyst is a highly versatile
pathway analysis tool, providing a wide range of MSEA methods
as well as topological and visualization tools (Xia et al., 2012).
CORRELATION-BASED NETWORK ANALYSIS
One of the main features of biologic data is the high level of correla-
tion existing between the different elements (i.e., mRNAs, proteins,
metabolites). Part of these relational patterns is due to metabolites
that belong to common metabolic pathways. In other cases, how-
ever, the observed correlations may be due to other causes like
global perturbations (i.e., metabolic compounds showing diur-
nal variation in time series analysis), specific perturbations (i.e.,
changes in enzyme concentrations spread through their related
metabolic pathways), or the intrinsic variability of metabolomic
data (Steuer et al., 2003; Camacho et al., 2005; Steuer, 2006). Con-
sequently, metabolites that do not show significant differences
across the studied phenotypes may still show different correlation
patterns with other metabolites in each phenotype. These patterns
can provide valuable information about the underlying metabolic
network associated to a specific biological process (Steuer, 2006).
Unlike pathway analysis, correlation-based methods build
metabolite networks according to the relationship patterns
observed in the experiment data. In the resulting network, each
metabolite is represented by a network node but, in contrast
to pathway analysis, the links between nodes represent the level
of mathematical correlation between each pair of metabolites.
In metabolomics data, high correlation coefficients are frequent
due to the presence of systemic and indirect associations (Krum-
siek et al., 2011). Using classical correlation coefficients leads
to highly crowded networks where direct and indirect associa-
tions are not distinguished (Langfelder and Horvath, 2008). This
problem can be successfully overcome using partial correlation
(Krumsiek et al., 2011; Valcárcel et al., 2011). In this approach, the
correlation between two metabolites is conditioned against the
correlation with the remaining metabolites. Consequently, par-
tial correlation allows to discriminate between direct and indirect
(i.e., mediated by other metabolites) metabolite correlations. Val-
cárcel et al. used this approach to build two different networks
corresponding to individuals with normal fasting glucose and
individuals with prediabetes (Valcárcel et al., 2011). Although
few differences were found between individual metabolite con-
centrations, the network analysis performed in this study revealed
significant changes in lipoprotein metabolism, which is known to
be associated with diabetes pathophysiology. Netzer et al. used
a similar approach to identify highly discriminant metabolites
between healthy controls and individuals with obesity (Netzer
et al., 2012). In this case, the metabolic network was built using
Pearson’s correlation coefficient, and the differential metabolites
were evaluated by using different network descriptors. In the same
study, Netzer et al. used the metabolic differences between two
sample groups to build a metabolite ratio network (Netzer et al.,
2011). In this approach, the link between two metabolites is scored
according to the differences in the ratios between the correspond-
ing metabolites in the two sample groups. The resulting network
topology is then based on the metabolic differences between the
two studied phenotypes. Recently, Kotze et al. have extended the
correlation-based network approach to include prior biological
knowledge (Kotze et al., 2013). In this approach, the resulting
network is mapped onto known metabolic pathways in order to
identify novel links within the metabolic network that may play a
key role in the phenotypic trait being studied.
INTEGRATION OF OMICS DATA
Systems biology is the computational modeling of complex bio-
logical systems at different molecular levels through the analysis
of high-throughput data. Systems biology methods can therefore
improve our understanding of the biological processes that are
associated with a certain phenotype. These approaches also allow
studying how the dysregulation of specific biological pathways is
propagated across the biological system. The characterization of
the complex and often noisy biological systems has become a major
challenge in bioinformatics.
METABOLOMICS INTEGRATION WITH WHOLE GENOME VARIATION
The association between genome-wide genetic variation and high-
throughput metabolomic data is one of the current main objec-
tives of omics data integration. The joint analysis of both types
of biological data, known as metabolite genome-wide association
studies (mGWAS), has allowed the identification of a large num-
ber of genomic regions associated with metabolite levels (Gieger
et al., 2008; Illig et al., 2010; Suhre et al., 2011a,b; Table 4). These
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Table 4 | List of studies integrating genomics and metabolomics data.
Cohort sizea Metabolites Biofluid Metabolomics platform Objectives Reference
284 363/40401 Serum ESI-MS/MS Study of GIMs Gieger et al. (2008)
4400 33 Plasma ESI-MS/MS Study of GIMs Hicks et al. (2009)
1809/422 163 Serum ESI-MS/MS Study of GIMs Illig et al. (2010)
1814 163 Serum ESI-MS/MS Study of GIMs Kolz et al. (2009)
862/2031 59 Urine NMR Study of GIMs Suhre et al. (2011b)
1768/1052 276 Serum UHPLC/MS/MS2, GC/MS Study of GIMs and overlap with loci of
biomedical and pharmaceutical interest
Suhre et al. (2011a)
211 526 Urine and
plasma
Multi-platform Study of GIMs and decomposition of
biological population variation in metabolic
traits
Nicholson et al. (2011)
4034 153 Plasma ESI-MS/MS Study of GIMs and pathway analysis Demirkan et al. (2012)
8330 216 Serum NMR Study of GIMs and heritability of metabolic
traits
Kettunen et al. (2012)
6600 130 Serum NMR Study of metabolic associations with
atherosclerosis using metabolic networks
Inouye et al. (2012)
2076 217 Plasma HPLC/MS Study of GIMs and heritability of metabolic
traits
Rhee et al. (2013)
7824 486 Plasma UHPLC/MS/MS2, GC/MS Study of GIMs, heritability of metabolic
traits, and network analysis
Shin et al. (2014)
This table provides an updated list of studies that have integrated metabolomics data with genomics data.
aStudies with discovery and validation cohorts are given as Ndiscovery/Nvalidation.
associations are commonly called genetically influenced metabo-
types (GIMs), and could play an important role in the heritability
of phenotypic traits. The association between genetic variants and
phenotypic traits that often show small association effect sizes can
be significantly increased when using intermediate phenotypes
like metabolite concentrations (Gieger et al., 2008). These inter-
mediate phenotypes (or endophenotypes) may be characterized by
larger effect size associations since they are continuous variables
that reflect the actual state of the biological system.
One of the main statistical problems when analyzing the asso-
ciation between genetic variants and metabolite concentrations
at a genome-wide level is the large number of tests that must be
performed. The number of genetic variants analyzed for each indi-
vidual by the current high-throughput genotyping technologies
usually ranges between 500,000 and 2e6. This number of genomic
variants can be further increased up to 5–10e6 variants with the
help of imputation techniques (Howie et al., 2009; Delaneau et al.,
2013). Compared to gene-expression data, metabolomic profiles
have a much lower number of variables, ranging from 100 s to
few 1,000 s. Nevertheless, performing all gene to metabolite asso-
ciation analyses in mGWAS can result in up to 1 · 107–1 · 1011
statistical tests. To date, there are multiple tools that can effi-
ciently perform this large number of quantitative trait analysis
like Matrix eQTL (Shabalin, 2012). However, the main limitation
of this type of studies is the number of tests that are performed
in parallel, and the associated increase in the false positive rate at
the nominal (α= 0.05) level of significance. Applying a conserva-
tive multiple test correction methods like the Bonferroni method
leads to extremely high significance thresholds (i.e., corrected α
levels= 1 · 10−9–1 · 10−13, depending on the total number of per-
formed tests; Gieger et al., 2008; Illig et al., 2010). In order to
set a less stringent correction threshold for this type of studies,
Demirkan et al. computed the effective number of independent
tests by using the number of significant principal components
of variation of the metabolomic data (Demirkan et al., 2012).
Other studies instead have chosen the genome-wide level of signif-
icance commonly used in single-trait GWAS (α= 5e−8; McCarthy
et al., 2008; Kolz et al., 2009; Tanaka et al., 2009; Rhee et al.,
2013).
While most published mGWAS have relied on univariate associ-
ation tests, there is an increasing effort to develop new multivariate
approaches. These approaches have been designed to simultane-
ously analyze sets of metabolites instead of individual metabolite
levels (Klei et al., 2008; Ferreira and Purcell, 2009; O’reilly et al.,
2012; Ried et al., 2012; Stephens, 2013). These new approaches
have several advantages (Galesloot et al., 2014):
• They take into account the pleiotropic nature of metabolomic
data. Subsequently, a genetic variant can be simultaneously
associated with multiple metabolites.
• When a genetic variant is associated with multiple metabo-
lites, the aggregated information of the entire set of metabolites
increases the statistical power of the analysis (Allison et al., 1998;
Zhu and Zhang, 2009).
• By performing a single test for each set of metabolites, the
multiple test burden is reduced.
However, one of the main disadvantages of this type of analy-
sis methods is the reduced number of metabolites that can be
tested simultaneously. This implies that current metabolite pan-
els (>100 metabolites) cannot be tested together. Inouye et al.
overcame this problem by using a two-step design (Inouye et al.,
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2012). First, using the metabolite correlation matrix they identified
the most relevant metabolic networks using hierarchical cluster-
ing. The second step consisted of a multivariate GWAS of each
selected network. Each genomic variant was therefore tested a
much reduced amount of times and, for each test, the loading
of each network metabolite was computed.
Pathway-based approaches are also an important approach for
the analysis of genetic variation associated with metabolite levels.
As described in Section “Correlation-Based Network Analysis,” the
methods based on partial correlation coefficients are optimal for
the analysis of metabolomic data (Krumsiek et al., 2011). One of
these methods, Gaussian Graphical Modeling (GGM), has been
recently used to identify unknown metabolites through the inte-
gration of metabolomics, GWAS, and pathway data (Krumsiek
et al., 2012). Recently, Shin et al. also used GGM to build a com-
plete network of genetic variation associated with human blood
metabolite levels (Shin et al., 2014).
METABOLOMICS INTEGRATION WITH OTHER OMICS SCIENCES
Recently, the first study analyzing the association of the genome
methylation patterns methylation with metabolic traits has been
performed (Petersen et al., 2014). In this study, Petersen et al.
used multivariate regression analyses to identify two types of
methylome–metabotype associations: (a) associations due to
underlying genetic variants and (b) independent associations
potentially driven by environmental factors influencing the methy-
lome.
In addition to mGWAS studies, several studies have also
explored the association between whole genome gene-expression
(i.e., transcriptomics) and metabolomics. The data provided by
these two omics sciences have been used, for example, to improve
the classification of breast cancers and to explore the correlation
between the transcriptional and metabolic levels (Borgan et al.,
2010). Borgan et al. used the transcriptional data to classify the
breast tumor samples according to previously published tumor
types. In a second step, they applied hierarchical clustering on each
type of samples using the metabolic data. Using this combined
approach, new molecular subtypes of tumors were found. Impor-
tantly, these new molecular subtypes were better classified than
subtypes based only on gene-expression patterns. Additionally,
new biological pathways associated with each molecular subtype
could be identified. Using GOrilla software (Eden et al., 2009), they
were able to identify potential gene groups regulating each ana-
lyzed metabolite. Bjerrum et al. recently combined transcriptomics
and metabolomics data from colon biopsies of ulcerative colitis
patients. They used O-PLS-DA and multivariate logistic regres-
sion models to improve the diagnosis of this autoimmune disease
(Bjerrum et al., 2014). Zhang et al. also integrated transcriptomics
and metabolomics data to study human pancreatic cancer samples
(Zhang et al., 2013). Using a correlation-based network analysis,
they identified a set of highly co-regulated and decreased metabo-
lites in these samples and subsequently identified the transcripts
correlated with these metabolites.
TOWARD A COMPLETE OMICS INTEGRATION
During the last years, high-throughput technologies have enabled
the analysis of the biologic variability at multiple molecular levels.
The data obtained from the genome, epigenome, transcriptome,
proteome, metabolome, or the microbiome can be now combined
using systems biology approaches. However, this group of ana-
lytical tools is still in its infancy and major improvements in this
field will come in the next years (Chen et al., 2012). 3Omics is
one good example of this new type of metabolomic analysis tools.
3Omics is one of the first systems biology tools to provide a full
integrative analysis including correlation analysis, co-expression
profiling, phenotype mapping, pathway enrichment analysis, and
GO enrichment analysis at three molecular levels (transcriptome,
proteome, and metabolome; Kuo et al., 2013).
CONCLUSION
Metabolomics is a research field rapidly evolving to allow the fast
and accurate analysis of high-throughput data from diverse biolog-
ical sources. Although the recent methodologies have been able to
overcome several challenges of metabolomics data analysis, there
is still much room for improvement. In untargeted metabolomic
studies, for example, major improvements are still required in
automatic metabolite identification and spectral deconvolution.
Although a big effort is being done to improve spectral databases,
the development of accurate automatic identification algorithms
is still subject to the availability of an exhaustive set of reference
metabolite spectra.
In addition to the necessary improvements in the analysis work-
flow, intense efforts are also being done in the standardization
of metabolomics data (Salek et al., 2013a). The Metabolomics
Standard Initiative (MSI; Fiehn et al., 2007), currently represents
the major community effort to define normalization standards
in metabolomics. These developments are based on previous
high-throughput data standardization initiatives like MIAME in
microarray studies (Brazma et al., 2001), and include the use
of minimal reported information, common syntax, data format
exchange, and common semantics (Field and Sansone, 2006). To
date, general guidelines have been proposed (Sumner et al., 2007)
that cover relevant areas in metabolomics studies like biologi-
cal sample processing, analytical technique details (i.e., instru-
ment description, technique-specific acquisition parameters, and
sample preparation), instrumental calibration, validation of the
quantification method, data pre-processing, metabolite identifica-
tion, and nomenclature. Very recently, the MetaboLights database
(www.ebi.ac.uk/metabolights) has been launched as a reposi-
tory to archive and distribute data on metabolomics experiments
(Steinbeck et al., 2012; Haug et al., 2013; Salek et al., 2013b).
Similar to the established public repositories of transcriptomics
data (Barrett et al., 2011), the availability of public repositories
for metabolomics data will clearly accelerate the progress in this
rapidly evolving field.
Omics sciences like metabolomics are increasing our ability to
generate knowledge from multiple aspects of biology. In order to
achieve these goals, however, the scientific community will require
tools and methods that are able to efficiently integrate all the dif-
ferent sources of molecular and phenotypic information. In the
near future, increasingly powerful analysis tools will be developed.
The access to these methods in an open-source environment will
guarantee its dissemination to the largest scientific community
possible.
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Metabolites are low-weight molecules that are present in multiple biochemical 
processes either as intermediates or as end products of the metabolism. Consequently, 
the types and quantities of metabolites in a cell, tissue or organ can be informative of 
an underlying pathological event. Metabolomics, the global analysis of the complete 
metabolite profile, is a fast-developing biomedical research area. In the present article, 
we introduce the main methodological aspects of metabolomics and we review the 
most recent contributions of this approach in the study of the following rheumatic 
diseases: rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, 
psoriatic arthritis, osteoarthritis and gouty arthritis.
Keywords:  bioinformatics • genomics • mass spectrometry • metabolites • metabolomics 
• nuclear magnetic resonance • rheumatic diseases • rheumatology 
The metabolome is the most 
dynamic level of the organism
At the molecular level, the human body is 
an extremely dynamic system, with thou-
sands of molecular reactions taking place at 
each instant, inside millions of cells. These 
biochemical reactions are responsible for 
maintaining the cell activity, preserving cell 
structure and maintaining cell-to-cell com-
munication. For example, glucose break-
down to generate the main energy transfer 
molecule, ATP, is performed through a series 
of multiple metabolic intermediates. Each 
metabolite, in turn, has singular physical and 
chemical properties that can be used to mea-
sure its concentration at a specific time point 
in a certain tissue or cell type. From a bio-
medical perspective, the characterization of 
the metabolomic profile of a sample obtained 
from a patient can be a powerful approach to 
identify the physiological processes that are 
altered in disease. This knowledge can be key 
in the development of new and more effective 
therapeutic approaches. In addition, disease-
associated metabolites can be useful biomark-
ers with clinically relevant applications like 
early diagnosis or treatment personalization.
Inflammation is a complex biological pro-
cess, in which vascular, immune and other 
tissue-specific cell types are activated to elimi-
nate an offending agent, either an infecting 
microorganism or a tissue injury. Conse-
quently, the tissue concentrations of multiple 
metabolites are modified from their normal 
homeostatic levels. An important subset of 
the most severe types of rheumatic diseases 
is characterized by the presence of chronic 
inflammation, leading to tissue destruc-
tion, pain, disability and the reduction of 
life expectancy. Identifying the metabolomic 
profile associated with each clinical entity 
would therefore be of major importance for 
the development of more individualized ther-
apeutic approaches. The recent technological 
and methodological advances are now allow-
ing the fast and accurate assessment of the 
metabolome in many different normal and 
pathological conditions. In the present article 
we will describe these technological advances 
and we will review the most significant 
results in the metabolomics study of rheu-
matic diseases. Supplementary Table 1 (see 
online at http://www.futuremedicine.com/
doi/full/10.2217/IJR.14.25) summarizes the 
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Figure 1. Metabolomics study workflow (see facing page). This figure shows the different steps associated with a 
metabolomics study. (A) According to the objectives of the study, the adequate cohorts and the type of biological 
samples that will be screened must be selected. (B) Shows the analytical instruments that are mostly used to 
acquire the spectral data from the biological samples. (C) Depending on the technological platform, the resulting 
spectral data are referred either in chemical shift (ppm) or in m/z and retention time. (D) Once the spectral data 
have been acquired, different processing pipelines must be applied in order to remove noise and bias and to 
accurately quantify each spectral peak. (E) This results in a feature matrix containing the quantification measures 
for each peak and each sample. This matrix is finally used to perform both the statistical analysis to identify 
significant associations and metabolite identification that will link each feature (i.e., peak) with the corresponding 
metabolite that will allow the biological interpretation of the identified associations. 
GC/MS: Gas chromotography mass spectometry; LC/MS: Liquid chromotography mass spectometry; NMR: Nuclear 
magnetic resonance; ppm: Parts per million.
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studies included in this review as well as the list of key 
metabolites identified in each disease.
Study design in metabolomic studies
There are two major study design approaches in 
metabolomics: targeted and untargeted studies [1,2]. 
In targeted studies, the researcher has a specific 
hypothesis to test that is based on previous knowl-
edge of a particular biological pathway or metabo-
lite family. In this type of studies, only a reduced set 
of metabolites is detected and quantified. Targeted 
studies are characterized for being very demanding 
in terms of sample preparation and analytical setup 
but, in exchange, metabolite measurements are sensi-
tive and highly accurate. Consequently, these types of 
metabolomic studies tend to require smaller sample 
sizes and less bioinformatic processing steps than 
untargeted studies.
In untargeted studies, the goal is the measurement 
of the largest possible number of metabolites per sam-
ple in order to obtain a global metabolomic profile. 
These types of metabolomic studies are normally part 
of a top–down strategy, where the results obtained 
at the global level are used to generate new hypoth-
eses that are subsequently validated using a targeted 
approach. In untargeted metabolomic studies, the 
large amount and complexity of the data generated 
require the development of highly efficient bioin-
formatic methods that are able to extract the most 
relevant biomedical information.
In metabolomics, like in many other biomedical 
research areas, different study designs can be con-
sidered: cross-sectional, cohort or case–control stud-
ies. Given its simplicity, one of the most commonly 
used study approaches in metabolomics has been the 
case–control design. In this design, samples from 
affected individuals and nonaffected individuals are 
drawn at random from the population at risk. With 
this approach, different clinically relevant compari-
sons can be performed to identify useful biomarkers 
like disease diagnostic biomarkers, disease activ-
ity biomarkers or biomarkers of drug response 
(Figure 1A). When using this approach in untargeted 
metabolomic studies of human samples, large sample 
sizes are generally required in order to efficiently con-
trol for potentially confounding variables like clinical 
and epidemiological variables (i.e., age, gender, diet 
or smoking status) as well as technological artifacts.
In metabolomics, the variability introduced by the 
observer (i.e., the biomedical researcher), can have a 
dramatic impact on the quality of the results. Sample 
manipulation, for example, is a critical step since vari-
ation at the collection, processing or sample storage 
steps can introduce significant biases in the resulting 
data. This high variability is largely due to the speed 
of degradation or modification of multiple metabo-
lites in the sample. In order to minimize the nega-
tive impact of sample manipulation, the collection of 
human biological samples must be carefully planned 
and the technical variables recorded. For example, 
when collecting biofluids like plasma or urine the 
researcher must attempt to standardize influential 
aspects like the diet, hour of the day at which the 
sample is collected or the fasting time. Previous stud-
ies have shown that variation in these aspects can 
introduce significant biases in downstream statisti-
cal analyses [3–5]. Even seemingly irrelevant aspects 
like the type of containers where the samples are col-
lected or the addition of preservatives during sample 
collection, can significantly alter the quality of the 
metabolomic data that can be obtained [4,6–8]. Conse-
quently, the introduction of quality control measures 
like the standardization of all processes, the use of 
internal controls as well as the adequate calibration 
of the equipment are of paramount importance in 
metabolomic analysis.
Recent technological improvements are 
boosting metabolomic studies
In the last years, the advances in metabolomic analysis 
technologies as well as on bioinformatic data analy-
sis methods have boosted the presence of metabolo-
mics in biomedical research [2,9]. To date, the two 
most widely used metabolomic analysis technologies 
are nuclear magnetic resonance (NMR) and mass 
spectrometry (MS) (Figure 1B).
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Figure 2. Analytical techniques: nuclear magnetic resonance. The NMR spectral acquisition is based on the 
behavior of the molecule spin under magnetic field variations. First, a constant magnetic field is applied to the 
sample, aligning the spins of all their molecules (i.e., step 1). The next step consists of applying a RF pulse to 
generate an interfering magnetic field which temporary misalign the molecules’ spins (i.e., step 2). Once the 
interfering magnetic field disappears (i.e., step 3), the molecules’ spins relax back to their original alignment. This 
spin relaxation results in a signal, FID, which can be measured and, after applying on the FT, is transformed on a 
peak spectrum where each peak is characterized by its amplitude (vertical axis) and its chemical shift (horizontal 
axis). The latter is usually measured in ppm and refers to the difference between the resonance frequency and 
that of a reference substance divided by the frequency of the spectrometer.
FID: Free induction decay; NMR: Nuclear magnetic resonance; ppm: Parts per million; RF: Radio frequency; 
FT: Fourier transform.
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NMR is a spectroscopic analysis technique [10,11] 
based on the physical properties of energy absorption 
and re-emission of the atom nuclei due to variations 
in the applied magnetic field (Figure 2). Measuring 
the energy emitted by the atom nuclei that build up a 
specific molecule (i.e., free induction decay) not only 
allows the quantification of the concentration of the 
molecule itself. NMR is a fast and highly reproducible 
metabolomic analysis technique and has the advan-
tage with respect to MS that it does not destroy the 
biological sample at study. Given its relatively low cost 
per sample analysis, NMR is generally the technol-
ogy of choice when performing large-scale explorative 
studies of the metabolome.
To date, NMR-based studies have been used to 
identify and quantify metabolites in different types of 
human samples such as urine [12], serum [13] or cerebro-
spinal fluid [14]. Among the different NMR analytical 
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Figure 3. Analytical techniques: mass spectrometry coupled to chromatography. This figure schematizes the mass 
spectometry-based spectral acquisition workflow. (A) The sample is injected into the chromatographic column 
using a solvent as mobile phase. (B) As the sample flows through the column, the different metabolites (M1, M2 
and M3) are separated due to their differential retention on the stationary phase inside the column. (C) Once the 
sample has traversed the entire column, it is introduced in the mass spectrometer, which obtains the m/z of the 
molecules comprising the sample.
m/z: Mass-to-charge ratio.
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approaches available, 1D proton NMR (1H-NMR) is 
the most commonly used technique. The main reasons 
for using 1H-NMR are the natural high abundance of 
hydrogen nuclei in metabolites, the increased sensitiv-
ity of 1H-NMR compared with other NMR approaches 
(i.e., 13C-NMR), as well as the time-efficient acquisi-
tion of spectra (see an example spectrum on Figure 1C). 
Together, these advantages make this technique suit-
able for untargeted metabolomic studies searching for 
biomarkers of diagnosis or prognosis, involving large 
sample sizes of patients and controls.
Very recently, technological advances like cryogeni-
cally cooled probes, micro-probes and increased mag-
netic field strength [11] are allowing a significant gain 
in sensitivity of NMR-based analyses. Nonetheless, 
NMR is unable to detect and quantify many low con-
centration metabolites. In order to detect and quantify 
this type of metabolites, MS-based technologies must 
be used instead.
MS is an analytical technique that generates spectral 
data in form of a mass-to-charge ratio (m/z) versus the 
relative intensity of the compounds that are generated 
after the ionization of the biological sample (Figure 3). 
The resulting ionized compounds are then measured 
by the MS spectrometer, generating peak signals at 
specific positions of the spectrum which, altogether, 
define the fingerprint of the original molecule. Nowa-
days, MS spectrometry can be performed on a broad 
range of instruments and techniques which use dif-
ferent ionization and mass selection methods [15,16]. 
When analyzing the metabolome, MS analysis is gen-
erally preceded by a chromatographic separation step. 
This step is required to reduce the high complexity of 
the biological sample which would otherwise be intrac-
table. Liquid and gas chromatography columns (LC 
and GC, respectively) are the most commonly used 
chromatographic separation techniques. In both cases, 
metabolite separation is based on the different amount 
of time required by each metabolite to pass through 
the chromatographic column. This time, called reten-
tion time, depends on the metabolite interaction with 
the adsorbent material inside the column.
Compared to NMR, MS-based metabolomic analy-
ses have a much higher sensitivity, and therefore they 
allow the detection and quantification metabolites 
that are in low concentrations in the biological sam-
ples. Compared with NMR, however, MS analyses 
require additional sample preparation steps [17] as well 
as a chromatography separation phase. For this reason, 
researchers performing large-scale and cost-effective 
exploratory studies might opt to initially use NMR 
techniques.
Among MS techniques, LC-MS is frequently used 
due to its high reproducibility and wide range of 
covered metabolites [18,19]. Metabolite sensitivity of 
LC-MS highly depends on the ionization method 
used (i.e., electrospray ionization is the most com-
monly used [20]) and also on the subsequently selected 
ionization mode (i.e., either positive or negative [21]). 
Other MS-based techniques such as GC-MS can be 
more reliable depending on the chemical nature of 
the studied metabolites (i.e., nonionizable compounds 
such as retinol). This technique requires the metabo-
lites to be volatile or suited for chemical derivatization 
and subsequent volatilization [22,23]. Finally, the recent 
technological advances in LC-MS, like the use of ultra-
performance liquid chromatography [20], are clearly 
boosting the capabilities of MS metabolomic analysis 
by significantly increasing specificity, sensitivity and 
acquisition time.
The need for bioinformatics in 
high-throughput metabolomic studies
The recent technological advances in metabolomic 
analysis have increased the quantity but also the com-
plexity of metabolomic data that can be extracted 
from one single biological sample. At the same time, 
the development of highly specialized sample collec-
tions for ‘omics’ studies like biobanks are allowing the 
analysis of large volumes of samples. Consequently, 
there is a clear need for bioinformatic methods that 
can process this large amount of complex data and 
extract meaningful information in a fast and reliable 
way (Figure 1D).
The raw spectral data generated by NMR (Figure 1C) 
are known to be subject to multiple experimental and 
technical biases. Macro-molecule signals and other 
inter-sample variant factors such as used solvent, pH, 
ion strength and sample dilution, can produce varia-
tions on spectral peak positions and areas as well as 
baseline spectral artifacts [24] requiring the application 
of bioinformatic methods that can correct these arti-
facts. The two main correction methods in NMR data 
processing are baseline correction and peak alignment 
methods [25]. After these corrections are applied, two 
alternative bioinformatic methods can be applied to 
the NMR data before performing the desired statisti-
cal analysis: spectral binning and peak-based analysis. 
The first method is based on the automatic partition-
ing of the spectra in equally spaced bins. The areas 
calculated from each of these bins are subsequently 
used in the statistical analysis, in order to identify the 
spectral regions that are associated with the trait of 
interest. Limitations of this approach are that it does 
not account for peak positions and also that it does 
not exploit the presence of correlation patterns at the 
peak level that can be useful to identify the metabo-
lite. In order to overcome these limitations, peak-based 
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methods have been developed. Making use of the cor-
relation patterns between peaks and the information 
stored in the metabolite spectral databases [26], these 
methods can accurately identify and quantify many 
different metabolites present in the biological sample. 
In the recent years, several open-source bioinformatic 
methods have been developed that can partially [27,28] 
or completely [29] overcome all the challenges of NMR 
data processing.
With regards to MS-based spectral data analysis, 
the processing pipeline is very similar to NMR-based 
workflow [30]. In MS analysis, several accurate and 
robust bioinformatics tools have been also developed to 
perform MS spectra processing [31] as well as end point 
metabolite identification [32,33]. These tools are often 
dependent on the type of chromatographic column 
used for separation and suited for  two-dimensional (i.e., 
retention time and m/z)  spectral analysis (Figure 1C).
In addition to spectral processing and metabolite 
identification, high throughput metabolomic stud-
ies also require the application of complex statisti-
cal methods in order to extract relevant information 
(i.e., sample group clustering, biomarker identifica-
tion). These multivariate analysis methods [34], also 
known as chemometrics methods, allow to perform 
tasks such as data overview, (i.e., principal component 
analysis), model building (i.e., partial least squares and 
orthogonal principal component analysis) and bio-
marker identification. Given the complexity associated 
with the metabolomics data processing and analysis, 
any metabolomics study will require the participation 
of highly trained specialists.
Metabolomic studies in rheumatoid arthritis
Since 1990, a relatively large number of studies have 
investigated the metabolomic changes that occur in 
rheumatoid arthritis (RA) pathology. Metabolomic 
studies in RA have evolved from using small sample 
sizes to investigate gross metabolic changes in changes 
on synovial fluid (SF) to using large sample sizes used 
to screen less invasive biofluids such as serum or urine, 
in order to disentangle the metabolome dynamics 
associated with disease activity and treatment response.
SF metabolome in RA
SF is a low abundance biological fluid produced from 
the synovial membrane filtrate of plasma and which 
contains high levels of hyaluronic acid. Its main pur-
pose is the lubrication of the joint and the nutrition 
of the neighboring cartilage tissue. In RA, the SF is 
enriched with inflammatory cells, proteins and metab-
olites from the inflamed tissue. Therefore, the SF is a 
direct surrogate for the main biological processes that 
are taking place in the inflamed joint in RA.
The first metabolomic studies in RA were per-
formed on SF and plasma samples from RA patients 
using simple NMR approaches [35–38]. The studies by 
Naughton et al. [37,38] confirmed the hypoxic nature of 
the inflamed synovial joint in RA, with the produc-
tion of high levels of lactate compared with SF from 
controls. Inflammation in RA also was shown to lead 
to a significant consumption of lipids (i.e., reduction 
in low-density lipoproteins, very-low-density lipopro-
teins and chylomicrons), which consequently increase 
the concentration of ketone bodies (i.e., acetone, 
3-D-hydroxybutyrate).
The anaerobic properties of RA SF were soon 
exploited in the search for useful disease biomark-
ers. Meshitsuka et al. [36] proposed the lactate/ala-
nine ratio as a biomarker of RA early diagnosis since 
it showed increased levels compared with osteoar-
thritis (OA), the most common non-autoimmune 
arthritis. More recently, Fuchs et al. [39] analyzed SF 
and matched plasma samples of patients undergoing 
anti-TNF therapy. Using matrix-assisted laser desorp-
tion and ionization time-of-flight MS technology, 
they measured the phospholipid profile before and 
during anti-TNF treatment, in order to evaluate the 
use of plasmatic metabolites as useful markers of dis-
ease activity in the joint. They found that the ratio 
between phosphatidylcholine and its derivate and 
powerful immune chemoattractant lysophosphati-
dylcholine (i.e., PC/LPC ratio) that was detected in 
SF samples from RA patients was still detectable in 
their corresponding plasma samples. This aspect is 
of importance since it demonstrates that metabolic 
variations in the target tissue (i.e., SF in RA), can also 
be detected in plasma, which is a much less invasive 
type of sample. As expected, PC/LPC ratio increased 
with anti-TNF treatment due to the reduction of joint 
inflammation and the subsequent reduced production 
of  lysophosphatidylcholine.
More recently, Giera et al. [40] used a more advanced 
technological approach to further characterize the lipid 
profile of RA SF. Using an untargeted LC-MS/MS 
system, they characterized 70 different lipid and lipid-
derived metabolites. Among these metabolites they 
identified high levels of 5S,12S-diHETE, an isomer 
of LTB
4
 leukotriene. 5S,12S-diHETE is produced by 
activated neutrophils and platelets, two cell types that 
have been closely related to RA pathophysiology [41,42]. 
The same group, using high resolution MS techniques, 
performed also a lipid profile analysis of RA and OA 
synovial samples [43]. While the unsupervised analysis 
of the lipid data was not able to distinguish between 
disease diagnostic, they were able to identify a new 
clustering pattern of the SF samples. A thorough 
analysis of this lipid profile showed that the observed 
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sample clustering was caused by the differential abun-
dance of esterified oxylipids. Additional studies are 
needed to identify the biological origin of this family 
of lipids and its association with rheumatic diseases.
Serum & plasma metabolomes
In the clinical setting, blood is a convenient and use-
ful tissue for the study of rheumatologic diseases since 
the collection of samples is clearly much less inva-
sive than the sampling of the affected target tissue. 
In metabolomics studies of blood, the non-cellular 
component is separated and analyzed. When extract-
ing the fluid component of blood, researchers can opt 
to use anticoagulant agents – in which case a plasma 
sample is obtained – or let blood clot and obtain a 
serum sample. The clotting of blood strongly influ-
ences the level of certain compounds like eicosanoids 
[13] or oxylipins. Consequently, researchers must aware 
of the potential impact of this non-physiologic clot-
ting process in the results of their metabolomic studies 
in blood.
One of the first metabolomic approaches to the 
characterization of the RA serum metabolome was per-
formed by Weljie et al. [44], using the K/BxN arthritic 
mouse model. The K/BxN model is a well-described 
model of inflammatory arthritis that shares many sim-
ilarities with human RA. Using 1H-NMR, serum sam-
ples from arthritic and control mice were compared, 
to identify a characteristic metabolite pattern. Uracil 
and TMAO were significantly increased in the serum 
of arthritic mice while xanthine, glycine, glycerol, 
hypoxanthine were significantly reduced compared to 
nonarthritic mice. Consequently, this study identified, 
for the first time, metabolites from the nucleic acid and 
oxidative stress pathways as potential biomarkers for 
RA pathology.
Using a cohort of patients and controls Lauridsen 
et al. [45] confirmed that the inflammatory state of RA 
is reflected in the 1H-NMR spectra of human plasma 
samples. Similar to the discoveries in RA synovial 
fluid, lactate concentrations were found to be higher 
in patients compared with controls, probably as a con-
sequence of the increase of the anaerobic metabolism 
occurring in the inflamed joints. Another likely con-
sequence of the inflammatory activity of the synovial 
membrane were the high levels of acetylated glyco-
proteins detected in RA plasma. Finally, and in con-
sistence with previous studies [46,47], elevated concen-
trations of cholesterol and low levels of high-density 
lipoprotein were also found to be associated with RA. 
High-density lipoproteins are mainly responsible for 
cholesterol removal from the bloodstream; together, 
this lipid bioprofile could explain the increased risk for 
coronary artery disease observed in RA patients.
Searching for a diagnostic metabolomic profile, 
Madsen et al. [48] analyzed the plasma from RA patients 
and compared it to controls and patients with psoriatic 
arthritis (PsA). In this case, a specific set of metabo-
lites were evaluated with GC-MS and LC-MS. They 
observed a significant decrease of histidine levels in RA 
patients compared with controls and PsA patients. Low 
levels of this amino acid have been one of the earliest 
characteristic plasmatic features observed in RA [49], 
although its origin is still not clear. Threonic acid, a 
metabolite of vitamin C, was also highly expressed 
in RA plasma compared with controls and could be 
a consequence of the high oxidative stress present in 
the disease. Contrary to the previous study in human 
plasma, however, they found significantly lower levels 
of cholesterol in RA patients. Other studies also sup-
port the lower concentrations of cholesterol in RA 
compared with controls [50], so there is a clear need for 
additional studies to identify the potential influence of 
confounding variables and define the precise associa-
tion of this metabolite with RA. Finally, similar to the 
K/BxN model screening analysis, they also found high 
levels of metabolites implicating the nucleotide biosyn-
thesis (i.e., pseudouridine and guanosine) with RA. 
Discrepancies like the increase in hypoxanthine levels 
compared with the reduction in the RA mouse model 
remind us, however, the limitations of using animal 
models in the characterization of human diseases.
Very recently, Jiang et al. [51] used GC-MS and 
LC-MS to perform a metabolic analysis of the serum 
profile of the most prevalent forms of arthritis including 
RA, OA, ankylosing spondilytis (AS) and gouty arthri-
tis (GA). Using multivariable analysis techniques on the 
set of measured metabolites they succeeded in discrimi-
nating all arthritis patients from healthy controls. The 
common arthritis profile included an increase of lactate, 
dihydroxyfumaric acid, glyceraldehyde, aspartic acid 
and homoserine, as well as a reduction in 4,8 dimethyl-
nonanoyl carnitine. Together, the levels of these metab-
olites in plasma could distinguish an arthritis patient 
from a control individual with an 81% sensitivity and 
88% specificity. In this study the differences between 
RA and OA (i.e., female patients) and between AS and 
GA (i.e., male patients) were also explored. The former 
comparison was based on a panel of the 13 top-ranked 
differential metabolites (e.g,. tryptophan, sarcosine, 
alanine) and yielded a classification model with an 86% 
sensitivity and 85% specificity. Similarly, a panel of the 
16 top-ranked differential metabolites between AS and 
GA (e.g., creatine, cysteine, uric acid and valine) were 
selected to build a prediction model that reached a 79% 
sensitivity and 85% specificity.
The early diagnosis of RA can be crucial to the 
improved management of the disease and the increase 
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in the rates of clinical remission. For this reason, the 
identification of biomarkers that are informative at ear-
lier stages of the disease can be of major importance. 
Using 1H-NMR technology Young et al. [52] performed 
a screen in the serum metabolome of RA patients at 
their most initial stages and compared it to patients 
with more advanced disease as well as controls. Similar 
to Lauridsen et al. [45], they found low levels of lipopro-
teins in RA patients compared with controls. Also, the 
presence of 3-hydroxybutyrate, a ketone body, is in line 
to the previous findings of an intense anaerobic metab-
olism in the inflamed RA joint [37]. In the early RA 
group, a strong correlation of the serum metabolite pro-
file and the degree of inflammation, represented by the 
levels of C-reactive protein, was found. It is therefore 
possible that these metabolites represent a more objec-
tive and reliable measure of the extent of the disease, 
including periods of apparent clinical inactivity.
Another highly relevant objective of metabolomic 
analysis is the identification of metabolites that are asso-
ciated to disease activity and treatment response. These 
biomarkers could provide more objective measurements 
of disease activity and, therefore, allow better disease 
management. In their 1H-NMR longitudinal analysis 
of human plasma, Lauridsen et al. [45] found that the 
metabolite profile of RA patients with active disease 
approached the profile of patients in remission after 
starting therapy. Importantly, both the active RA and 
the remission RA profiles were significantly different 
from the normal controls’ profiles along the longitudi-
nal study. In another longitudinal study, Madsen et al. 
[53] used GC-MS and LC-MS to identify serum metab-
olites correlated with the RA activity in patients start-
ing anti-TNF therapy. In this study, the correlation of 
serum metabolite levels with the DAS28 disease activ-
ity score was analyzed using two independent patient 
cohorts. Interestingly, while highly significant linear 
models associated with disease activity were built in 
each study cohort (p-values: 6.4 × 10-6 and 9.2 × 10-3), 
the predictor metabolites were quite different between 
both studies. A detailed analysis of the metabolite pro-
files of all patients suggested the existence of different 
underlying disease mechanisms. The existence of dif-
ferent RA subclasses at the molecular level has been pre-
viously suggested by whole blood transcriptomic analy-
ses [54]. The presence of heterogeneity in RA is a clear 
complicating factor in the metabolomic study of the 
disease and consequently imposes the use of large and 
well-characterized patient cohorts in order to  identify 
clinically useful biomarkers.
Urine RA metabolome
From a biomarker perspective, urine is an even more 
interesting biofluid than blood since it is easy to obtain 
and clearly non-invasive. Inflammatory diseases have 
shown to influence the metabolomic profile in urine 
[55]. Kapoor et al. [56] used NMR to evaluate the associ-
ation of urine metabolites and the clinical outcomes of 
RA and PsA treated with anti-TNF therapies. For this 
objective, urine samples were obtained and analyzed 
at baseline and at 12 weeks of treatment. Multivariate 
analysis of the NMR spectra showed that urine metab-
olites could segregate RA patients with a good response 
from patients with a bad response to anti-TNF therapy. 
Among the predictor metabolites, histamine showed 
the highest correlation with anti-TNF response. 
Patients showing higher levels of this powerful cyto-
kine were more likely to respond to anti-TNF therapy. 
The existence of subgroups patients showing differing 
levels of this metabolite could therefore explain results 
on its precursor histidine, which has been found to 
 display opposing levels in different studies [48,57].
Metabolomic studies in systemic lupus 
erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune 
disease characterized by a variety of clinical manifesta-
tions and a wide production of auto-antibodies [58]. 
This marked heterogeneity makes it a challenge for 
clinical specialists to diagnose SLE, particularly at the 
first stages of the disease. Consequently, the identifica-
tion of metabolomic biomarkers that can help diagnose 
SLE or any of its clinical subphenotypes, would be of 
major importance in the management of this yet incur-
able disease. Studies characterizing SLE metabolomic 
profile are very recent and have focused on the analysis 
of the serum and the urine metabolome.
Serum SLE metabolome
In order to identify a metabolomic profile characteristic 
of SLE, 2011 Ouyang et al. [59] performed a 1H-NMR 
metabolomic analysis on serum samples from SLE 
patients and compared it to the serum profiles of con-
trols and patients with RA. Multivariate analysis of the 
1H-NMR spectra showed a higher discrimination power 
between both rheumatic diseases and controls than 
between RA and SLE. This result is in accordance with 
previous studies demonstrating the existence a common 
core of metabolites in chronic inflammatory diseases. 
Histidine was found to have a low concentration in the 
serum of both RA and SLE compared with controls. 
Low levels of this amino acid had been also detected 
in the analysis of RA plasma [48]. Previous evidence in 
chronic kidney disease patients suggests that low histi-
dine levels are inversely correlated with the presence of 
inflammation and thus could exert anti-inflammatory 
and antioxidant effects [60]. Other additional amino 
acids (alanine, tyrosine, isoleucine, valine, phenylala-
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nine, lysine, histidine and glutamine) were also found 
to be expressed in lower levels in RA and SLE compared 
with controls, possibly linked to the protein turnover 
associated to the high inflammatory activity occur-
ring in both diseases. Similarly, Krebs cycle metabolites 
citrate and pyruvate were also in low concentrations in 
the serum of SLE and RA patients, suggesting an asso-
ciation with the increase in the energy requirements in 
both inflammatory diseases. As found previously in RA 
plasma [45], SLE serum also shows reduced levels of low-
density lipoproteins. The globally altered lipid profile 
observed in SLE patients might be an important factor 
in the pathogenesis of atherosclerosis in this disease [61]. 
Elevated levels of lactate were also found to be a pow-
erful discriminative biomarker between in RA patients 
and SLE patients or controls.
In a more recent study, Xinghong et al. [62] used 
LC-MS to analyze a subset of metabolites in sera of 
SLE patients and controls. Multivariate analysis of the 
metabolite profile confirmed the clear classification 
of both groups. Looking for those metabolites with a 
stronger ability to separate SLE patients from controls, 
they identified an increase of proline amino acid and 
several lysophosphatidyl cholines as well as a decrease 
of phenylalanine, tryptophyan and bilirubin. Low lev-
els of phenylalanine had been also detected in the pre-
vious study [59], suggesting a potential use as diagnostic 
biomarker in the early phases of SLE.
Using also MS technologies, Wu et al. [63] performed 
a case–control study to find additional serum metabo-
lites associated with SLE. Importantly, in this study 
they included an additional group of cases and controls 
to validate the metabolites associated with SLE in the 
initial (discovery) cohort. In this study they identified 
a marked increase in lipid peroxidation products like 
9-HODE and 13-HODE. Importantly, the level of 
these metabolites correlated with the increase of disease 
activity in patients, indicating a potential applicability 
as biomarkers. In concordance with this rise in oxidative 
stress, the levels of glutathione were also reduced in SLE 
patients. Vitamin B6, which is necessary for the produc-
tion of glutathione, was found to be significantly reduced 
in SLE patients’ sera, which might explain the reduc-
tion of this powerful antioxidant. This finding indicates 
vitamin supplementation could be a potential adjunctive 
therapy to reduce oxidative damage in SLE. While most 
differential metabolites were found to be reduced in SLE 
patients, two metabolites associated with the leukotriene 
production pathway, leukotriene B4 and 5-HETE, were 
found to be significantly overexpressed in serum.
Urine SLE metabolome
Renal involvement is the strongest predictor of mor-
bidity and mortality in SLE and, consequently, there 
is major need to identify useful biomarkers associated 
to this severe outcome. However, while lupus nephritis 
has been largely studied from a proteomics perspective 
[64–67], metabolomic studies on lupus nephritis are still 
infrequent. Recently, Romick et al. [68] used 1H-NMR 
to perform a metabolomic screen of urine to identify 
metabolites that can help discriminate proliferative, pure 
membranous and focal segmental glomerulosclerosis in 
SLE. They found that taurine and citrate, which have 
been previously associated to tubular renal function 
[69], were strong biomarkers distinguishing proliferative 
(classes III/IV) from pure membranous classes (class V). 
While class III/IV patients had low taurine levels and 
normal citrate levels in urine, class V patients had low 
citrate levels and high taurine levels. These differences 
lead to an almost perfect discrimination between the 
two lupus nephritis subtypes. The plasmatic levels of the 
two metabolites are known to be regulated by the kid-
ney. Pathological differences between both SLE neph-
ritis subclasses might explain the differential amount of 
metabolite finally excreted to urine.
Brain SLE metabolome
Compared to other rheumatic diseases, the nervous 
system is frequently affected in SLE patients leading 
to neuropsychiatric syndromes [70]. An altered glu-
cose metabolism in the brain has been associated to 
the development of these psychiatric symptoms in SLE 
patients [71]. Using a well known SLE mouse model, 
Alexander et al. [71] used 13C NMR and 1H-NMR to 
evaluate the incorporation of glucose in brain extracts 
compared with control mice. The results clearly con-
firmed the altered brain metabolism in SLE. Choline 
was found to be highly increased in the brains of the 
diseased mice. Choline is a precursor for the synthe-
sis of phospholipids and it is known to participate 
in inflammation by contributing to the production 
of arachidonic acid [72] which, in turn, leads to the 
increase of prostaglandins which exert multiple roles 
in the inflammatory response [73]. Glutamate and glu-
tamine were also significantly increased and, together, 
suggest a predominant role for the glial cells (astro-
cytes and microglia) rather than neurons in the patho-
logical events in the SLE brain. Also, lactate levels were 
found to be increased; lactate might be a product of 
infiltrating macrophages in the inflamed brain and 
it could also contribute to the alteration of the brain 
 functionality in SLE.
Metabolomic studies in AS
AS is a chronic inflammatory disease characterized by 
axial skeleton ankylosis, enthesitis inflammation and, 
occasionally, peripheral arthritis. AS has an overall 
incidence between 0.5 and 14 per 100,000 people per 
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year and is more common in men [74]. Metabolomic 
studies in AS are very recent and have been all per-
formed in blood samples with the final objective of 
detecting diagnostic biomarkers [51,75,76].
AS blood metabolome
Gao et al. [76] performed a case–control study using 
GC-MS an LC-MS to identify AS biomarkers in 
plasma samples. Supervised partial least squares dis-
criminant analysis was able to accurately discriminate 
both samples groups demonstrating the potential of 
metabolomics as a reliable diagnostic tool in AS. In 
this study, proline, glucose, phosphate, phenylalanine, 
urea, glycerol and homocysteine were detected at higher 
concentrations in AS patients than in healthy controls. 
Instead, propanoic acid, tryptophan and several phos-
phatidylcholines were present at lower concentrations 
in AS patients compared with controls. Tryptophan 
reduction might respond to the indoleamine 2,3-diox-
ygenase enzyme activation by the high levels of inter-
feron gamma produced by the disease. AS patients 
responding to anti-inflammatory treatments have 
shown to increase this amino acid and, consequently, 
it could become a useful biomarker of disease activity. 
Cartilage breakdown by the chronic inflammation in 
AS could explain the observed high levels of proline. 
Consequently, the high levels of urea would therefore 
caused by the rise in this and  additional amino acids 
detected in AS patients.
Using LC-MS, Fischer et al. [75] also performed a 
case–control study with serum samples of AS patients 
and healthy controls. Like Gao et al. [76], multivari-
ate analysis on the measured metabolomic profile was 
able to distinguish patients from controls. Importantly, 
the metabolomic data could also separate AS patients 
according to the Bath Ankylosing Spondylitis Disease 
Activity Index (i.e., BASDAI). Although most of the 
associated molecular features detected by LC-MS were 
not linked to known metabolites, they were able to 
identify 25-hydroxyvitamin D3 26,23-peroxylactone 
as a metabolite clearly downregulated in AS. The lower 
levels of this metabolite might reflect an alteration in 
the vitamin D3 metabolism, which has been shown to 
have profound effects in bone remodeling and immune 
cell activation [77]. Consequently, targeting this biolog-
ical pathway could have protective effects in the bone 
destruction process associated to AS.
Finally, the arthritis screening study performed 
by Jiang et al. [51] provided additional support to the 
utility of serum as a useful surrogate of AS pathology. 
Using GC-MS and LC-MS on male subjects, they 
were able to identify several metabolites that could effi-
ciently distinguish AS from GA patients. Creatinine, 
uric acid, arabitol, succinic acid, valine and 5-oxopro-
line were among the metabolites found to be signifi-
cantly underexpressed in AS serum compared with GA 
serum.
Metabolomic studies in PsA
PsA is an inflammatory arthritis that is associated 
with psoriasis. PsA has specific clinical features such as 
arthritis of the distal interphalangeal joints to spondy-
litis and sacroiliitis. PsA occurs in approximately 12% 
of psoriasis patients [78] and it is associated with higher 
morbidity and mortality and also requires a mark-
edly different therapeutic approach. Therefore, the 
identification of metabolites that can characterize PsA 
from purely cutaneous psoriasis could become a useful 
clinical tool. To date, however, no studies have directly 
compared PsA and psoriasis metabolomics profiles.
PsA blood metabolome
In their MS screen of RA, Madsen et al. [48] included 
a PsA cohort as an additional control group to evalu-
ate the specificity of the metabolomic markers. Inter-
estingly, the metabolomic profiles from RA patients 
were found to be more different between RA and PsA 
patients than RA and control patients. In this study, 
however, no direct contrast between PsA and controls 
was performed. Consequently, the identification of 
metabolites specifically associated with PsA can only 
be extrapolated from the differences between RA and 
controls and RA and PsA patients. Several amino acids 
including aspartic acid, glutamic acid, glutamate and 
serine were increased in PsA patients compared with 
RA and were not different between RA and controls. 
Therefore, it is likely that PsA is characterized by a 
major protein turnover and a higher increase of free 
amino acids in serum. However, specific case–control 
design studies must still be carried out to confirm the 
specificity of this metabolomic profile in PsA.
PsA urine metabolome
In their NMR longitudinal study of the urine metabo-
lite profile associated to the response to anti-TNF treat-
ment, Kapoor et al. [56] also included a cohort of PsA 
patients. Like for RA patients, the urine metabolome 
in PsA correlated with the changes in disease activity 
induced by the biologic treatment. The metabolite lev-
els influenced by anti-TNF treatment were found to 
be similar between both diseases. In particular, high 
levels of glutamine, phenylacetic acid and histamine in 
the baseline urine samples were found to be predictors 
of the good response to anti-TNF treatment.
Metabolomic studies in OA
OA is the most common type of arthritis and is a major 
cause of pain and disability in the elderly [79]. The clin-
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ical and radiologic findings that form the basis of the 
diagnosis of OA are poorly sensitive for monitoring the 
progression of the disease. Consequently, the identifi-
cation of metabolites that can better reflect quantita-
tive and dynamic changes of the joint tissue turnover 
would be of major utility in daily clinical practice.
OA urine metabolome
A first approach to the characterization of metabolites 
associated to OA pathology was performed by Lam-
ers et al. analyzing the urine profiles of animal mod-
els with 1H-NMR [80]. The Hartley outbred strain of 
guinea pigs has shown to develop progressive knee OA 
and, consequently, are a useful animal model to screen 
for potential biomarkers in OA. Principal component 
analysis, a multivariate approach commonly used in 
genomic studies, showed a clear separation between the 
urine profile of the OA model and the urine profile of 
the control strain. The major changes associated with 
OA were found in lactate, malate, hypoxanthine and 
alanine levels, which support the hypothesis that in OA 
there is an increase in energy utilization and an altered 
metabolism of purines. Having proven the existence 
of a urine metabolite pattern correlated with the pres-
ence of the disease, the same group performed a study 
using a cohort of OA patients and matched controls. 
Using the same multivariate analysis approach as in 
the animal model they were also able to discriminate 
between patients and controls. The prediction model 
built from the metabolite concentrations showed a 
strong correlation with the Kellgren–Lawrence radio-
graphic scores for the evaluation of OA severity. Addi-
tionally, the metabolite profile that characterized the 
human OA patients shared many features with the 
profile obtained in the guinea pig model, confirming 
the usefulness of this model to pursue clinically rel-
evant biomarkers. Like in the animal model, several 
of the differential NMR signals could not be identi-
fied. This aspect is characteristic of the exploratory 
nature of 1H-NMR; in these cases, additional studies 
using more sensitive technologies like correlation spec-
troscopy NMR, LC-MS or GS-MS are required to 
characterize the associated metabolites. The increased 
metabolites in OA that could be identified with cer-
tainty were hydroxybutyrate, pyruvate, creatine/creati-
nine and glycerol. These results suggest the increased 
use of fat as an energy source in OA. Histidine and 
methylhistidine were found to be in significant lower 
concentration in the urine OA patients compared with 
controls. Low levels of histidine in OA could be associ-
ated to an over expression of histidine decarboxylase in 
OA chondrocytes and the subsequent increase in the 
production of histamine observed in the OA joint [81]. 
There is evidence supporting that histamine promotes 
the formation of the chondrocyte clusters characteristic 
of the osteoarthritic cartilage [82].
OA blood metabolome
Using 1H-NMR Zhai et al. [83] analyzed the metabolo-
mics profile in the serum of OA patients and controls. 
Importantly, in this study an independent replication 
cohort of patients and controls was also recruited to 
validate the metabolite associations identified in the 
discovery phase. Also, in this study they also used the 
ratios between metabolites since it has been shown 
to provide an improved quantification of some of 
the metabolic reactions present in the tissue of inter-
est. After correcting for the number of statistical tests 
performed, they found the valine/histidine and the 
xleucine(isoleucine and leucine)/histidine ratios to be 
significantly associated with the presence of knee OA. 
These ratios showed also to be predictive of the OA 
severity, showing a correlation with the Kellgren–Law-
rence OA grade. Interestingly, valine, isoleucine and 
leucine belong to the branched-chain family of amino 
acids (BCAA). BCAA are characterized for being 
essential amino acids (i.e., they cannot be synthesized 
by the body), having a similar molecular structure and 
being important constituents of the skeletal muscle. 
Elevated levels of BCAA have been also found both 
associated to obesity [84] and aging [85]. Importantly, 
BMI and age were discarded as confounders from the 
observed association between the two ratios and knee 
OA. Another potential explanation for the increased 
levels of these amino acids could be the collagen break-
down that is associated with this disease. A recent 
study comparing the metabolomic profile of media 
conditioned by cultured synovial fibroblasts from OA 
patients and controls also found additional evidence 
implicating the BCAA metabolism with OA etiology 
[86]. Consequently, the BCAA/histidine ratio could 
become a valuable biomarker in the management of 
OA.
Metabolomic studies in GA
Approximately 1% of the adult men in western coun-
tries have gout. GA is characterized by recurrent attacks 
of acute monoarticular or oligoarticular inflammation 
caused by the formation of urate crystals in the joint 
[87]. Misdiagnosis in the early stages of the disease can 
influence the outcome of the disease. Consequently, 
there is a need to identify biomarkers that can help to 
reliably diagnose the disease.
GA metabolome
Liu et al. [88] used high performance liquid chromatog-
raphy to analyze both the serum and urine profiles of 
GA patients and matched controls. The multivariate 
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Executive summary
The metabolome is the most dynamic level of the organism
•	 The characterization of the metabolomic profile of patients can be a powerful approach to identify the 
physiological processes that are altered in disease.
•	 The recent technological and methodological advances are now allowing the fast and accurate assessment of 
the metabolome.
Study design in metabolomic studies
•	 There are two major study design approaches in metabolomics: targeted and untargeted studies.
•	 Given its simplicity, one of the most commonly used study approaches in metabolomics has been the 
case–control design.
•	 In metabolomics, the technical and biological variabilites can have a dramatic impact on the quality of the 
results and must be controlled.
Recent technological improvements are boosting metabolomic studies
•	 The two most widely used metabolomic analysis technologies are nuclear magnetic resonance (NMR) and mass 
spectrometry (MS).
•	 NMR is a fast and highly reproducible metabolomic analysis.
•	 MS has a higher sensitivity than NMR, but is more demanding in terms of sample preparation and technical 
requirements.
The need for bioinformatics in high-throughput metabolomic studies
•	 There is a clear need for bioinformatic methods that can process these large amounts of complex data in 
metabolomic studies and extract meaningful information.
•	 In the recent years, several open-source bioinformatic methods have been developed that can overcome 
several challenges of NMR and MS data processing.
Metabolomic studies in rheumatoid arthritis
•	 Metabolomic studies confirm the hypoxic nature of the inflamed synovial joint in rheumatoid arthritis (RA).
•	 Metabolite profiles in RA plasma are associated to disease activity and treatment response.
•	 Metabolites from the nucleic acid and oxidative stress pathways are potential biomarkers for RA pathology.
Metabolomic studies in systemic lupus erythematosus
•	 Low histidine levels have been identified in the serum of systemic lupus erythematosus (SLE) and RA.
•	 The commonly altered lipid profile in SLE and RA could explain the increased incidence of cardiovascular 
disease observed for both rheumatic diseases.
•	 Taurine and citrate levels in the SLE urine metabolome have potential utility as biomarkers for SLE nephritis 
subtype discrimination.
Metabolomic studies in ankylosing spondylitis
•	 Metabolomic studies of patients and controls identified reduced levels of tryptophan in ankylosing 
spondylitis, probably due to IFN-γ expression in the disease.
•	 Metabolite levels in serum reflect an alteration in the vitamin D3 metabolism in ankylosing spondylitis.
Metabolomic studies in psoriatic arthritis
•	 To date, no studies have directly compared psoriatic arthritis and psoriasis metabolomics profiles.
•	 The urine metabolome in psoriatic arthritis is correlated with the changes in disease activity induced by 
 anti-TNF treatment.
Metabolomic studies in osteoarthritis
•	 The prediction model built from the urine metabolite concentrations correlates significantly with the 
Kellgren–Lawrence radiographic scores of osteoarthritis severity.
•	 The valine/histidine and the xleucine(isoleucine and leucine)/histidine ratios are potential biomarkers of the 
development of knee osteoarthritis.
Metabolomic studies in gouty arthritis
•	 Uric acid is not a sufficiently informative biomarker of gouty arthritis and additional markers must be 
identified.
•	 Gouty arthritis also expresses the common core of serum metabolites found in other prevalent arthritis. This 
common set of metabolites could be useful for the development of improved diagnostic systems.
analysis of the obtained profiles was able to discrimi-
nate between the case and controls groups. Patients 
with GA showed increased serum levels of uric acid, 
creatinine and tryptophan. Uric acid is the end product 
of purine degradation and, in high concentrations, it 
leads to the formation of monosodium urate crystals in 
the joint. Although this is a well established pathologi-
cal process of GA, this study shows that while it uric 
acid could be an informative biomarker at the earlier 
stages of the disease, it is not sufficiently informative 
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to be used as a single diagnostic marker. Creatinine, 
a widely used biomarker of the renal function, could 
be associated to the renal affection by the deposition 
of urate crystals. Compared to RA, AS or SLE, where 
tryptophan serum levels are significantly reduced, it 
appears to be significantly increased in GA. The origin 
of this variation is not clear and, while it could be asso-
ciated to GA pathology, it could also be a metabolism 
product resulting from the treatment received by the 
patients. Therapies can therefore be a major confounder 
in metabolomic studies if inadequately controlled.
Interestingly, uric acid and creatinine levels in urine 
showed an opposite variation compared with serum of 
GA patients. This inverse relation could be explained 
by the defects of tubular secretion associated with this 
disease. Hippuric acid, a conjugate of benzoic acid and 
glycine normally generated by microfloral metabolism, 
was also found to be reduced in GA urine. The authors, 
however, suggest that the increased energy consump-
tion associated with GA associated inflammation could 
be responsible for this observed metabolite reduction.
In their recent screen of the serum metabolomic pro-
files of four different types of arthritis, Jiang [51], con-
firmed the high diagnostic utility of uric acid and cre-
atine for GA. Also, additional metabolites like cystine, 
arabitol and alloxanoic acid were found to be in high 
concentrations in patients with GA. Used together in 
a multivariate model, they could clearly distinguish 
GA patients from AS patients or controls. The results 
of this study are a strong basis for the development of 
diagnostic systems based on the screening of multiple 
informative biomarkers.
Future perspective
Recent technological advances have boosted the capacity 
to mine the metabolite composition of biological sam-
ples associated with different diseases. This new layer of 
information strongly complements the previously estab-
lished genomic, transcriptomic and proteomic technolo-
gies. In the near future, studies integrating these differ-
ent layers of biological information will provide essential 
knowledge for the identification of the biological mecha-
nisms that operate in each disease and will provide an 
accurate molecular profile of each patient. This indi-
vidual profile will have a high translational potential in 
rheumatic disease since it could help to advance the time 
of diagnosis as well as help medical specialists to perform 
more guided therapeutic decisions.
There are still, however, several challenges that need 
to be overcome. The annotation of many metabolites 
must clearly evolve, a task that is actually being car-
ried out by different databases [26,89,90]. Metabolome 
analysis technologies must improve in sensitivity and 
be less time consuming and costly and the associated 
analysis algorithms must improve their accuracy. Also, 
if large cohort analyses are to be performed, there is 
a clear need for improvement in the throughput of 
most metabolomics platforms. Additionally, sample 
and clinical collection procedures must be standard-
ized to ensure the quality of the results and the mini-
mization of technical and biological confounders. 
Although metabolomics is an emergent discipline, it 
is rapidly evolving and, in the next years, new findings 
will clearly increase our knowledge of the molecular 
basis of rheumatic diseases and contribute to improve 
the prognosis of these patients.
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